data_2lqk_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lqk _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 . . . . . 0 CA--C 1.538 0.483 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 . . . . . 0 CA--C 1.539 0.541 0 CA-C-O 121.298 0.57 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 . . . . . 0 CA--C 1.536 0.432 0 CA-C-O 121.449 0.642 . . . . 0.0 112.346 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 . . . . . 0 CA--C 1.541 0.626 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 . . . . . 0 CA--C 1.539 0.551 0 CA-C-O 121.357 0.598 . . . . 0.0 112.593 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 121.377 0.608 . . . . 0.0 112.057 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 CA-C-O 121.11 0.481 . . . . 0.0 112.01 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 . . . . . 0 CA--C 1.542 0.643 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 . . . . . 0 CA--C 1.538 0.501 0 CA-C-O 121.396 0.617 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 . . . . . 0 CA--C 1.536 0.44 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 . . . . . 0 CA--C 1.538 0.511 0 CA-C-O 121.054 0.454 . . . . 0.0 111.91 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 . . . . . 0 CA--C 1.541 0.603 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 . . . . . 0 CA--C 1.54 0.574 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 13.4 m-85 . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.236 0.541 . . . . 0.0 112.377 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 CA--C 1.54 0.592 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 . . . . . 0 CA--C 1.539 0.554 0 CA-C-O 120.878 0.371 . . . . 0.0 111.779 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.709 0.29 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -92.66 -151.58 27.9 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.689 1.614 . . . . 0.0 112.675 175.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -149.97 -56.08 0.17 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.35 1.06 . . . . 0.0 112.992 177.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.5 mtt -149.12 -52.17 0.16 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 126.126 1.771 . . . . 0.0 112.483 177.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -82.4 154.21 25.32 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.65 0.78 . . . . 0.0 111.435 175.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -122.26 -66.67 1.01 Allowed 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.692 1.597 . . . . 0.0 110.24 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -84.46 116.27 23.0 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.933 0.893 . . . . 0.0 112.311 177.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.39 175.15 7.96 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.0 pp -145.11 146.62 31.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.092 0.957 . . . . 0.0 110.254 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -113.01 159.32 35.07 Favored Pre-proline 0 CA--C 1.547 0.86 0 C-N-CA 124.675 1.19 . . . . 0.0 111.489 175.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -71.2 177.61 6.37 Favored 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.733 2.956 . . . . 0.0 112.513 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -109.43 -60.17 1.81 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.584 1.554 . . . . 0.0 111.91 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.38 1.872 . . . . 0.0 113.28 175.158 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.28 -170.12 38.61 Favored Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.881 1.229 . . . . 0.0 113.076 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -110.38 98.81 7.95 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.303 1.441 . . . . 0.0 110.76 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -152.03 -43.43 0.11 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -114.91 153.25 30.87 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.661 1.584 . . . . 0.0 111.098 175.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -109.6 170.76 7.86 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.038 1.335 . . . . 0.0 111.807 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -72.63 130.23 40.1 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.525 0.73 . . . . 0.0 111.848 175.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.98 178.25 6.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.2 tt -147.32 87.96 1.69 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.364 -0.835 . . . . 0.0 111.31 -175.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.97 159.61 85.0 Favored Pre-proline 0 CA--C 1.553 1.076 0 C-N-CA 124.319 1.048 . . . . 0.0 112.617 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -72.22 176.86 7.96 Favored 'Trans proline' 0 CA--C 1.543 0.951 0 C-N-CA 123.98 3.12 . . . . 0.0 112.537 174.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -139.43 120.41 14.54 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.204 1.402 . . . . 0.0 110.685 179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.026 1.73 . . . . 0.0 114.808 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.53 -161.59 40.83 Favored Glycine 0 CA--C 1.537 1.447 0 CA-C-N 119.11 0.868 . . . . 0.0 113.087 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 63.7 m-70 -127.81 41.35 3.52 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.15 1.78 . . . . 0.0 112.843 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.2 mmt -129.44 26.23 5.38 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.663 1.985 . . . . 0.0 113.01 -177.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.53 96.92 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 126.111 1.765 . . . . 0.0 112.304 174.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -97.83 -69.99 0.74 Allowed 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 126.556 1.943 . . . . 0.0 110.56 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -83.65 114.36 21.5 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.986 0.914 . . . . 0.0 112.346 178.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -56.74 4.26 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -168.89 81.66 0.14 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.491 1.516 . . . . 0.0 111.901 -177.031 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.74 158.64 82.4 Favored Pre-proline 0 CA--C 1.555 1.164 0 O-C-N 121.216 -0.927 . . . . 0.0 113.262 177.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.81 104.55 1.64 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.093 3.195 . . . . 0.0 112.297 175.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -91.76 -41.2 10.81 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 121.458 -0.776 . . . . 0.0 113.088 174.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 . . . . . 0 C--O 1.252 1.23 0 C-N-CA 125.091 1.356 . . . . 0.0 112.456 176.987 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 86.45 0.12 Allowed Glycine 0 N--CA 1.476 1.32 0 CA-C-N 120.12 1.327 . . . . 0.0 113.869 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -68.76 137.02 53.69 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.139 0.976 . . . . 0.0 112.334 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.5 mmt -108.45 101.72 10.87 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.194 1.797 . . . . 0.0 111.57 179.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -92.75 100.8 13.22 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.688 1.595 . . . . 0.0 111.881 175.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.47 -75.41 0.48 Allowed 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.609 1.163 . . . . 0.0 110.964 175.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -82.87 114.78 21.41 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 118.999 0.818 . . . . 0.0 112.752 177.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.33 175.03 11.01 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.51 131.98 18.69 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.481 -0.762 . . . . 0.0 110.722 177.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -115.71 155.99 46.86 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 125.585 1.554 . . . . 0.0 111.438 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.56 -20.7 26.68 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.079 2.519 . . . . 0.0 113.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -73.01 -33.11 65.56 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.691 1.196 . . . . 0.0 113.328 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 C-N-CA 129.256 3.023 . . . . 0.0 115.889 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 119.661 -0.209 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.31 -166.76 26.97 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.015 1.293 . . . . 0.0 114.409 176.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.6 p-80 -119.18 173.12 7.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 126.78 2.032 . . . . 0.0 111.802 178.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.99 -77.47 0.43 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.965 1.706 . . . . 0.0 110.846 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mttp -79.44 110.17 14.5 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.106 1.363 . . . . 0.0 112.24 177.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -79.0 -68.6 0.64 Allowed 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.953 0.901 . . . . 0.0 110.225 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -84.91 113.98 21.79 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.13 167.84 20.75 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 18.0 tp -149.21 134.46 18.3 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.5 1.12 . . . . 0.0 109.722 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -65.45 159.55 66.21 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 123.004 0.521 . . . . 0.0 111.708 175.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -70.97 171.51 15.64 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 123.113 2.542 . . . . 0.0 112.872 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -136.99 20.52 3.02 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 125.645 1.578 . . . . 0.0 113.867 -177.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.254 1.342 0 C-N-CA 124.861 1.265 . . . . 0.0 113.527 174.992 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.212 0 CA-C-O 120.48 0.181 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.07 -177.19 29.95 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.206 1.384 . . . . 0.0 113.3 -178.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.0 m80 -92.5 -65.03 1.03 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.839 1.255 . . . . 0.0 112.321 175.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -91.23 95.57 10.11 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.95 0.9 . . . . 0.0 110.961 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -66.81 158.34 30.68 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.389 0.614 . . . . 0.0 111.816 175.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -70.88 170.65 12.18 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.301 1.44 . . . . 0.0 112.58 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -70.93 113.34 7.88 Favored 'General case' 0 CA--C 1.54 0.589 0 O-C-N 121.217 -0.927 . . . . 0.0 112.56 175.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.16 168.58 19.71 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.5 tp -148.8 110.08 4.4 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.558 0.743 . . . . 0.0 110.955 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -61.48 156.63 51.58 Favored Pre-proline 0 CA--C 1.553 1.07 0 C-N-CA 123.924 0.89 . . . . 0.0 112.355 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -69.39 99.93 0.74 Allowed 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.87 3.047 . . . . 0.0 111.638 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -74.96 -33.24 61.89 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 123.775 0.83 . . . . 0.0 112.598 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.252 1.222 0 C-N-CA 125.919 1.687 . . . . 0.0 113.806 175.17 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.635 0.255 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.38 71.56 1.28 Allowed Glycine 0 CA--C 1.535 1.335 0 C-N-CA 124.68 1.133 . . . . 0.0 114.595 176.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -90.16 -39.96 12.52 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -90.01 -64.43 1.14 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.543 1.137 . . . . 0.0 111.969 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mppt? -109.27 121.25 44.77 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.855 1.662 . . . . 0.0 110.741 175.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -115.93 -66.85 1.04 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.5 1.52 . . . . 0.0 109.231 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -75.88 118.49 18.73 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.879 0.872 . . . . 0.0 112.593 176.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.3 -52.69 6.69 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -164.52 130.47 2.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.794 1.638 . . . . 0.0 110.21 178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -129.0 157.94 74.27 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 125.37 1.468 . . . . 0.0 111.92 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.99 166.68 28.34 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 123.493 2.795 . . . . 0.0 112.918 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -97.71 -27.49 14.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.88 1.272 . . . . 0.0 113.91 179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.196 0 C-N-CA 127.172 2.189 . . . . 0.0 114.816 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.728 0.299 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.56 149.98 18.58 Favored Glycine 0 CA--C 1.535 1.3 0 C-N-CA 125.285 1.421 . . . . 0.0 112.232 176.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -136.77 27.4 3.0 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.827 1.251 . . . . 0.0 113.268 -178.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 mtp -131.56 118.9 20.75 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.905 1.682 . . . . 0.0 111.571 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -132.73 155.53 48.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.555 1.942 . . . . 0.0 110.156 175.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -136.84 169.76 17.22 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.168 1.787 . . . . 0.0 111.051 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -73.13 119.28 17.16 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 121.463 -0.773 . . . . 0.0 112.463 175.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.63 86.85 2.37 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -71.16 95.27 1.23 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 123.982 0.913 . . . . 0.0 110.592 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.67 155.28 30.88 Favored Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 124.886 1.274 . . . . 0.0 112.79 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -66.96 123.07 10.5 Favored 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 123.242 2.628 . . . . 0.0 111.445 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -129.31 93.09 3.49 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.597 1.559 . . . . 0.0 110.095 -179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 . . . . . 0 C--O 1.253 1.242 0 C-N-CA 125.066 1.346 . . . . 0.0 112.927 178.559 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 N-CA-C 110.569 -0.16 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.58 -171.0 54.98 Favored Glycine 0 CA--C 1.536 1.36 0 O-C-N 121.194 -0.941 . . . . 0.0 113.372 -176.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -146.57 20.01 1.33 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 125.28 1.432 . . . . 0.0 114.085 -175.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.83 10.12 40.15 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.148 1.379 . . . . 0.0 114.353 -174.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -127.31 146.1 50.56 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.935 1.694 . . . . 0.0 111.13 -176.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -142.0 -64.21 0.43 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.346 1.058 . . . . 0.0 111.011 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -82.46 121.89 27.33 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.258 1.023 . . . . 0.0 112.057 176.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.9 81.01 7.27 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tp -58.22 101.22 0.07 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.014 1.726 . . . . 0.0 111.405 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -84.95 165.4 37.27 Favored Pre-proline 0 CA--C 1.553 1.065 0 C-N-CA 123.933 0.893 . . . . 0.0 112.064 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -74.41 -38.03 2.17 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.722 2.281 . . . . 0.0 112.894 174.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -92.25 -48.19 6.82 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.234 1.014 . . . . 0.0 113.197 177.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 . . . . . 0 C--O 1.254 1.299 0 C-N-CA 125.935 1.694 . . . . 0.0 113.252 -179.503 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 121.07 175.18 15.1 Favored Glycine 0 CA--C 1.537 1.442 0 C-N-CA 125.513 1.53 . . . . 0.0 113.187 -172.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.45 148.4 24.47 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.999 1.719 . . . . 0.0 111.663 175.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.62 141.21 14.35 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.586 1.954 . . . . 0.0 109.508 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -129.58 161.71 29.91 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.047 1.739 . . . . 0.0 111.208 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 15.7 mp0 -80.43 -69.4 0.6 Allowed 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.49 0.716 . . . . 0.0 111.806 176.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -93.34 118.02 30.78 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.109 1.363 . . . . 0.0 112.01 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.15 165.35 23.41 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.44 120.85 7.9 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 111.44 -177.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.25 159.57 85.05 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 123.605 0.762 . . . . 0.0 111.854 176.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.93 -38.98 3.56 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.892 2.395 . . . . 0.0 113.348 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.99 -44.27 22.69 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.988 0.915 . . . . 0.0 112.861 175.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.238 0 C-N-CA 127.221 2.208 . . . . 0.0 115.033 -171.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -110.63 -91.39 2.08 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 120.817 -1.177 . . . . 0.0 112.218 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -155.6 46.74 0.49 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.375 1.47 . . . . 0.0 112.853 -175.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.4 129.52 40.56 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 121.252 -0.905 . . . . 0.0 111.863 175.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.4 tptt -143.11 94.69 2.66 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.193 1.397 . . . . 0.0 111.012 178.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -107.09 174.44 5.89 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.375 1.47 . . . . 0.0 112.343 178.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.23 117.67 20.45 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.072 0.949 . . . . 0.0 112.619 175.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.94 177.81 7.43 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -149.57 114.78 5.46 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.587 0.755 . . . . 0.0 111.03 -177.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -102.65 158.37 31.9 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 125.305 1.442 . . . . 0.0 111.861 178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.61 168.13 22.26 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 123.333 2.688 . . . . 0.0 112.743 176.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -121.88 91.29 3.48 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.53 1.532 . . . . 0.0 110.872 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 . . . . . 0 N--CA 1.486 1.332 0 C-N-CA 128.913 2.885 . . . . 0.0 117.611 177.878 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 120.957 0.408 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.62 51.37 0.14 Allowed Glycine 0 CA--C 1.533 1.193 0 C-N-CA 123.989 0.804 . . . . 0.0 113.745 -175.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.2 m-70 -129.28 163.91 24.64 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 125.674 1.589 . . . . 0.0 111.739 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -99.53 95.72 7.18 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.936 1.294 . . . . 0.0 111.207 177.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 tptt -141.45 15.11 2.19 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.059 1.344 . . . . 0.0 113.726 176.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -105.97 168.67 8.97 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.683 1.193 . . . . 0.0 112.262 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -74.26 131.99 41.7 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.625 -0.672 . . . . 0.0 112.532 175.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.74 172.85 6.91 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.0 tp -142.4 129.37 20.71 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.711 0.804 . . . . 0.0 111.537 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.88 159.64 74.38 Favored Pre-proline 0 CA--C 1.552 1.039 0 C-N-CA 124.466 1.106 . . . . 0.0 112.677 175.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.04 85.61 0.99 Allowed 'Trans proline' 0 CA--C 1.544 1.014 0 C-N-CA 123.957 3.104 . . . . 0.0 111.922 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -125.66 -57.3 1.46 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.108 1.763 . . . . 0.0 112.573 175.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 . . . . . 0 C--O 1.253 1.275 0 C-N-CA 126.346 1.858 . . . . 0.0 111.832 -179.499 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 119.474 -0.298 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 177.89 -45.35 0.1 OUTLIER Glycine 0 N--CA 1.474 1.233 0 C-N-CA 124.059 0.838 . . . . 0.0 113.487 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -67.69 166.32 15.4 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.13 0.972 . . . . 0.0 111.584 174.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.8 ttm -77.16 119.11 20.39 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.161 0.984 . . . . 0.0 111.035 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -125.85 155.53 41.03 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 126.569 1.948 . . . . 0.0 111.249 179.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -91.62 170.44 9.92 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.942 1.297 . . . . 0.0 113.512 174.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -80.49 114.81 19.65 Favored 'General case' 0 CA--C 1.536 0.44 0 O-C-N 121.168 -0.957 . . . . 0.0 112.169 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -72.62 171.81 11.79 Favored 'General case' 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -140.45 143.94 35.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.94 0.896 . . . . 0.0 110.624 -179.48 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.51 159.2 85.75 Favored Pre-proline 0 CA--C 1.553 1.068 0 C-N-CA 123.396 0.679 . . . . 0.0 111.465 175.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.36 -9.91 26.93 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.043 2.495 . . . . 0.0 113.896 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -129.34 23.21 5.55 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 127.013 2.125 . . . . 0.0 113.435 -175.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 128.639 2.776 . . . . 0.0 114.853 -174.526 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.281 0 N-CA-C 112.092 0.404 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.41 168.94 41.65 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.852 1.215 . . . . 0.0 113.375 -176.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -113.39 86.95 2.49 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.761 1.624 . . . . 0.0 110.664 -175.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 30.2 ttm -140.98 74.38 1.46 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.986 1.314 . . . . 0.0 111.384 -178.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.54 70.42 0.73 Allowed 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.669 1.588 . . . . 0.0 112.24 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -68.17 -69.91 0.29 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 124.598 1.159 . . . . 0.0 112.346 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -89.59 123.21 33.45 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.073 0.949 . . . . 0.0 111.91 177.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.83 81.38 8.57 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.92 109.15 0.77 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.189 1.796 . . . . 0.0 111.486 -178.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.24 159.26 81.35 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 124.35 1.06 . . . . 0.0 113.065 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.32 177.86 6.79 Favored 'Trans proline' 0 CA--C 1.545 1.043 0 C-N-CA 124.015 3.143 . . . . 0.0 112.734 174.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.6 74.0 1.53 Allowed 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.168 1.787 . . . . 0.0 111.581 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.252 1.215 0 C-N-CA 124.644 1.178 . . . . 0.0 113.851 -178.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.26 174.26 48.81 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.437 1.018 . . . . 0.0 112.86 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -117.09 47.12 1.55 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.508 1.123 . . . . 0.0 112.952 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mtt -73.71 156.28 38.07 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.62 1.168 . . . . 0.0 111.294 175.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 45.8 mttt -137.74 95.72 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.72 1.608 . . . . 0.0 111.6 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.89 169.28 18.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.394 1.078 . . . . 0.0 112.514 174.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -76.73 131.27 38.66 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.885 0.874 . . . . 0.0 112.364 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 176.25 6.65 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -149.2 119.75 7.44 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.89 0.876 . . . . 0.0 110.411 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.9 160.04 72.01 Favored Pre-proline 0 CA--C 1.554 1.103 0 C-N-CA 123.104 0.562 . . . . 0.0 111.567 176.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.68 169.91 17.7 Favored 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 122.898 2.399 . . . . 0.0 112.314 175.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.97 125.47 49.49 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.577 1.551 . . . . 0.0 110.326 177.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 C--O 1.254 1.318 0 C-N-CA 125.535 1.534 . . . . 0.0 113.887 175.298 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 112.203 0.445 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -84.07 1.14 Allowed Glycine 0 CA--C 1.534 1.246 0 O-C-N 120.336 -1.478 . . . . 0.0 112.873 -177.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -147.72 89.63 1.78 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.139 1.376 . . . . 0.0 111.525 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 10.4 ttm -152.96 -52.78 0.11 Allowed 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.12 1.155 . . . . 0.0 114.12 177.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -137.73 72.73 1.42 Allowed 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 126.246 1.818 . . . . 0.0 110.244 175.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -119.65 168.22 11.25 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.264 1.426 . . . . 0.0 111.575 177.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -74.19 126.86 31.52 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.01 0.924 . . . . 0.0 112.799 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.12 173.35 12.67 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.56 121.86 6.73 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.741 1.216 . . . . 0.0 111.276 -177.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.88 158.11 84.5 Favored Pre-proline 0 CA--C 1.551 1.012 0 C-N-CA 123.584 0.753 . . . . 0.0 111.555 174.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.48 164.94 32.38 Favored 'Trans proline' 0 CA--C 1.542 0.906 0 C-N-CA 123.178 2.586 . . . . 0.0 112.461 176.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.82 117.06 8.98 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.948 1.699 . . . . 0.0 110.326 -177.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 C-N-CA 128.57 2.748 . . . . 0.0 116.541 -177.179 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.763 -0.088 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.64 67.77 0.05 OUTLIER Glycine 0 CA--C 1.533 1.199 0 C-N-CA 123.527 0.584 . . . . 0.0 114.432 179.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.27 -23.99 19.12 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 114.288 1.218 . . . . 0.0 114.288 175.024 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 mtt -120.05 82.81 1.95 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.685 1.594 . . . . 0.0 111.233 177.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.48 113.02 16.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.589 0.756 . . . . 0.0 109.32 174.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.06 -72.26 0.69 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.537 1.135 . . . . 0.0 111.06 176.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 13.4 m-85 -83.9 133.45 34.72 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.998 0.919 . . . . 0.0 112.377 175.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.25 169.68 13.25 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.9 116.43 5.07 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.636 0.774 . . . . 0.0 111.745 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.03 158.1 88.26 Favored Pre-proline 0 CA--C 1.554 1.098 0 C-N-CA 123.568 0.747 . . . . 0.0 112.337 175.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -70.0 110.93 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.966 3.11 . . . . 0.0 111.764 176.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -144.61 101.41 3.67 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.193 1.397 . . . . 0.0 110.905 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.25 0 C-N-CA 125.374 1.47 . . . . 0.0 114.298 177.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -58.57 158.69 17.96 Favored Glycine 0 CA--C 1.537 1.461 0 C-N-CA 124.372 0.987 . . . . 0.0 114.706 178.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -124.97 -34.25 2.81 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 125.829 1.652 . . . . 0.0 113.799 -175.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -72.62 -44.17 62.31 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.248 1.019 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mmtp -87.39 165.36 15.64 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.436 1.495 . . . . 0.0 110.834 174.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -131.09 -76.02 0.52 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.063 1.345 . . . . 0.0 110.702 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -83.91 117.81 23.58 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 123.782 0.833 . . . . 0.0 112.636 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.23 -46.42 12.7 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -159.65 -179.14 7.62 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.926 1.691 . . . . 0.0 111.529 178.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -141.12 160.53 57.49 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 125.386 1.474 . . . . 0.0 112.483 175.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -73.45 -32.59 7.81 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 123.626 2.884 . . . . 0.0 113.947 -177.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -128.6 -36.82 1.83 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 126.384 1.874 . . . . 0.0 112.168 -178.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.254 1.321 0 C-N-CA 127.913 2.485 . . . . 0.0 114.45 176.812 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 112.208 0.447 . . . . 0.0 112.208 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.95 -155.97 9.42 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 124.796 1.189 . . . . 0.0 113.298 174.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -102.08 157.05 17.15 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.246 1.418 . . . . 0.0 112.211 176.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -93.51 132.93 37.33 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.229 1.412 . . . . 0.0 111.377 175.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mtmt -143.33 85.72 1.87 Allowed 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 126.842 2.057 . . . . 0.0 110.378 175.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -92.94 169.42 10.45 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.132 0.973 . . . . 0.0 111.396 174.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -77.15 122.63 25.28 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.387 -0.821 . . . . 0.0 112.584 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.84 176.06 9.93 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 39.0 tp -148.58 131.19 15.88 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.551 1.14 . . . . 0.0 111.143 178.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -92.79 159.05 36.91 Favored Pre-proline 0 CA--C 1.554 1.115 0 C-N-CA 125.082 1.353 . . . . 0.0 112.804 175.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.04 103.57 1.51 Allowed 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 124.304 3.336 . . . . 0.0 112.306 179.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.4 177.19 8.17 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.367 1.867 . . . . 0.0 112.265 178.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 127.868 2.467 . . . . 0.0 113.697 -179.77 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 CA-C-O 120.574 0.226 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 138.42 -66.0 0.54 Allowed Glycine 0 N--CA 1.473 1.148 0 C-N-CA 125.373 1.463 . . . . 0.0 112.881 178.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -127.49 33.88 4.77 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 125.464 1.506 . . . . 0.0 113.114 -178.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 tpt -102.51 139.54 37.96 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.606 1.563 . . . . 0.0 110.707 177.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.5 mmtm -121.61 90.81 3.38 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 126.135 1.774 . . . . 0.0 109.474 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -127.42 165.22 20.2 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.322 1.449 . . . . 0.0 112.366 178.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -84.27 117.63 23.66 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.977 1.311 . . . . 0.0 111.779 175.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.8 80.56 5.15 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 tt -61.28 102.17 0.21 Allowed 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.764 1.626 . . . . 0.0 111.127 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.02 157.3 89.57 Favored Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 124.264 1.026 . . . . 0.0 112.142 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.05 -32.59 21.19 Favored 'Trans proline' 0 CA--C 1.54 0.79 0 C-N-CA 122.541 2.16 . . . . 0.0 112.982 -179.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.88 118.37 12.2 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.507 1.923 . . . . 0.0 110.147 -177.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.223 0 C-N-CA 125.821 1.648 . . . . 0.0 112.817 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.9 m-85 . . . . . 0 CA--C 1.538 0.483 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.531 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.637 HG11 HD12 ' A' ' 62' ' ' LEU . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.531 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.637 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.49 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.2 m-85 . . . . . 0 CA--C 1.539 0.541 0 CA-C-O 121.298 0.57 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.406 HD22 HD13 ' A' ' 62' ' ' LEU . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.532 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.509 HG11 ' NE ' ' A' ' 36' ' ' ARG . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.509 ' NE ' HG11 ' A' ' 31' ' ' VAL . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.532 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.644 HG21 HD22 ' A' ' 62' ' ' LEU . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.644 HD22 HG21 ' A' ' 52' ' ' VAL . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.58 ' CE2' HD13 ' A' ' 62' ' ' LEU . 26.9 m-85 . . . . . 0 CA--C 1.536 0.432 0 CA-C-O 121.449 0.642 . . . . 0.0 112.346 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.499 HG21 ' HB3' ' A' ' 7' ' ' PHE . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.493 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.493 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.522 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.522 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.495 ' CE2' HD23 ' A' ' 62' ' ' LEU . 20.7 m-85 . . . . . 0 CA--C 1.541 0.626 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.474 HD22 HD13 ' A' ' 62' ' ' LEU . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.476 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.476 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.495 HD23 ' CE2' ' A' ' 7' ' ' PHE . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.464 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.1 m-85 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 7' ' ' PHE . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.542 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.542 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.477 ' CZ ' HD22 ' A' ' 62' ' ' LEU . 29.1 m-85 . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 7' ' ' PHE . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.426 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.426 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.506 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.545 HG11 HD12 ' A' ' 62' ' ' LEU . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.506 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.545 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.519 ' CE2' HD23 ' A' ' 62' ' ' LEU . 24.7 m-85 . . . . . 0 CA--C 1.539 0.551 0 CA-C-O 121.357 0.598 . . . . 0.0 112.593 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.475 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.528 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.528 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.519 HD23 ' CE2' ' A' ' 7' ' ' PHE . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.405 ' HB3' HG21 ' A' ' 23' ' ' VAL . 27.7 m-85 . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 7' ' ' PHE . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.504 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.574 HG21 HD22 ' A' ' 62' ' ' LEU . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.504 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.574 HD22 HG21 ' A' ' 52' ' ' VAL . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.46 ' CE2' HD23 ' A' ' 62' ' ' LEU . 18.4 m-85 . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 121.377 0.608 . . . . 0.0 112.057 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.453 HD22 HD13 ' A' ' 62' ' ' LEU . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.417 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.417 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.485 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.591 HG21 HD22 ' A' ' 62' ' ' LEU . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.485 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.591 HD22 HG21 ' A' ' 52' ' ' VAL . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.506 ' CE2' HD23 ' A' ' 62' ' ' LEU . 21.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 CA-C-O 121.11 0.481 . . . . 0.0 112.01 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.536 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.557 HG21 HD22 ' A' ' 62' ' ' LEU . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.536 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 52' ' ' VAL . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.48 ' CE2' HD13 ' A' ' 62' ' ' LEU . 17.0 m-85 . . . . . 0 CA--C 1.542 0.643 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.602 HG11 HD12 ' A' ' 62' ' ' LEU . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.602 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.471 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.1 m-85 . . . . . 0 CA--C 1.538 0.501 0 CA-C-O 121.396 0.617 . . . . 0.0 112.532 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.546 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.581 HG21 HD22 ' A' ' 62' ' ' LEU . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.546 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.581 HD22 HG21 ' A' ' 52' ' ' VAL . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.474 ' HB3' HG21 ' A' ' 23' ' ' VAL . 24.2 m-85 . . . . . 0 CA--C 1.536 0.44 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 7' ' ' PHE . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.441 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.441 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.511 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 62' ' ' LEU . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.511 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 52' ' ' VAL . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 . . . . . 0 CA--C 1.538 0.511 0 CA-C-O 121.054 0.454 . . . . 0.0 111.91 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.432 HD22 HD13 ' A' ' 62' ' ' LEU . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.444 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.444 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.549 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.635 HG21 HD22 ' A' ' 62' ' ' LEU . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.635 HD22 HG21 ' A' ' 52' ' ' VAL . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.452 ' CE2' HD23 ' A' ' 62' ' ' LEU . 14.5 m-85 . . . . . 0 CA--C 1.541 0.603 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.457 HD22 HD13 ' A' ' 62' ' ' LEU . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.477 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.477 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.541 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.656 HG21 HD22 ' A' ' 62' ' ' LEU . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.541 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.656 HD22 HG21 ' A' ' 52' ' ' VAL . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.472 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.7 m-85 . . . . . 0 CA--C 1.54 0.574 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.48 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.555 HG21 HD22 ' A' ' 62' ' ' LEU . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.555 HD22 HG21 ' A' ' 52' ' ' VAL . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.4 m-85 . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.236 0.541 . . . . 0.0 112.377 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.452 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.521 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.605 HG21 HD22 ' A' ' 62' ' ' LEU . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.605 HD22 HG21 ' A' ' 52' ' ' VAL . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 CA--C 1.54 0.592 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.491 HD22 HD13 ' A' ' 62' ' ' LEU . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.523 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.625 HG21 HD22 ' A' ' 62' ' ' LEU . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.523 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.4 ' O ' HG12 ' A' ' 60' ' ' VAL . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.625 HD22 HG21 ' A' ' 52' ' ' VAL . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.444 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.9 m-85 . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.458 HD22 HD13 ' A' ' 62' ' ' LEU . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.47 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.55 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.649 HG21 HD22 ' A' ' 62' ' ' LEU . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.55 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.649 HD22 HG21 ' A' ' 52' ' ' VAL . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.568 ' CE2' HD23 ' A' ' 62' ' ' LEU . 19.4 m-85 . . . . . 0 CA--C 1.539 0.554 0 CA-C-O 120.878 0.371 . . . . 0.0 111.779 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.501 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.501 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.619 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.405 ' HB ' ' HB3' ' A' ' 50' ' ' ALA . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 59' ' ' SER . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.401 ' O ' HG12 ' A' ' 60' ' ' VAL . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.425 ' HB2' ' HB1' ' A' ' 56' ' ' ALA . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.568 HD23 ' CE2' ' A' ' 7' ' ' PHE . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.709 0.29 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -92.66 -151.58 27.9 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.689 1.614 . . . . 0.0 112.675 175.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -149.97 -56.08 0.17 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.35 1.06 . . . . 0.0 112.992 177.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.5 mtt -149.12 -52.17 0.16 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 126.126 1.771 . . . . 0.0 112.483 177.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -82.4 154.21 25.32 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.65 0.78 . . . . 0.0 111.435 175.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -122.26 -66.67 1.01 Allowed 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.692 1.597 . . . . 0.0 110.24 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.9 m-85 -84.46 116.27 23.0 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.933 0.893 . . . . 0.0 112.311 177.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.531 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.637 HG11 HD12 ' A' ' 62' ' ' LEU . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.531 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.637 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.39 175.15 7.96 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.0 pp -145.11 146.62 31.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.092 0.957 . . . . 0.0 110.254 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -113.01 159.32 35.07 Favored Pre-proline 0 CA--C 1.547 0.86 0 C-N-CA 124.675 1.19 . . . . 0.0 111.489 175.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -71.2 177.61 6.37 Favored 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.733 2.956 . . . . 0.0 112.513 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -109.43 -60.17 1.81 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.584 1.554 . . . . 0.0 111.91 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.38 1.872 . . . . 0.0 113.28 175.158 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.28 -170.12 38.61 Favored Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.881 1.229 . . . . 0.0 113.076 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -110.38 98.81 7.95 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.303 1.441 . . . . 0.0 110.76 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -152.03 -43.43 0.11 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -114.91 153.25 30.87 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.661 1.584 . . . . 0.0 111.098 175.358 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -109.6 170.76 7.86 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.038 1.335 . . . . 0.0 111.807 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.49 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.2 m-85 -72.63 130.23 40.1 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.525 0.73 . . . . 0.0 111.848 175.376 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.406 HD22 HD13 ' A' ' 62' ' ' LEU . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.532 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.509 HG11 ' NE ' ' A' ' 36' ' ' ARG . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.509 ' NE ' HG11 ' A' ' 31' ' ' VAL . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.532 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.644 HG21 HD22 ' A' ' 62' ' ' LEU . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.644 HD22 HG21 ' A' ' 52' ' ' VAL . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.98 178.25 6.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.2 tt -147.32 87.96 1.69 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.364 -0.835 . . . . 0.0 111.31 -175.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.97 159.61 85.0 Favored Pre-proline 0 CA--C 1.553 1.076 0 C-N-CA 124.319 1.048 . . . . 0.0 112.617 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -72.22 176.86 7.96 Favored 'Trans proline' 0 CA--C 1.543 0.951 0 C-N-CA 123.98 3.12 . . . . 0.0 112.537 174.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -139.43 120.41 14.54 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.204 1.402 . . . . 0.0 110.685 179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.026 1.73 . . . . 0.0 114.808 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.53 -161.59 40.83 Favored Glycine 0 CA--C 1.537 1.447 0 CA-C-N 119.11 0.868 . . . . 0.0 113.087 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 63.7 m-70 -127.81 41.35 3.52 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.15 1.78 . . . . 0.0 112.843 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.2 mmt -129.44 26.23 5.38 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.663 1.985 . . . . 0.0 113.01 -177.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.53 96.92 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 126.111 1.765 . . . . 0.0 112.304 174.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -97.83 -69.99 0.74 Allowed 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 126.556 1.943 . . . . 0.0 110.56 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.58 ' CE2' HD13 ' A' ' 62' ' ' LEU . 26.9 m-85 -83.65 114.36 21.5 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.986 0.914 . . . . 0.0 112.346 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.499 HG21 ' HB3' ' A' ' 7' ' ' PHE . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.493 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.493 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.522 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.522 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -56.74 4.26 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -168.89 81.66 0.14 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.491 1.516 . . . . 0.0 111.901 -177.031 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.74 158.64 82.4 Favored Pre-proline 0 CA--C 1.555 1.164 0 O-C-N 121.216 -0.927 . . . . 0.0 113.262 177.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.81 104.55 1.64 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.093 3.195 . . . . 0.0 112.297 175.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -91.76 -41.2 10.81 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 121.458 -0.776 . . . . 0.0 113.088 174.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 . . . . . 0 C--O 1.252 1.23 0 C-N-CA 125.091 1.356 . . . . 0.0 112.456 176.987 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 86.45 0.12 Allowed Glycine 0 N--CA 1.476 1.32 0 CA-C-N 120.12 1.327 . . . . 0.0 113.869 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -68.76 137.02 53.69 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.139 0.976 . . . . 0.0 112.334 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.5 mmt -108.45 101.72 10.87 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.194 1.797 . . . . 0.0 111.57 179.143 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -92.75 100.8 13.22 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.688 1.595 . . . . 0.0 111.881 175.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.47 -75.41 0.48 Allowed 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.609 1.163 . . . . 0.0 110.964 175.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.495 ' CE2' HD23 ' A' ' 62' ' ' LEU . 20.7 m-85 -82.87 114.78 21.41 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 118.999 0.818 . . . . 0.0 112.752 177.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.474 HD22 HD13 ' A' ' 62' ' ' LEU . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.476 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.476 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.495 HD23 ' CE2' ' A' ' 7' ' ' PHE . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.33 175.03 11.01 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.51 131.98 18.69 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.481 -0.762 . . . . 0.0 110.722 177.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -115.71 155.99 46.86 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 125.585 1.554 . . . . 0.0 111.438 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.56 -20.7 26.68 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.079 2.519 . . . . 0.0 113.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -73.01 -33.11 65.56 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.691 1.196 . . . . 0.0 113.328 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 C-N-CA 129.256 3.023 . . . . 0.0 115.889 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 119.661 -0.209 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.31 -166.76 26.97 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.015 1.293 . . . . 0.0 114.409 176.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.6 p-80 -119.18 173.12 7.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 126.78 2.032 . . . . 0.0 111.802 178.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.99 -77.47 0.43 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.965 1.706 . . . . 0.0 110.846 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mttp -79.44 110.17 14.5 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.106 1.363 . . . . 0.0 112.24 177.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -79.0 -68.6 0.64 Allowed 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.953 0.901 . . . . 0.0 110.225 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.464 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.1 m-85 -84.91 113.98 21.79 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 177.317 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 7' ' ' PHE . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.542 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.542 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.13 167.84 20.75 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 18.0 tp -149.21 134.46 18.3 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.5 1.12 . . . . 0.0 109.722 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -65.45 159.55 66.21 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 123.004 0.521 . . . . 0.0 111.708 175.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -70.97 171.51 15.64 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 123.113 2.542 . . . . 0.0 112.872 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -136.99 20.52 3.02 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 125.645 1.578 . . . . 0.0 113.867 -177.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.254 1.342 0 C-N-CA 124.861 1.265 . . . . 0.0 113.527 174.992 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.212 0 CA-C-O 120.48 0.181 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.07 -177.19 29.95 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.206 1.384 . . . . 0.0 113.3 -178.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.0 m80 -92.5 -65.03 1.03 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.839 1.255 . . . . 0.0 112.321 175.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -91.23 95.57 10.11 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.95 0.9 . . . . 0.0 110.961 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -66.81 158.34 30.68 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.389 0.614 . . . . 0.0 111.816 175.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -70.88 170.65 12.18 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.301 1.44 . . . . 0.0 112.58 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.477 ' CZ ' HD22 ' A' ' 62' ' ' LEU . 29.1 m-85 -70.93 113.34 7.88 Favored 'General case' 0 CA--C 1.54 0.589 0 O-C-N 121.217 -0.927 . . . . 0.0 112.56 175.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 7' ' ' PHE . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.426 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.426 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.506 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.545 HG11 HD12 ' A' ' 62' ' ' LEU . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.506 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.545 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.16 168.58 19.71 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.5 tp -148.8 110.08 4.4 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.558 0.743 . . . . 0.0 110.955 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -61.48 156.63 51.58 Favored Pre-proline 0 CA--C 1.553 1.07 0 C-N-CA 123.924 0.89 . . . . 0.0 112.355 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -69.39 99.93 0.74 Allowed 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.87 3.047 . . . . 0.0 111.638 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -74.96 -33.24 61.89 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 123.775 0.83 . . . . 0.0 112.598 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.252 1.222 0 C-N-CA 125.919 1.687 . . . . 0.0 113.806 175.17 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.635 0.255 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.38 71.56 1.28 Allowed Glycine 0 CA--C 1.535 1.335 0 C-N-CA 124.68 1.133 . . . . 0.0 114.595 176.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -90.16 -39.96 12.52 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -90.01 -64.43 1.14 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.543 1.137 . . . . 0.0 111.969 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mppt? -109.27 121.25 44.77 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.855 1.662 . . . . 0.0 110.741 175.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -115.93 -66.85 1.04 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.5 1.52 . . . . 0.0 109.231 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.519 ' CE2' HD23 ' A' ' 62' ' ' LEU . 24.7 m-85 -75.88 118.49 18.73 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.879 0.872 . . . . 0.0 112.593 176.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.475 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.528 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.528 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.519 HD23 ' CE2' ' A' ' 7' ' ' PHE . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.3 -52.69 6.69 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -164.52 130.47 2.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.794 1.638 . . . . 0.0 110.21 178.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -129.0 157.94 74.27 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 125.37 1.468 . . . . 0.0 111.92 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.99 166.68 28.34 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 123.493 2.795 . . . . 0.0 112.918 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -97.71 -27.49 14.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.88 1.272 . . . . 0.0 113.91 179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.196 0 C-N-CA 127.172 2.189 . . . . 0.0 114.816 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.728 0.299 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.56 149.98 18.58 Favored Glycine 0 CA--C 1.535 1.3 0 C-N-CA 125.285 1.421 . . . . 0.0 112.232 176.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -136.77 27.4 3.0 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.827 1.251 . . . . 0.0 113.268 -178.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 mtp -131.56 118.9 20.75 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.905 1.682 . . . . 0.0 111.571 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -132.73 155.53 48.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.555 1.942 . . . . 0.0 110.156 175.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -136.84 169.76 17.22 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.168 1.787 . . . . 0.0 111.051 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.405 ' HB3' HG21 ' A' ' 23' ' ' VAL . 27.7 m-85 -73.13 119.28 17.16 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 121.463 -0.773 . . . . 0.0 112.463 175.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 7' ' ' PHE . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.504 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.574 HG21 HD22 ' A' ' 62' ' ' LEU . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.504 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.574 HD22 HG21 ' A' ' 52' ' ' VAL . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.63 86.85 2.37 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -71.16 95.27 1.23 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 123.982 0.913 . . . . 0.0 110.592 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.67 155.28 30.88 Favored Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 124.886 1.274 . . . . 0.0 112.79 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -66.96 123.07 10.5 Favored 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 123.242 2.628 . . . . 0.0 111.445 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -129.31 93.09 3.49 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.597 1.559 . . . . 0.0 110.095 -179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 . . . . . 0 C--O 1.253 1.242 0 C-N-CA 125.066 1.346 . . . . 0.0 112.927 178.559 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 N-CA-C 110.569 -0.16 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.58 -171.0 54.98 Favored Glycine 0 CA--C 1.536 1.36 0 O-C-N 121.194 -0.941 . . . . 0.0 113.372 -176.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -146.57 20.01 1.33 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 125.28 1.432 . . . . 0.0 114.085 -175.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.83 10.12 40.15 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.148 1.379 . . . . 0.0 114.353 -174.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -127.31 146.1 50.56 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.935 1.694 . . . . 0.0 111.13 -176.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -142.0 -64.21 0.43 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.346 1.058 . . . . 0.0 111.011 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.46 ' CE2' HD23 ' A' ' 62' ' ' LEU . 18.4 m-85 -82.46 121.89 27.33 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.258 1.023 . . . . 0.0 112.057 176.305 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.453 HD22 HD13 ' A' ' 62' ' ' LEU . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.417 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.417 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.485 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.591 HG21 HD22 ' A' ' 62' ' ' LEU . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.485 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.591 HD22 HG21 ' A' ' 52' ' ' VAL . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.9 81.01 7.27 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tp -58.22 101.22 0.07 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.014 1.726 . . . . 0.0 111.405 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -84.95 165.4 37.27 Favored Pre-proline 0 CA--C 1.553 1.065 0 C-N-CA 123.933 0.893 . . . . 0.0 112.064 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -74.41 -38.03 2.17 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.722 2.281 . . . . 0.0 112.894 174.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -92.25 -48.19 6.82 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.234 1.014 . . . . 0.0 113.197 177.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 . . . . . 0 C--O 1.254 1.299 0 C-N-CA 125.935 1.694 . . . . 0.0 113.252 -179.503 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 121.07 175.18 15.1 Favored Glycine 0 CA--C 1.537 1.442 0 C-N-CA 125.513 1.53 . . . . 0.0 113.187 -172.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.45 148.4 24.47 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.999 1.719 . . . . 0.0 111.663 175.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.62 141.21 14.35 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.586 1.954 . . . . 0.0 109.508 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -129.58 161.71 29.91 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.047 1.739 . . . . 0.0 111.208 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 15.7 mp0 -80.43 -69.4 0.6 Allowed 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.49 0.716 . . . . 0.0 111.806 176.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.506 ' CE2' HD23 ' A' ' 62' ' ' LEU . 21.1 m-85 -93.34 118.02 30.78 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.109 1.363 . . . . 0.0 112.01 179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.536 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.557 HG21 HD22 ' A' ' 62' ' ' LEU . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.536 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 52' ' ' VAL . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.15 165.35 23.41 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.44 120.85 7.9 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 111.44 -177.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.25 159.57 85.05 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 123.605 0.762 . . . . 0.0 111.854 176.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.93 -38.98 3.56 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.892 2.395 . . . . 0.0 113.348 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.99 -44.27 22.69 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.988 0.915 . . . . 0.0 112.861 175.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.238 0 C-N-CA 127.221 2.208 . . . . 0.0 115.033 -171.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -110.63 -91.39 2.08 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 120.817 -1.177 . . . . 0.0 112.218 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -155.6 46.74 0.49 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.375 1.47 . . . . 0.0 112.853 -175.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.4 129.52 40.56 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 121.252 -0.905 . . . . 0.0 111.863 175.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.4 tptt -143.11 94.69 2.66 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.193 1.397 . . . . 0.0 111.012 178.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -107.09 174.44 5.89 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.375 1.47 . . . . 0.0 112.343 178.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.48 ' CE2' HD13 ' A' ' 62' ' ' LEU . 17.0 m-85 -79.23 117.67 20.45 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.072 0.949 . . . . 0.0 112.619 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.602 HG11 HD12 ' A' ' 62' ' ' LEU . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.602 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.94 177.81 7.43 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -149.57 114.78 5.46 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.587 0.755 . . . . 0.0 111.03 -177.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -102.65 158.37 31.9 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 125.305 1.442 . . . . 0.0 111.861 178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.61 168.13 22.26 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 123.333 2.688 . . . . 0.0 112.743 176.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -121.88 91.29 3.48 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.53 1.532 . . . . 0.0 110.872 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 . . . . . 0 N--CA 1.486 1.332 0 C-N-CA 128.913 2.885 . . . . 0.0 117.611 177.878 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 120.957 0.408 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.62 51.37 0.14 Allowed Glycine 0 CA--C 1.533 1.193 0 C-N-CA 123.989 0.804 . . . . 0.0 113.745 -175.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.2 m-70 -129.28 163.91 24.64 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 125.674 1.589 . . . . 0.0 111.739 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -99.53 95.72 7.18 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.936 1.294 . . . . 0.0 111.207 177.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 tptt -141.45 15.11 2.19 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.059 1.344 . . . . 0.0 113.726 176.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -105.97 168.67 8.97 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.683 1.193 . . . . 0.0 112.262 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.471 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.1 m-85 -74.26 131.99 41.7 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.625 -0.672 . . . . 0.0 112.532 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.546 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.581 HG21 HD22 ' A' ' 62' ' ' LEU . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.546 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.581 HD22 HG21 ' A' ' 52' ' ' VAL . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.74 172.85 6.91 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.0 tp -142.4 129.37 20.71 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.711 0.804 . . . . 0.0 111.537 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.88 159.64 74.38 Favored Pre-proline 0 CA--C 1.552 1.039 0 C-N-CA 124.466 1.106 . . . . 0.0 112.677 175.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.04 85.61 0.99 Allowed 'Trans proline' 0 CA--C 1.544 1.014 0 C-N-CA 123.957 3.104 . . . . 0.0 111.922 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -125.66 -57.3 1.46 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.108 1.763 . . . . 0.0 112.573 175.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 . . . . . 0 C--O 1.253 1.275 0 C-N-CA 126.346 1.858 . . . . 0.0 111.832 -179.499 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 119.474 -0.298 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 177.89 -45.35 0.1 OUTLIER Glycine 0 N--CA 1.474 1.233 0 C-N-CA 124.059 0.838 . . . . 0.0 113.487 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -67.69 166.32 15.4 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.13 0.972 . . . . 0.0 111.584 174.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.8 ttm -77.16 119.11 20.39 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.161 0.984 . . . . 0.0 111.035 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -125.85 155.53 41.03 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 126.569 1.948 . . . . 0.0 111.249 179.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -91.62 170.44 9.92 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.942 1.297 . . . . 0.0 113.512 174.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.474 ' HB3' HG21 ' A' ' 23' ' ' VAL . 24.2 m-85 -80.49 114.81 19.65 Favored 'General case' 0 CA--C 1.536 0.44 0 O-C-N 121.168 -0.957 . . . . 0.0 112.169 175.281 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 7' ' ' PHE . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.441 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.441 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.511 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 62' ' ' LEU . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.511 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 52' ' ' VAL . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -72.62 171.81 11.79 Favored 'General case' 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -140.45 143.94 35.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.94 0.896 . . . . 0.0 110.624 -179.48 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.51 159.2 85.75 Favored Pre-proline 0 CA--C 1.553 1.068 0 C-N-CA 123.396 0.679 . . . . 0.0 111.465 175.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.36 -9.91 26.93 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.043 2.495 . . . . 0.0 113.896 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -129.34 23.21 5.55 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 127.013 2.125 . . . . 0.0 113.435 -175.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 128.639 2.776 . . . . 0.0 114.853 -174.526 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.281 0 N-CA-C 112.092 0.404 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.41 168.94 41.65 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.852 1.215 . . . . 0.0 113.375 -176.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -113.39 86.95 2.49 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.761 1.624 . . . . 0.0 110.664 -175.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 30.2 ttm -140.98 74.38 1.46 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.986 1.314 . . . . 0.0 111.384 -178.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.54 70.42 0.73 Allowed 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.669 1.588 . . . . 0.0 112.24 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -68.17 -69.91 0.29 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 124.598 1.159 . . . . 0.0 112.346 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -89.59 123.21 33.45 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.073 0.949 . . . . 0.0 111.91 177.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.432 HD22 HD13 ' A' ' 62' ' ' LEU . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.444 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.444 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.549 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.635 HG21 HD22 ' A' ' 62' ' ' LEU . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.635 HD22 HG21 ' A' ' 52' ' ' VAL . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.83 81.38 8.57 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.92 109.15 0.77 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.189 1.796 . . . . 0.0 111.486 -178.718 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.24 159.26 81.35 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 124.35 1.06 . . . . 0.0 113.065 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.32 177.86 6.79 Favored 'Trans proline' 0 CA--C 1.545 1.043 0 C-N-CA 124.015 3.143 . . . . 0.0 112.734 174.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.6 74.0 1.53 Allowed 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.168 1.787 . . . . 0.0 111.581 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.252 1.215 0 C-N-CA 124.644 1.178 . . . . 0.0 113.851 -178.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.26 174.26 48.81 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.437 1.018 . . . . 0.0 112.86 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -117.09 47.12 1.55 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.508 1.123 . . . . 0.0 112.952 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mtt -73.71 156.28 38.07 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.62 1.168 . . . . 0.0 111.294 175.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 45.8 mttt -137.74 95.72 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.72 1.608 . . . . 0.0 111.6 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.89 169.28 18.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.394 1.078 . . . . 0.0 112.514 174.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.452 ' CE2' HD23 ' A' ' 62' ' ' LEU . 14.5 m-85 -76.73 131.27 38.66 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.885 0.874 . . . . 0.0 112.364 175.024 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.457 HD22 HD13 ' A' ' 62' ' ' LEU . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.477 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.477 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.541 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.656 HG21 HD22 ' A' ' 62' ' ' LEU . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.541 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.656 HD22 HG21 ' A' ' 52' ' ' VAL . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 176.25 6.65 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -149.2 119.75 7.44 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.89 0.876 . . . . 0.0 110.411 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.9 160.04 72.01 Favored Pre-proline 0 CA--C 1.554 1.103 0 C-N-CA 123.104 0.562 . . . . 0.0 111.567 176.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.68 169.91 17.7 Favored 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 122.898 2.399 . . . . 0.0 112.314 175.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.97 125.47 49.49 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.577 1.551 . . . . 0.0 110.326 177.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 C--O 1.254 1.318 0 C-N-CA 125.535 1.534 . . . . 0.0 113.887 175.298 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 112.203 0.445 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -84.07 1.14 Allowed Glycine 0 CA--C 1.534 1.246 0 O-C-N 120.336 -1.478 . . . . 0.0 112.873 -177.161 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -147.72 89.63 1.78 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.139 1.376 . . . . 0.0 111.525 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 10.4 ttm -152.96 -52.78 0.11 Allowed 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.12 1.155 . . . . 0.0 114.12 177.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -137.73 72.73 1.42 Allowed 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 126.246 1.818 . . . . 0.0 110.244 175.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -119.65 168.22 11.25 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.264 1.426 . . . . 0.0 111.575 177.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.472 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.7 m-85 -74.19 126.86 31.52 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.01 0.924 . . . . 0.0 112.799 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.48 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.555 HG21 HD22 ' A' ' 62' ' ' LEU . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.555 HD22 HG21 ' A' ' 52' ' ' VAL . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.12 173.35 12.67 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.56 121.86 6.73 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.741 1.216 . . . . 0.0 111.276 -177.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.88 158.11 84.5 Favored Pre-proline 0 CA--C 1.551 1.012 0 C-N-CA 123.584 0.753 . . . . 0.0 111.555 174.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.48 164.94 32.38 Favored 'Trans proline' 0 CA--C 1.542 0.906 0 C-N-CA 123.178 2.586 . . . . 0.0 112.461 176.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.82 117.06 8.98 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.948 1.699 . . . . 0.0 110.326 -177.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 C-N-CA 128.57 2.748 . . . . 0.0 116.541 -177.179 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.763 -0.088 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.64 67.77 0.05 OUTLIER Glycine 0 CA--C 1.533 1.199 0 C-N-CA 123.527 0.584 . . . . 0.0 114.432 179.399 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.27 -23.99 19.12 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 114.288 1.218 . . . . 0.0 114.288 175.024 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 mtt -120.05 82.81 1.95 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.685 1.594 . . . . 0.0 111.233 177.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.48 113.02 16.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.589 0.756 . . . . 0.0 109.32 174.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.06 -72.26 0.69 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.537 1.135 . . . . 0.0 111.06 176.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.4 m-85 -83.9 133.45 34.72 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.998 0.919 . . . . 0.0 112.377 175.326 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.452 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.521 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.605 HG21 HD22 ' A' ' 62' ' ' LEU . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.605 HD22 HG21 ' A' ' 52' ' ' VAL . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.25 169.68 13.25 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.9 116.43 5.07 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.636 0.774 . . . . 0.0 111.745 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.03 158.1 88.26 Favored Pre-proline 0 CA--C 1.554 1.098 0 C-N-CA 123.568 0.747 . . . . 0.0 112.337 175.109 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -70.0 110.93 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.966 3.11 . . . . 0.0 111.764 176.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -144.61 101.41 3.67 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.193 1.397 . . . . 0.0 110.905 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.25 0 C-N-CA 125.374 1.47 . . . . 0.0 114.298 177.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -58.57 158.69 17.96 Favored Glycine 0 CA--C 1.537 1.461 0 C-N-CA 124.372 0.987 . . . . 0.0 114.706 178.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -124.97 -34.25 2.81 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 125.829 1.652 . . . . 0.0 113.799 -175.653 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -72.62 -44.17 62.31 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.248 1.019 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mmtp -87.39 165.36 15.64 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.436 1.495 . . . . 0.0 110.834 174.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -131.09 -76.02 0.52 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.063 1.345 . . . . 0.0 110.702 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -83.91 117.81 23.58 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 123.782 0.833 . . . . 0.0 112.636 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.491 HD22 HD13 ' A' ' 62' ' ' LEU . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.523 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.625 HG21 HD22 ' A' ' 62' ' ' LEU . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.523 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.4 ' O ' HG12 ' A' ' 60' ' ' VAL . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.625 HD22 HG21 ' A' ' 52' ' ' VAL . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.23 -46.42 12.7 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -159.65 -179.14 7.62 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.926 1.691 . . . . 0.0 111.529 178.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -141.12 160.53 57.49 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 125.386 1.474 . . . . 0.0 112.483 175.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -73.45 -32.59 7.81 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 123.626 2.884 . . . . 0.0 113.947 -177.501 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -128.6 -36.82 1.83 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 126.384 1.874 . . . . 0.0 112.168 -178.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.254 1.321 0 C-N-CA 127.913 2.485 . . . . 0.0 114.45 176.812 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 112.208 0.447 . . . . 0.0 112.208 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.95 -155.97 9.42 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 124.796 1.189 . . . . 0.0 113.298 174.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -102.08 157.05 17.15 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.246 1.418 . . . . 0.0 112.211 176.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -93.51 132.93 37.33 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.229 1.412 . . . . 0.0 111.377 175.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mtmt -143.33 85.72 1.87 Allowed 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 126.842 2.057 . . . . 0.0 110.378 175.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -92.94 169.42 10.45 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.132 0.973 . . . . 0.0 111.396 174.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.444 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.9 m-85 -77.15 122.63 25.28 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.387 -0.821 . . . . 0.0 112.584 176.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.458 HD22 HD13 ' A' ' 62' ' ' LEU . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.47 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.55 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.649 HG21 HD22 ' A' ' 62' ' ' LEU . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.55 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.649 HD22 HG21 ' A' ' 52' ' ' VAL . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.84 176.06 9.93 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 39.0 tp -148.58 131.19 15.88 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.551 1.14 . . . . 0.0 111.143 178.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -92.79 159.05 36.91 Favored Pre-proline 0 CA--C 1.554 1.115 0 C-N-CA 125.082 1.353 . . . . 0.0 112.804 175.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.04 103.57 1.51 Allowed 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 124.304 3.336 . . . . 0.0 112.306 179.091 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.4 177.19 8.17 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.367 1.867 . . . . 0.0 112.265 178.044 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 127.868 2.467 . . . . 0.0 113.697 -179.77 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 CA-C-O 120.574 0.226 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 138.42 -66.0 0.54 Allowed Glycine 0 N--CA 1.473 1.148 0 C-N-CA 125.373 1.463 . . . . 0.0 112.881 178.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -127.49 33.88 4.77 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 125.464 1.506 . . . . 0.0 113.114 -178.193 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 tpt -102.51 139.54 37.96 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.606 1.563 . . . . 0.0 110.707 177.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.5 mmtm -121.61 90.81 3.38 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 126.135 1.774 . . . . 0.0 109.474 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -127.42 165.22 20.2 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.322 1.449 . . . . 0.0 112.366 178.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.568 ' CE2' HD23 ' A' ' 62' ' ' LEU . 19.4 m-85 -84.27 117.63 23.66 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.977 1.311 . . . . 0.0 111.779 175.335 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.501 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.501 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.619 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.405 ' HB ' ' HB3' ' A' ' 50' ' ' ALA . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 59' ' ' SER . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.401 ' O ' HG12 ' A' ' 60' ' ' VAL . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.425 ' HB2' ' HB1' ' A' ' 56' ' ' ALA . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.568 HD23 ' CE2' ' A' ' 7' ' ' PHE . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.8 80.56 5.15 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 tt -61.28 102.17 0.21 Allowed 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.764 1.626 . . . . 0.0 111.127 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.02 157.3 89.57 Favored Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 124.264 1.026 . . . . 0.0 112.142 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.05 -32.59 21.19 Favored 'Trans proline' 0 CA--C 1.54 0.79 0 C-N-CA 122.541 2.16 . . . . 0.0 112.982 -179.497 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.88 118.37 12.2 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.507 1.923 . . . . 0.0 110.147 -177.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.223 0 C-N-CA 125.821 1.648 . . . . 0.0 112.817 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.9 m-85 . . . . . 0 CA--C 1.538 0.483 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.531 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.637 HG11 HD12 ' A' ' 62' ' ' LEU . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.531 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.637 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.49 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.2 m-85 . . . . . 0 CA--C 1.539 0.541 0 CA-C-O 121.298 0.57 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.406 HD22 HD13 ' A' ' 62' ' ' LEU . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.532 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.509 HG11 ' NE ' ' A' ' 36' ' ' ARG . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.509 ' NE ' HG11 ' A' ' 31' ' ' VAL . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.532 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.644 HG21 HD22 ' A' ' 62' ' ' LEU . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.644 HD22 HG21 ' A' ' 52' ' ' VAL . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.58 ' CE2' HD13 ' A' ' 62' ' ' LEU . 26.9 m-85 . . . . . 0 CA--C 1.536 0.432 0 CA-C-O 121.449 0.642 . . . . 0.0 112.346 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.499 HG21 ' HB3' ' A' ' 7' ' ' PHE . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.493 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.493 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.522 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.522 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.495 ' CE2' HD23 ' A' ' 62' ' ' LEU . 20.7 m-85 . . . . . 0 CA--C 1.541 0.626 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.474 HD22 HD13 ' A' ' 62' ' ' LEU . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.476 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.476 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.495 HD23 ' CE2' ' A' ' 7' ' ' PHE . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.464 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.1 m-85 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 7' ' ' PHE . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.542 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.542 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.477 ' CZ ' HD22 ' A' ' 62' ' ' LEU . 29.1 m-85 . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 7' ' ' PHE . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.426 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.426 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.506 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.545 HG11 HD12 ' A' ' 62' ' ' LEU . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.506 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.545 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.519 ' CE2' HD23 ' A' ' 62' ' ' LEU . 24.7 m-85 . . . . . 0 CA--C 1.539 0.551 0 CA-C-O 121.357 0.598 . . . . 0.0 112.593 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.475 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.528 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.528 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.519 HD23 ' CE2' ' A' ' 7' ' ' PHE . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.405 ' HB3' HG21 ' A' ' 23' ' ' VAL . 27.7 m-85 . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 7' ' ' PHE . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.504 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.574 HG21 HD22 ' A' ' 62' ' ' LEU . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.504 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.574 HD22 HG21 ' A' ' 52' ' ' VAL . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.46 ' CE2' HD23 ' A' ' 62' ' ' LEU . 18.4 m-85 . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 121.377 0.608 . . . . 0.0 112.057 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.453 HD22 HD13 ' A' ' 62' ' ' LEU . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.417 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.417 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.485 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.591 HG21 HD22 ' A' ' 62' ' ' LEU . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.485 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.591 HD22 HG21 ' A' ' 52' ' ' VAL . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.506 ' CE2' HD23 ' A' ' 62' ' ' LEU . 21.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 CA-C-O 121.11 0.481 . . . . 0.0 112.01 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.536 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.557 HG21 HD22 ' A' ' 62' ' ' LEU . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.536 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 52' ' ' VAL . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.48 ' CE2' HD13 ' A' ' 62' ' ' LEU . 17.0 m-85 . . . . . 0 CA--C 1.542 0.643 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.602 HG11 HD12 ' A' ' 62' ' ' LEU . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.602 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.471 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.1 m-85 . . . . . 0 CA--C 1.538 0.501 0 CA-C-O 121.396 0.617 . . . . 0.0 112.532 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.546 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.581 HG21 HD22 ' A' ' 62' ' ' LEU . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.546 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.581 HD22 HG21 ' A' ' 52' ' ' VAL . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.474 ' HB3' HG21 ' A' ' 23' ' ' VAL . 24.2 m-85 . . . . . 0 CA--C 1.536 0.44 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 7' ' ' PHE . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.441 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.441 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.511 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 62' ' ' LEU . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.511 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 52' ' ' VAL . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 . . . . . 0 CA--C 1.538 0.511 0 CA-C-O 121.054 0.454 . . . . 0.0 111.91 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.432 HD22 HD13 ' A' ' 62' ' ' LEU . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.444 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.444 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.549 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.635 HG21 HD22 ' A' ' 62' ' ' LEU . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.635 HD22 HG21 ' A' ' 52' ' ' VAL . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.452 ' CE2' HD23 ' A' ' 62' ' ' LEU . 14.5 m-85 . . . . . 0 CA--C 1.541 0.603 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.457 HD22 HD13 ' A' ' 62' ' ' LEU . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.477 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.477 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.541 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.656 HG21 HD22 ' A' ' 62' ' ' LEU . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.541 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.656 HD22 HG21 ' A' ' 52' ' ' VAL . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.472 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.7 m-85 . . . . . 0 CA--C 1.54 0.574 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.48 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.555 HG21 HD22 ' A' ' 62' ' ' LEU . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.555 HD22 HG21 ' A' ' 52' ' ' VAL . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.4 m-85 . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.236 0.541 . . . . 0.0 112.377 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.452 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.521 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.605 HG21 HD22 ' A' ' 62' ' ' LEU . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.605 HD22 HG21 ' A' ' 52' ' ' VAL . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 CA--C 1.54 0.592 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.491 HD22 HD13 ' A' ' 62' ' ' LEU . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.523 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.625 HG21 HD22 ' A' ' 62' ' ' LEU . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.523 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.4 ' O ' HG12 ' A' ' 60' ' ' VAL . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.625 HD22 HG21 ' A' ' 52' ' ' VAL . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.444 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.9 m-85 . . . . . 0 CA--C 1.539 0.528 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.458 HD22 HD13 ' A' ' 62' ' ' LEU . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.47 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.55 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.649 HG21 HD22 ' A' ' 62' ' ' LEU . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.55 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.649 HD22 HG21 ' A' ' 52' ' ' VAL . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.568 ' CE2' HD23 ' A' ' 62' ' ' LEU . 19.4 m-85 . . . . . 0 CA--C 1.539 0.554 0 CA-C-O 120.878 0.371 . . . . 0.0 111.779 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.501 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.501 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.619 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.405 ' HB ' ' HB3' ' A' ' 50' ' ' ALA . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 59' ' ' SER . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.401 ' O ' HG12 ' A' ' 60' ' ' VAL . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.425 ' HB2' ' HB1' ' A' ' 56' ' ' ALA . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.568 HD23 ' CE2' ' A' ' 7' ' ' PHE . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 120.709 0.29 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -92.66 -151.58 27.9 Favored Glycine 0 CA--C 1.535 1.315 0 C-N-CA 125.689 1.614 . . . . 0.0 112.675 175.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -149.97 -56.08 0.17 Allowed 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.35 1.06 . . . . 0.0 112.992 177.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.5 mtt -149.12 -52.17 0.16 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 126.126 1.771 . . . . 0.0 112.483 177.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -82.4 154.21 25.32 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.65 0.78 . . . . 0.0 111.435 175.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -122.26 -66.67 1.01 Allowed 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.692 1.597 . . . . 0.0 110.24 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.544 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.9 m-85 -84.46 116.27 23.0 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.933 0.893 . . . . 0.0 112.311 177.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.55 158.01 51.94 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 125.125 1.37 . . . . 0.0 113.216 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.64 133.12 26.84 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 123.375 2.716 . . . . 0.0 111.73 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -11.08 60.73 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.198 1.38 . . . . 0.0 114.095 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -58.34 129.37 41.7 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 118.629 1.214 . . . . 0.0 110.091 175.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.2 mttt -69.56 111.86 5.67 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 124.127 0.971 . . . . 0.0 110.323 176.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.7 m -127.04 153.7 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 124.492 1.117 . . . . 0.0 111.123 -178.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -96.49 128.39 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.039 0.936 . . . . 0.0 109.974 174.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.7 tp -143.08 101.48 5.28 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 123.545 0.738 . . . . 0.0 110.505 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.0 161.89 44.26 Favored 'Trans proline' 0 CA--C 1.549 1.271 0 C-N-CA 122.68 2.253 . . . . 0.0 112.795 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -74.91 -8.6 23.45 Favored 'Cis proline' 0 CA--C 1.542 0.912 0 N-CA-C 114.35 0.865 . . . . 0.0 114.35 -0.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -56.67 -43.13 80.1 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 125.199 1.399 . . . . 0.0 112.504 176.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.93 -23.41 20.61 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 126.366 1.936 . . . . 0.0 113.802 176.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.3 t -145.38 139.86 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.606 1.562 . . . . 0.0 109.468 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.45 168.84 31.58 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.972 1.748 . . . . 0.0 111.325 175.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.7 m -129.87 135.11 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 124.286 1.034 . . . . 0.0 109.519 174.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.5 t -72.8 141.02 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -102.92 -45.13 5.06 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.723 1.209 . . . . 0.0 112.658 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 173.69 174.27 40.52 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.511 1.053 . . . . 0.0 113.291 177.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.7 mp -83.86 104.54 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 C-N-CA 124.468 1.107 . . . . 0.0 108.89 178.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.56 115.68 30.71 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.347 1.059 . . . . 0.0 109.712 175.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -81.95 115.87 21.31 Favored 'General case' 0 CA--C 1.542 0.653 0 O-C-N 121.351 -0.843 . . . . 0.0 112.13 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -94.92 139.16 31.71 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.737 1.615 . . . . 0.0 111.69 175.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.6 m -90.89 100.18 13.08 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.426 1.89 . . . . 0.0 111.353 176.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.6 t -139.54 147.32 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 125.544 1.537 . . . . 0.0 109.677 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.8 t 56.47 25.44 9.68 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 120.649 -1.282 . . . . 0.0 113.733 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.29 15.37 67.77 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.002 1.287 . . . . 0.0 114.984 -174.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -130.8 135.06 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.22 1.808 . . . . 0.0 111.049 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.6 t -82.97 119.98 25.13 Favored 'General case' 0 C--O 1.235 0.338 0 O-C-N 121.383 -0.823 . . . . 0.0 109.121 175.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -119.05 134.11 55.4 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 123.895 0.878 . . . . 0.0 110.286 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.23 136.52 44.66 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 123.682 0.793 . . . . 0.0 111.629 176.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -138.56 126.13 22.0 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 125.361 1.465 . . . . 0.0 111.078 179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.531 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.3 m-85 -65.63 111.18 3.04 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -70.55 102.47 2.25 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 174.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.77 150.31 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 121.351 -0.843 . . . . 0.0 109.829 175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -135.21 136.01 41.43 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.545 1.138 . . . . 0.0 110.286 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -120.57 144.91 39.61 Favored Pre-proline 0 CA--C 1.54 0.565 0 C-N-CA 124.723 1.209 . . . . 0.0 110.792 -176.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -68.95 161.26 46.47 Favored 'Trans proline' 0 CA--C 1.54 0.808 0 C-N-CA 122.575 2.184 . . . . 0.0 112.398 178.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.23 -16.23 24.23 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 125.42 1.486 . . . . 0.0 115.427 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -151.49 -174.77 4.94 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 125.872 1.669 . . . . 0.0 111.333 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -110.6 6.43 21.81 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 125.747 1.619 . . . . 0.0 113.33 175.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 38.4 m -52.25 141.75 18.39 Favored 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.538 1.135 . . . . 0.0 110.906 175.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.66 144.27 37.56 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 125.766 1.626 . . . . 0.0 109.672 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.52 117.61 29.47 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 124.322 1.049 . . . . 0.0 109.022 177.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -80.82 98.87 8.0 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.311 0.644 . . . . 0.0 110.761 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.637 HG11 HD12 ' A' ' 62' ' ' LEU . 85.3 t -88.81 127.3 56.58 Favored Pre-proline 0 N--CA 1.476 0.864 0 CA-C-O 118.56 -0.733 . . . . 0.0 110.968 -177.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -66.12 134.47 36.85 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 123.354 2.702 . . . . 0.0 112.326 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.531 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.7 m -71.42 -23.63 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 113.991 1.108 . . . . 0.0 113.991 175.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -71.73 -40.09 69.64 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 124.055 0.942 . . . . 0.0 112.905 178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.35 70.79 33.08 Favored Pre-proline 0 CA--C 1.546 0.79 0 C-N-CA 124.704 1.201 . . . . 0.0 111.631 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -70.22 -30.28 20.39 Favored 'Trans proline' 0 CA--C 1.536 0.606 0 C-N-CA 122.132 1.888 . . . . 0.0 112.127 -177.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -75.26 -24.24 57.58 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.861 0.865 . . . . 0.0 113.097 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.8 t -60.61 -41.86 95.64 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 124.995 1.318 . . . . 0.0 112.516 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 p -68.41 -16.58 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.628 0.771 . . . . 0.0 112.979 174.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.31 16.83 26.26 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 125.628 1.585 . . . . 0.0 114.767 -176.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.637 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.51 125.93 29.06 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 118.858 1.329 . . . . 0.0 109.996 176.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -130.99 157.7 42.27 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 125.664 1.586 . . . . 0.0 111.407 175.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 83.0 mttt -75.71 131.57 39.95 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.452 0.701 . . . . 0.0 109.505 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.39 175.15 7.96 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 121.336 0.589 . . . . 0.0 109.95 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.0 pp -145.11 146.62 31.89 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.092 0.957 . . . . 0.0 110.254 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -113.01 159.32 35.07 Favored Pre-proline 0 CA--C 1.547 0.86 0 C-N-CA 124.675 1.19 . . . . 0.0 111.489 175.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -71.2 177.61 6.37 Favored 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.733 2.956 . . . . 0.0 112.513 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -109.43 -60.17 1.81 Allowed 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 125.584 1.554 . . . . 0.0 111.91 -178.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.38 1.872 . . . . 0.0 113.28 175.158 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.28 -170.12 38.61 Favored Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.881 1.229 . . . . 0.0 113.076 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -110.38 98.81 7.95 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 125.303 1.441 . . . . 0.0 110.76 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -152.03 -43.43 0.11 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -114.91 153.25 30.87 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.661 1.584 . . . . 0.0 111.098 175.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -109.6 170.76 7.86 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 125.038 1.335 . . . . 0.0 111.807 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.49 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.2 m-85 -72.63 130.23 40.1 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.525 0.73 . . . . 0.0 111.848 175.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.6 mtt180 -100.23 157.92 32.93 Favored Pre-proline 0 N--CA 1.477 0.898 0 C-N-CA 126.392 1.877 . . . . 0.0 112.255 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.8 134.99 29.23 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.895 2.397 . . . . 0.0 111.511 178.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.93 -7.01 76.64 Favored Glycine 0 CA--C 1.534 1.228 0 C-N-CA 125.412 1.482 . . . . 0.0 113.924 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -62.95 129.28 39.73 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 118.328 1.064 . . . . 0.0 110.17 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.1 mttm -70.21 111.24 5.69 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 123.86 0.864 . . . . 0.0 109.985 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.93 159.87 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 125.042 1.337 . . . . 0.0 111.14 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -101.8 131.56 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.258 1.023 . . . . 0.0 109.333 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.406 HD22 HD13 ' A' ' 62' ' ' LEU . 8.8 tp -146.64 101.02 4.0 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.282 1.033 . . . . 0.0 110.311 175.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.67 160.23 50.5 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 122.33 2.02 . . . . 0.0 112.646 177.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -76.8 -8.43 29.56 Favored 'Cis proline' 0 CA--C 1.545 1.051 0 N-CA-C 113.888 0.688 . . . . 0.0 113.888 1.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -57.36 -43.6 83.66 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.071 1.348 . . . . 0.0 112.468 176.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.74 -22.37 28.43 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.536 2.017 . . . . 0.0 113.831 175.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.34 140.37 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 125.991 1.717 . . . . 0.0 108.979 175.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.54 169.26 31.06 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.813 1.673 . . . . 0.0 111.66 175.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.36 132.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 C-N-CA 124.081 0.952 . . . . 0.0 110.106 175.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.6 t -70.33 143.02 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.119 0.568 . . . . 0.0 109.774 176.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.49 -39.5 5.39 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.939 1.296 . . . . 0.0 112.962 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.64 -178.95 44.46 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 124.619 1.104 . . . . 0.0 113.135 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.532 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -94.16 115.5 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.577 1.551 . . . . 0.0 109.79 177.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 115.79 30.63 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.932 1.293 . . . . 0.0 110.124 174.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -79.72 112.8 17.34 Favored 'General case' 0 CA--C 1.535 0.386 0 O-C-N 121.691 -0.63 . . . . 0.0 109.572 175.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.24 179.67 6.06 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 124.877 1.271 . . . . 0.0 111.686 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.7 t -116.11 132.5 56.64 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 126.026 1.73 . . . . 0.0 111.363 177.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.509 HG11 ' NE ' ' A' ' 36' ' ' ARG . 3.3 p -155.12 120.56 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 126.414 1.886 . . . . 0.0 110.992 178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.2 t 54.63 30.76 13.86 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 120.737 -1.227 . . . . 0.0 114.216 176.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 75.75 10.33 84.89 Favored Glycine 0 CA--C 1.539 1.575 0 O-C-N 120.567 -1.333 . . . . 0.0 114.872 -174.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 t -109.55 149.83 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 127.256 2.223 . . . . 0.0 110.119 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.21 120.13 40.78 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 125.334 1.453 . . . . 0.0 110.147 175.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.509 ' NE ' HG11 ' A' ' 31' ' ' VAL . 24.7 mtm180 -119.31 134.29 55.29 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.421 1.088 . . . . 0.0 109.506 176.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.532 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.31 142.68 43.21 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.546 0.738 . . . . 0.0 111.259 175.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -140.84 128.25 21.22 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.383 1.473 . . . . 0.0 111.39 179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -72.43 116.74 13.24 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 122.832 0.453 . . . . 0.0 110.092 175.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.2 mt-30 -74.56 103.35 4.84 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.738 1.215 . . . . 0.0 109.434 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.2 t -95.06 109.63 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 O-C-N 120.901 -1.124 . . . . 0.0 109.284 176.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -95.92 138.9 32.9 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.416 1.086 . . . . 0.0 110.303 174.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -115.42 146.61 36.92 Favored Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 124.316 1.047 . . . . 0.0 111.004 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.23 160.05 51.37 Favored 'Trans proline' 0 CA--C 1.542 0.92 0 C-N-CA 122.426 2.084 . . . . 0.0 112.322 177.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.19 -14.61 43.77 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.482 1.515 . . . . 0.0 115.543 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 12.7 p -154.95 179.63 8.94 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 126.415 1.886 . . . . 0.0 111.939 179.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.2 mmt180 -100.19 8.42 43.83 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 126.236 1.815 . . . . 0.0 112.994 175.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 m -53.8 129.32 33.12 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.292 1.037 . . . . 0.0 110.329 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -123.82 140.89 52.54 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.245 1.018 . . . . 0.0 109.308 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.51 131.89 56.23 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 124.26 1.024 . . . . 0.0 109.406 176.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -101.21 100.82 11.41 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.499 1.12 . . . . 0.0 109.986 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.644 HG21 HD22 ' A' ' 62' ' ' LEU . 93.6 t -88.64 126.95 58.21 Favored Pre-proline 0 N--CA 1.478 0.929 0 C-N-CA 123.64 0.776 . . . . 0.0 110.887 -176.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -65.0 127.78 19.25 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.261 2.64 . . . . 0.0 111.794 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 30.2 m -63.61 -23.88 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 176.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -72.89 -46.43 52.79 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.247 1.019 . . . . 0.0 112.267 -178.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.78 70.64 64.89 Favored Pre-proline 0 CA--C 1.545 0.777 0 C-N-CA 124.787 1.235 . . . . 0.0 111.067 178.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.53 -30.57 18.51 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.032 1.821 . . . . 0.0 111.69 -176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -72.79 -24.71 60.96 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.288 1.035 . . . . 0.0 113.515 175.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.5 m -62.07 -35.48 78.78 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 119.683 1.129 . . . . 0.0 113.399 -179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.0 m -75.01 -11.46 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 123.628 0.771 . . . . 0.0 112.908 175.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.3 4.17 59.8 Favored Glycine 0 CA--C 1.538 1.523 0 C-N-CA 126.267 1.889 . . . . 0.0 115.159 -174.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.644 HD22 HG21 ' A' ' 52' ' ' VAL . 7.2 tp -73.23 124.04 24.87 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.333 1.566 . . . . 0.0 110.764 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -146.8 162.0 39.5 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.434 1.493 . . . . 0.0 111.549 175.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.4 mtmt -62.76 133.09 54.26 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 123.664 0.785 . . . . 0.0 110.97 175.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.98 178.25 6.42 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.13 0.972 . . . . 0.0 110.288 175.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.2 tt -147.32 87.96 1.69 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.364 -0.835 . . . . 0.0 111.31 -175.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.97 159.61 85.0 Favored Pre-proline 0 CA--C 1.553 1.076 0 C-N-CA 124.319 1.048 . . . . 0.0 112.617 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -72.22 176.86 7.96 Favored 'Trans proline' 0 CA--C 1.543 0.951 0 C-N-CA 123.98 3.12 . . . . 0.0 112.537 174.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -139.43 120.41 14.54 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.204 1.402 . . . . 0.0 110.685 179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.27 0 C-N-CA 126.026 1.73 . . . . 0.0 114.808 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 112.474 0.546 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.53 -161.59 40.83 Favored Glycine 0 CA--C 1.537 1.447 0 CA-C-N 119.11 0.868 . . . . 0.0 113.087 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 63.7 m-70 -127.81 41.35 3.52 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.15 1.78 . . . . 0.0 112.843 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.2 mmt -129.44 26.23 5.38 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.663 1.985 . . . . 0.0 113.01 -177.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -57.53 96.92 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 126.111 1.765 . . . . 0.0 112.304 174.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -97.83 -69.99 0.74 Allowed 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 126.556 1.943 . . . . 0.0 110.56 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.58 ' CE2' HD13 ' A' ' 62' ' ' LEU . 26.9 m-85 -83.65 114.36 21.5 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.986 0.914 . . . . 0.0 112.346 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -85.21 158.83 57.66 Favored Pre-proline 0 N--CA 1.475 0.803 0 C-N-CA 125.573 1.549 . . . . 0.0 113.137 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.53 133.97 25.31 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.042 2.494 . . . . 0.0 111.354 177.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -9.94 64.17 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.06 1.314 . . . . 0.0 114.237 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.99 129.31 41.15 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 125.325 1.45 . . . . 0.0 110.359 178.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 28.2 mttp -71.48 106.33 3.92 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.434 0.694 . . . . 0.0 111.275 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.7 m -120.8 154.72 24.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 124.97 1.308 . . . . 0.0 111.194 -178.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.07 127.92 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.982 0.913 . . . . 0.0 110.294 175.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.6 tp -141.88 100.16 6.04 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 123.889 0.876 . . . . 0.0 110.489 175.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -69.45 161.49 45.67 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.595 2.197 . . . . 0.0 112.763 177.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -75.19 -8.44 24.25 Favored 'Cis proline' 0 CA--C 1.544 1.0 0 N-CA-C 114.322 0.855 . . . . 0.0 114.322 0.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -56.8 -43.95 81.46 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.195 1.398 . . . . 0.0 112.451 176.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.3 -22.81 27.83 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.357 1.932 . . . . 0.0 113.751 175.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.0 t -145.29 142.36 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 125.974 1.709 . . . . 0.0 109.197 174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -155.01 170.1 33.17 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 125.78 1.657 . . . . 0.0 111.529 174.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 24.7 m -131.45 134.18 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 124.385 1.074 . . . . 0.0 110.022 174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.499 HG21 ' HB3' ' A' ' 7' ' ' PHE . 44.7 t -71.96 142.79 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.74 -46.24 4.38 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 125.049 1.34 . . . . 0.0 112.237 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.63 179.75 47.93 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.661 1.124 . . . . 0.0 113.178 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.493 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 117.99 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 C-N-CA 125.213 1.405 . . . . 0.0 109.527 176.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.62 115.71 30.07 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.536 1.134 . . . . 0.0 110.278 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -80.45 112.81 18.15 Favored 'General case' 0 CA--C 1.539 0.555 0 O-C-N 121.534 -0.729 . . . . 0.0 110.718 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -97.92 121.4 39.8 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.336 1.454 . . . . 0.0 110.876 176.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.2 p -64.6 107.72 1.48 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 127.044 2.138 . . . . 0.0 111.972 174.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 59.5 t -135.67 125.75 42.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.705 1.602 . . . . 0.0 110.586 -178.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.5 t 57.12 25.47 10.9 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 113.813 1.042 . . . . 0.0 113.813 -178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.39 -11.61 65.25 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 126.173 1.844 . . . . 0.0 115.3 -175.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.2 m -106.75 127.55 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 125.491 1.516 . . . . 0.0 111.33 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.38 119.9 22.36 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.679 -1.263 . . . . 0.0 109.611 176.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 -105.8 134.04 49.56 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.575 0.75 . . . . 0.0 110.203 177.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.493 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.45 140.13 49.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.259 0.624 . . . . 0.0 111.838 177.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.8 m-85 -140.98 124.88 17.08 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.982 1.713 . . . . 0.0 111.255 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.522 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -69.58 118.89 13.03 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 123.405 0.682 . . . . 0.0 110.403 174.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -78.65 102.71 8.15 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.199 1.0 . . . . 0.0 110.212 176.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.3 t -93.33 108.24 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 O-C-N 120.914 -1.116 . . . . 0.0 109.766 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -98.25 130.59 44.96 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.73 1.212 . . . . 0.0 110.202 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.89 144.79 30.35 Favored Pre-proline 0 N--CA 1.471 0.623 0 C-N-CA 123.891 0.876 . . . . 0.0 111.504 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -67.89 161.91 42.01 Favored 'Trans proline' 0 CA--C 1.541 0.844 0 C-N-CA 122.534 2.156 . . . . 0.0 112.319 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.98 -12.6 35.78 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 125.248 1.404 . . . . 0.0 115.291 -178.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.8 -172.25 4.13 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 125.635 1.574 . . . . 0.0 112.042 178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.6 mtm180 -107.66 7.19 28.41 Favored 'General case' 0 N--CA 1.484 1.226 0 C-N-CA 126.533 1.933 . . . . 0.0 113.406 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -51.21 128.72 22.8 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 124.191 0.996 . . . . 0.0 110.484 175.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -122.6 140.8 52.4 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.454 1.502 . . . . 0.0 109.298 174.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.75 126.51 51.24 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 124.305 1.042 . . . . 0.0 109.171 175.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -96.67 103.24 15.15 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 124.378 1.071 . . . . 0.0 110.423 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 96.0 t -92.73 127.41 48.09 Favored Pre-proline 0 N--CA 1.477 0.914 0 CA-C-O 118.778 -0.63 . . . . 0.0 111.547 -176.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -64.52 124.39 13.2 Favored 'Trans proline' 0 CA--C 1.534 0.512 0 C-N-CA 123.759 2.973 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.522 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.8 m -65.5 -25.49 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 177.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -70.99 -38.78 72.69 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.58 1.552 . . . . 0.0 112.942 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.18 71.03 34.11 Favored Pre-proline 0 CA--C 1.547 0.863 0 C-N-CA 124.475 1.11 . . . . 0.0 112.409 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -70.2 -25.38 26.63 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.335 2.023 . . . . 0.0 112.251 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 14.9 p-80 -77.0 -22.14 53.56 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 124.412 1.085 . . . . 0.0 112.754 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.7 t -61.71 -42.22 98.65 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.786 1.235 . . . . 0.0 112.014 -179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.0 m -71.77 -11.38 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 175.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.61 16.22 52.88 Favored Glycine 0 CA--C 1.536 1.35 0 C-N-CA 125.24 1.4 . . . . 0.0 114.914 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.3 OUTLIER -69.19 126.29 29.31 Favored 'General case' 0 CA--C 1.543 0.691 0 CA-C-N 119.184 1.492 . . . . 0.0 109.89 175.65 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 38.8 mtp85 -134.29 158.26 44.23 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.806 1.242 . . . . 0.0 111.233 176.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 4.7 mtmt -73.68 121.53 20.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.59 0.756 . . . . 0.0 109.135 174.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -56.74 4.26 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 122.633 0.373 . . . . 0.0 110.745 175.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -168.89 81.66 0.14 Allowed 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 125.491 1.516 . . . . 0.0 111.901 -177.031 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.74 158.64 82.4 Favored Pre-proline 0 CA--C 1.555 1.164 0 O-C-N 121.216 -0.927 . . . . 0.0 113.262 177.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.81 104.55 1.64 Allowed 'Trans proline' 0 CA--C 1.543 0.94 0 C-N-CA 124.093 3.195 . . . . 0.0 112.297 175.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -91.76 -41.2 10.81 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 121.458 -0.776 . . . . 0.0 113.088 174.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 . . . . . 0 C--O 1.252 1.23 0 C-N-CA 125.091 1.356 . . . . 0.0 112.456 176.987 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 86.45 0.12 Allowed Glycine 0 N--CA 1.476 1.32 0 CA-C-N 120.12 1.327 . . . . 0.0 113.869 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -68.76 137.02 53.69 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.139 0.976 . . . . 0.0 112.334 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.5 mmt -108.45 101.72 10.87 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 126.194 1.797 . . . . 0.0 111.57 179.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -92.75 100.8 13.22 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.688 1.595 . . . . 0.0 111.881 175.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -91.47 -75.41 0.48 Allowed 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.609 1.163 . . . . 0.0 110.964 175.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.495 ' CE2' HD23 ' A' ' 62' ' ' LEU . 20.7 m-85 -82.87 114.78 21.41 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 118.999 0.818 . . . . 0.0 112.752 177.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.6 mtm-85 -77.77 158.16 78.48 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 126.09 1.756 . . . . 0.0 112.852 175.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -70.91 133.23 23.01 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 123.169 2.579 . . . . 0.0 111.082 178.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.81 -5.38 82.45 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.211 -0.771 . . . . 0.0 114.708 -178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -61.57 131.71 50.97 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 119.039 1.42 . . . . 0.0 111.444 177.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -66.98 104.95 1.5 Allowed 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.198 1.399 . . . . 0.0 109.467 174.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -120.75 155.69 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 124.933 1.293 . . . . 0.0 110.868 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -103.94 127.81 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.907 1.283 . . . . 0.0 110.072 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.474 HD22 HD13 ' A' ' 62' ' ' LEU . 7.9 tp -143.35 99.74 5.32 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.663 1.185 . . . . 0.0 110.301 176.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.13 159.23 54.03 Favored 'Trans proline' 0 CA--C 1.55 1.317 0 C-N-CA 122.358 2.038 . . . . 0.0 111.935 176.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -76.84 -8.17 29.61 Favored 'Cis proline' 0 CA--C 1.544 1.003 0 N-CA-C 114.373 0.874 . . . . 0.0 114.373 0.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -60.1 -38.97 84.56 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.945 1.298 . . . . 0.0 112.471 177.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.4 -23.63 11.73 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 126.777 2.132 . . . . 0.0 114.601 176.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 54.4 t -145.48 127.12 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 125.782 1.633 . . . . 0.0 108.572 175.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.07 165.96 14.82 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 125.981 1.753 . . . . 0.0 111.59 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.22 118.88 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 125.494 1.518 . . . . 0.0 109.977 175.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 47.9 t -69.83 124.64 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 123.742 0.817 . . . . 0.0 109.749 174.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.29 -46.62 8.63 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.812 1.245 . . . . 0.0 112.831 176.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.87 175.44 42.35 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.719 1.152 . . . . 0.0 113.727 -178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.2 mp -85.42 105.58 14.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.194 1.398 . . . . 0.0 109.591 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.43 115.54 30.79 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.299 1.039 . . . . 0.0 110.061 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -80.75 117.17 21.19 Favored 'General case' 0 CA--C 1.543 0.687 0 O-C-N 121.108 -0.995 . . . . 0.0 112.294 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -102.03 127.09 49.07 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 126.273 1.829 . . . . 0.0 110.51 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.7 t -70.52 116.85 11.32 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 125.168 1.387 . . . . 0.0 112.141 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.11 125.95 24.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 125.97 1.708 . . . . 0.0 109.917 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 71.1 m 52.57 26.4 4.29 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 114.387 1.255 . . . . 0.0 114.387 -176.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.36 -4.76 85.76 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.814 1.673 . . . . 0.0 115.327 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -108.76 128.25 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.607 1.563 . . . . 0.0 110.143 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 60.8 p -80.08 119.84 23.42 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 121.091 -1.006 . . . . 0.0 109.195 174.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 60.9 mtt180 -105.94 134.15 49.51 Favored 'General case' 0 N--CA 1.476 0.863 0 O-C-N 121.524 -0.735 . . . . 0.0 109.528 175.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.71 135.03 48.0 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.625 0.77 . . . . 0.0 111.429 175.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -137.37 128.5 27.73 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.456 1.503 . . . . 0.0 111.324 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.476 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.9 m-85 -67.72 113.65 5.67 Favored 'General case' 0 CA--C 1.536 0.42 0 O-C-N 121.826 -0.546 . . . . 0.0 109.553 174.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.0 tt0 -72.53 102.47 3.25 Favored 'General case' 0 CA--C 1.538 0.481 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -86.46 147.39 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 O-C-N 121.628 -0.67 . . . . 0.0 109.922 174.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -132.05 142.78 49.66 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 125.322 1.449 . . . . 0.0 110.515 175.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -125.63 148.0 60.3 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 125.413 1.485 . . . . 0.0 110.959 -175.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -70.09 161.3 46.49 Favored 'Trans proline' 0 CA--C 1.542 0.915 0 C-N-CA 122.269 1.98 . . . . 0.0 112.479 176.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.55 -11.52 38.76 Favored Glycine 0 CA--C 1.54 1.631 0 C-N-CA 125.548 1.547 . . . . 0.0 115.778 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 84.4 p -155.02 -171.8 3.96 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.193 1.797 . . . . 0.0 111.789 176.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.87 6.62 21.4 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.253 1.821 . . . . 0.0 112.24 174.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 m -55.89 145.79 23.81 Favored 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 123.527 0.731 . . . . 0.0 111.11 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -141.62 140.88 33.41 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.818 1.247 . . . . 0.0 111.092 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -115.41 117.63 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 125.212 1.405 . . . . 0.0 108.784 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 60.0 m-85 -81.19 98.75 8.22 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.44 0.696 . . . . 0.0 110.872 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 84.5 t -86.57 124.63 69.25 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.69 -0.671 . . . . 0.0 111.512 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.62 130.97 23.25 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.599 2.866 . . . . 0.0 112.389 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.476 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.0 m -68.82 -23.96 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 178.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -71.59 -39.64 70.39 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.485 1.114 . . . . 0.0 113.331 178.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.3 70.61 33.43 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 124.76 1.224 . . . . 0.0 112.249 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -70.37 -34.59 12.28 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.902 1.735 . . . . 0.0 112.232 -174.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -69.34 -24.56 63.92 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 175.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 46.3 t -62.17 -40.93 97.68 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 124.67 1.188 . . . . 0.0 113.156 -176.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.9 p -70.42 -12.68 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 C-N-CA 124.41 1.084 . . . . 0.0 113.299 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.89 -0.07 51.93 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 126.078 1.799 . . . . 0.0 114.976 -177.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.495 HD23 ' CE2' ' A' ' 7' ' ' PHE . 10.8 tp -69.68 122.38 19.01 Favored 'General case' 0 CA--C 1.542 0.643 0 CA-C-N 119.27 1.535 . . . . 0.0 111.129 175.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 28.6 ptt180 -141.59 165.73 26.7 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.01 1.324 . . . . 0.0 111.052 174.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -66.18 133.88 51.57 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.007 0.523 . . . . 0.0 110.512 175.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.33 175.03 11.01 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.08 0.952 . . . . 0.0 110.045 175.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -146.51 131.98 18.69 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.481 -0.762 . . . . 0.0 110.722 177.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -115.71 155.99 46.86 Favored Pre-proline 0 CA--C 1.546 0.81 0 C-N-CA 125.585 1.554 . . . . 0.0 111.438 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.56 -20.7 26.68 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.079 2.519 . . . . 0.0 113.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -73.01 -33.11 65.56 Favored 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.691 1.196 . . . . 0.0 113.328 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.33 0 C-N-CA 129.256 3.023 . . . . 0.0 115.889 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.236 0 CA-C-O 119.661 -0.209 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.31 -166.76 26.97 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.015 1.293 . . . . 0.0 114.409 176.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.6 p-80 -119.18 173.12 7.12 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 126.78 2.032 . . . . 0.0 111.802 178.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -135.99 -77.47 0.43 Allowed 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.965 1.706 . . . . 0.0 110.846 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.3 mttp -79.44 110.17 14.5 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.106 1.363 . . . . 0.0 112.24 177.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -79.0 -68.6 0.64 Allowed 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.953 0.901 . . . . 0.0 110.225 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.464 ' CE2' HD13 ' A' ' 62' ' ' LEU . 25.1 m-85 -84.91 113.98 21.79 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.557 0.694 . . . . 0.0 111.193 177.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.0 mtt180 -80.51 158.35 71.41 Favored Pre-proline 0 N--CA 1.476 0.827 0 C-N-CA 125.775 1.63 . . . . 0.0 112.422 176.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.97 132.58 23.3 Favored 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 122.976 2.451 . . . . 0.0 111.181 176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.85 -8.66 68.69 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 123.76 0.695 . . . . 0.0 114.029 -179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -60.95 132.7 54.68 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 118.641 1.22 . . . . 0.0 110.4 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.19 107.33 3.65 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.865 1.266 . . . . 0.0 110.166 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.2 m -126.6 155.96 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 C-N-CA 124.749 1.22 . . . . 0.0 111.663 -177.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -102.99 129.43 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.845 1.258 . . . . 0.0 110.379 175.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -144.52 100.88 4.73 Favored Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 124.26 1.024 . . . . 0.0 110.439 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -69.96 160.98 47.69 Favored 'Trans proline' 0 CA--C 1.549 1.245 0 C-N-CA 122.471 2.114 . . . . 0.0 112.728 177.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -75.66 -8.14 25.69 Favored 'Cis proline' 0 CA--C 1.545 1.061 0 N-CA-C 114.441 0.9 . . . . 0.0 114.441 0.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.2 m-85 -58.28 -41.31 84.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 125.242 1.417 . . . . 0.0 112.515 177.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.35 -22.7 22.24 Favored Glycine 0 CA--C 1.533 1.185 0 C-N-CA 126.494 1.997 . . . . 0.0 113.926 175.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.7 t -145.39 126.0 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 125.935 1.694 . . . . 0.0 108.713 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -122.74 164.91 15.54 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 125.565 1.555 . . . . 0.0 111.815 174.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.1 t -130.98 117.52 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 C-N-CA 125.097 1.359 . . . . 0.0 109.488 176.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 7' ' ' PHE . 55.2 t -66.84 131.68 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.283 1.033 . . . . 0.0 109.333 174.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.09 -45.81 5.53 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.93 1.292 . . . . 0.0 112.811 177.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 175.04 42.46 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.995 1.283 . . . . 0.0 113.242 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mp -86.25 129.19 38.63 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 C-N-CA 124.508 1.123 . . . . 0.0 109.912 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.94 115.84 23.96 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 124.987 1.315 . . . . 0.0 110.123 175.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -82.04 112.82 19.46 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 121.617 -0.677 . . . . 0.0 111.077 175.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 35.6 mmm-85 -97.46 115.49 27.87 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 126.932 2.093 . . . . 0.0 111.282 176.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 57.2 p -63.46 105.4 0.76 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.603 1.561 . . . . 0.0 112.207 175.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 91.2 t -133.86 125.08 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 125.473 1.509 . . . . 0.0 109.874 -176.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 m 57.64 25.6 11.88 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 124.357 1.063 . . . . 0.0 113.843 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.51 -8.33 77.67 Favored Glycine 0 CA--C 1.537 1.435 0 C-N-CA 125.841 1.686 . . . . 0.0 115.398 -176.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.92 125.14 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 125.542 1.537 . . . . 0.0 110.775 177.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.54 119.87 24.32 Favored 'General case' 0 N--CA 1.465 0.279 0 O-C-N 120.858 -1.151 . . . . 0.0 110.405 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -102.69 134.15 46.55 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.45 0.7 . . . . 0.0 109.964 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.62 135.62 41.99 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.586 0.708 . . . . 0.0 111.334 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -137.0 126.92 25.78 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.593 1.557 . . . . 0.0 111.029 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.542 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.1 m-85 -68.23 113.38 5.8 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.936 0.495 . . . . 0.0 109.995 174.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -73.01 102.58 3.53 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 t -86.54 148.07 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 121.401 -0.812 . . . . 0.0 109.803 175.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.59 142.78 50.46 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 126.118 1.767 . . . . 0.0 109.609 175.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -127.0 145.54 54.35 Favored Pre-proline 0 CA--C 1.54 0.596 0 C-N-CA 125.124 1.37 . . . . 0.0 110.474 -178.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -69.26 161.52 45.52 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 122.407 2.071 . . . . 0.0 112.358 177.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.19 -11.3 37.4 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 125.283 1.42 . . . . 0.0 115.542 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -154.88 -171.99 4.03 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.535 1.534 . . . . 0.0 112.078 177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -111.7 4.91 18.88 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 126.68 1.992 . . . . 0.0 113.347 174.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.8 m -51.29 143.79 10.75 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 124.189 0.996 . . . . 0.0 111.793 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 17.4 pttm -141.47 144.26 34.28 Favored 'General case' 0 C--O 1.233 0.214 0 C-N-CA 125.51 1.524 . . . . 0.0 110.877 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -118.22 117.57 29.48 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 124.743 1.217 . . . . 0.0 109.325 178.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -80.63 99.99 8.42 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.708 0.803 . . . . 0.0 111.274 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.598 HG11 HD12 ' A' ' 62' ' ' LEU . 91.3 t -89.66 127.09 55.7 Favored Pre-proline 0 N--CA 1.478 0.936 0 CA-C-O 118.397 -0.811 . . . . 0.0 111.111 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -66.75 133.87 33.1 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.396 2.731 . . . . 0.0 112.046 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.542 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 34.1 m -68.82 -23.73 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 114.305 1.224 . . . . 0.0 114.305 176.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -74.58 -47.03 34.82 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.86 0.864 . . . . 0.0 112.384 -178.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -133.43 70.86 76.62 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.392 1.077 . . . . 0.0 111.354 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -69.23 -25.51 30.96 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.747 2.298 . . . . 0.0 111.992 -177.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -72.18 -21.8 61.38 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.189 0.996 . . . . 0.0 112.642 174.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.33 -37.1 86.31 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 124.646 1.178 . . . . 0.0 112.378 -174.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.5 m -74.89 -10.78 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 124.756 1.223 . . . . 0.0 112.961 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.01 11.0 58.13 Favored Glycine 0 CA--C 1.538 1.506 0 C-N-CA 125.946 1.736 . . . . 0.0 115.383 -175.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.598 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -65.97 123.47 19.92 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 119.381 1.59 . . . . 0.0 110.274 177.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.1 mtm-85 -129.66 159.19 37.2 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 125.793 1.637 . . . . 0.0 111.577 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 42.9 mttt -77.02 130.55 37.61 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.611 0.764 . . . . 0.0 109.001 175.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.13 167.84 20.75 Favored 'General case' 0 CA--C 1.547 0.837 0 CA-C-O 121.444 0.64 . . . . 0.0 109.892 175.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 18.0 tp -149.21 134.46 18.3 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.5 1.12 . . . . 0.0 109.722 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -65.45 159.55 66.21 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 123.004 0.521 . . . . 0.0 111.708 175.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -70.97 171.51 15.64 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 123.113 2.542 . . . . 0.0 112.872 177.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -136.99 20.52 3.02 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 125.645 1.578 . . . . 0.0 113.867 -177.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.254 1.342 0 C-N-CA 124.861 1.265 . . . . 0.0 113.527 174.992 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.212 0 CA-C-O 120.48 0.181 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.07 -177.19 29.95 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.206 1.384 . . . . 0.0 113.3 -178.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.0 m80 -92.5 -65.03 1.03 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.839 1.255 . . . . 0.0 112.321 175.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -91.23 95.57 10.11 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.95 0.9 . . . . 0.0 110.961 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -66.81 158.34 30.68 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.389 0.614 . . . . 0.0 111.816 175.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -70.88 170.65 12.18 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.301 1.44 . . . . 0.0 112.58 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.477 ' CZ ' HD22 ' A' ' 62' ' ' LEU . 29.1 m-85 -70.93 113.34 7.88 Favored 'General case' 0 CA--C 1.54 0.589 0 O-C-N 121.217 -0.927 . . . . 0.0 112.56 175.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -85.19 158.02 58.7 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 126.115 1.766 . . . . 0.0 113.172 176.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.45 133.06 25.21 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 123.086 2.524 . . . . 0.0 111.714 178.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.77 -7.99 71.46 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.415 1.483 . . . . 0.0 114.492 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -60.69 129.89 43.78 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.933 1.367 . . . . 0.0 110.522 174.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 23.5 mttm -68.46 111.89 4.96 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.437 1.095 . . . . 0.0 109.649 174.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 155.9 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 124.713 1.205 . . . . 0.0 110.764 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.34 127.44 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 123.95 0.9 . . . . 0.0 110.152 175.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -141.27 100.66 6.3 Favored Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 124.369 1.067 . . . . 0.0 110.211 175.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -69.23 160.87 48.17 Favored 'Trans proline' 0 CA--C 1.548 1.223 0 C-N-CA 122.619 2.213 . . . . 0.0 112.378 176.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -75.89 -7.59 26.21 Favored 'Cis proline' 0 CA--C 1.544 0.979 0 N-CA-C 114.434 0.898 . . . . 0.0 114.434 0.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -59.04 -41.04 86.91 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.941 1.297 . . . . 0.0 112.47 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.52 -22.07 29.24 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 126.365 1.936 . . . . 0.0 113.706 175.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.5 148.42 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.146 1.778 . . . . 0.0 109.682 174.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -160.51 169.41 36.27 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.523 1.535 . . . . 0.0 111.358 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.3 134.03 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 C-N-CA 124.273 1.029 . . . . 0.0 109.639 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.471 HG21 ' HB3' ' A' ' 7' ' ' PHE . 58.2 t -72.36 138.29 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 123.578 0.751 . . . . 0.0 109.123 176.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -100.77 -40.19 7.45 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.603 1.161 . . . . 0.0 112.988 178.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.01 174.74 37.83 Favored Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.682 1.134 . . . . 0.0 113.526 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.426 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -85.15 105.99 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 124.889 1.275 . . . . 0.0 109.254 179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.81 115.64 30.99 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.597 1.159 . . . . 0.0 110.253 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 7.6 mt-30 -80.56 112.9 18.35 Favored 'General case' 0 CA--C 1.543 0.676 0 O-C-N 121.211 -0.931 . . . . 0.0 111.875 175.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -94.08 151.4 19.53 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.539 1.536 . . . . 0.0 111.145 175.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 m -100.65 96.24 7.22 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.528 1.531 . . . . 0.0 110.382 -177.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.4 t -133.99 143.96 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 125.105 1.362 . . . . 0.0 110.015 -175.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 55.02 25.39 6.88 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -179.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.11 13.86 79.22 Favored Glycine 0 CA--C 1.54 1.598 0 C-N-CA 125.045 1.307 . . . . 0.0 115.269 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.98 132.02 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.865 1.666 . . . . 0.0 111.668 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.1 m -73.48 119.86 18.29 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 121.272 -0.893 . . . . 0.0 108.633 175.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -119.84 134.11 55.35 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.153 0.981 . . . . 0.0 110.067 175.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.426 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.16 135.12 46.06 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.781 0.832 . . . . 0.0 111.408 175.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.5 m-85 -136.46 127.5 27.8 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.539 1.536 . . . . 0.0 110.898 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.506 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 22.7 m-85 -67.0 112.47 4.37 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 25.4 tt0 -71.67 102.51 2.8 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 174.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 t -87.88 149.54 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 O-C-N 121.424 -0.798 . . . . 0.0 110.199 175.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -132.9 144.68 50.33 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.305 1.442 . . . . 0.0 110.653 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -129.26 144.32 52.31 Favored Pre-proline 0 N--CA 1.472 0.658 0 C-N-CA 125.277 1.431 . . . . 0.0 110.799 -175.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.35 161.97 43.75 Favored 'Trans proline' 0 CA--C 1.542 0.902 0 C-N-CA 122.583 2.189 . . . . 0.0 112.657 178.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.48 -19.71 10.43 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 125.726 1.632 . . . . 0.0 115.655 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -146.67 -174.49 4.49 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.358 1.863 . . . . 0.0 111.305 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 22.6 ttm-85 -113.58 11.98 18.42 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 125.18 1.392 . . . . 0.0 112.197 174.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 8.3 m -53.53 138.46 33.94 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 124.509 1.124 . . . . 0.0 110.942 175.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -131.18 140.8 49.98 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.632 1.173 . . . . 0.0 110.001 176.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.06 121.52 42.43 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 124.882 1.273 . . . . 0.0 108.878 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -89.24 99.93 12.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 124.248 1.019 . . . . 0.0 110.979 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.545 HG11 HD12 ' A' ' 62' ' ' LEU . 97.5 t -91.46 127.24 51.52 Favored Pre-proline 0 N--CA 1.477 0.906 0 CA-C-O 118.492 -0.766 . . . . 0.0 111.026 -176.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -66.38 132.23 28.76 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 123.419 2.746 . . . . 0.0 112.094 -178.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.506 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 33.9 m -67.21 -22.68 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 176.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -74.88 -47.19 31.35 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.53 1.132 . . . . 0.0 112.209 -178.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.82 70.69 70.83 Favored Pre-proline 0 CA--C 1.545 0.775 0 C-N-CA 124.685 1.194 . . . . 0.0 111.535 177.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -69.06 -28.09 29.01 Favored 'Trans proline' 0 CA--C 1.536 0.591 0 C-N-CA 122.415 2.077 . . . . 0.0 112.178 -177.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -71.32 -23.37 61.92 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.031 0.932 . . . . 0.0 112.983 175.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.0 t -63.06 -39.49 94.88 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 124.652 1.181 . . . . 0.0 112.706 -176.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.31 -14.38 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.14 0.976 . . . . 0.0 112.826 174.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.85 14.54 28.99 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.741 1.639 . . . . 0.0 115.011 -177.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.545 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -73.22 127.74 33.49 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 119.0 1.4 . . . . 0.0 110.628 177.171 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 79.5 mtt180 -134.65 157.01 47.72 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 126.474 1.91 . . . . 0.0 111.37 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -73.94 131.11 41.11 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.16 168.58 19.71 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 121.01 0.434 . . . . 0.0 110.208 174.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.5 tp -148.8 110.08 4.4 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.558 0.743 . . . . 0.0 110.955 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -61.48 156.63 51.58 Favored Pre-proline 0 CA--C 1.553 1.07 0 C-N-CA 123.924 0.89 . . . . 0.0 112.355 175.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -69.39 99.93 0.74 Allowed 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.87 3.047 . . . . 0.0 111.638 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -74.96 -33.24 61.89 Favored 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 123.775 0.83 . . . . 0.0 112.598 179.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.252 1.222 0 C-N-CA 125.919 1.687 . . . . 0.0 113.806 175.17 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.635 0.255 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.38 71.56 1.28 Allowed Glycine 0 CA--C 1.535 1.335 0 C-N-CA 124.68 1.133 . . . . 0.0 114.595 176.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -90.16 -39.96 12.52 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -90.01 -64.43 1.14 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.543 1.137 . . . . 0.0 111.969 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.5 mppt? -109.27 121.25 44.77 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.855 1.662 . . . . 0.0 110.741 175.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -115.93 -66.85 1.04 Allowed 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.5 1.52 . . . . 0.0 109.231 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.519 ' CE2' HD23 ' A' ' 62' ' ' LEU . 24.7 m-85 -75.88 118.49 18.73 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.879 0.872 . . . . 0.0 112.593 176.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -91.53 158.26 40.86 Favored Pre-proline 0 N--CA 1.476 0.84 0 C-N-CA 126.488 1.915 . . . . 0.0 112.704 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.83 133.62 25.87 Favored 'Trans proline' 0 CA--C 1.538 0.683 0 C-N-CA 123.011 2.474 . . . . 0.0 111.24 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.18 -7.36 71.87 Favored Glycine 0 CA--C 1.534 1.281 0 C-N-CA 125.056 1.312 . . . . 0.0 114.368 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -61.33 131.26 49.72 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 118.627 1.214 . . . . 0.0 110.455 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.8 mttp -68.97 104.86 2.2 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.288 1.035 . . . . 0.0 110.491 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.6 m -119.14 153.63 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.957 1.303 . . . . 0.0 111.182 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 p -100.46 124.96 54.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 124.735 1.214 . . . . 0.0 109.638 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.0 tp -140.72 100.63 6.65 Favored Pre-proline 0 CA--C 1.541 0.618 0 C-N-CA 124.339 1.055 . . . . 0.0 110.369 176.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -69.22 161.39 46.05 Favored 'Trans proline' 0 CA--C 1.55 1.307 0 C-N-CA 122.598 2.199 . . . . 0.0 112.436 176.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -75.22 -8.45 24.35 Favored 'Cis proline' 0 CA--C 1.542 0.908 0 N-CA-C 114.479 0.915 . . . . 0.0 114.479 -0.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -57.85 -42.08 83.68 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.086 1.354 . . . . 0.0 112.537 177.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.75 -23.31 20.55 Favored Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.575 2.036 . . . . 0.0 114.02 175.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.4 t -145.44 141.6 22.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 C-N-CA 125.824 1.65 . . . . 0.0 109.037 174.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.08 170.31 32.64 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.837 1.684 . . . . 0.0 111.528 174.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.7 m -130.05 135.86 60.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 124.198 0.999 . . . . 0.0 109.704 175.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.441 HG21 ' HB3' ' A' ' 7' ' ' PHE . 47.0 t -72.91 141.36 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 175.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -103.39 -42.26 5.76 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 124.78 1.232 . . . . 0.0 112.805 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.08 174.68 39.06 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.708 1.146 . . . . 0.0 113.319 178.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.475 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.2 104.73 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 C-N-CA 124.859 1.263 . . . . 0.0 109.224 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.25 115.79 30.73 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.325 1.05 . . . . 0.0 110.227 174.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -81.08 118.38 22.47 Favored 'General case' 0 CA--C 1.541 0.597 0 O-C-N 121.2 -0.937 . . . . 0.0 111.879 175.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -96.83 136.34 37.51 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.405 1.482 . . . . 0.0 111.175 175.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.9 p -87.85 103.91 16.1 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 126.066 1.746 . . . . 0.0 111.868 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 36.5 t -135.46 128.42 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 124.121 0.968 . . . . 0.0 110.865 -178.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 58.75 25.45 13.45 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 125.001 1.32 . . . . 0.0 114.101 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 74.72 11.48 83.19 Favored Glycine 0 CA--C 1.539 1.541 0 O-C-N 120.864 -1.148 . . . . 0.0 114.393 -172.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.63 108.3 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 126.505 1.922 . . . . 0.0 109.542 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.31 119.92 15.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -121.06 134.05 55.26 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.503 0.721 . . . . 0.0 110.53 177.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.475 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.24 136.64 46.39 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 123.847 0.859 . . . . 0.0 111.765 176.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -137.71 125.01 21.77 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 125.675 1.59 . . . . 0.0 111.008 178.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.528 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 26.7 m-85 -64.87 112.37 3.24 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -72.13 102.46 3.03 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.028 0.931 . . . . 0.0 108.584 175.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.4 t -87.97 148.13 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 O-C-N 121.541 -0.724 . . . . 0.0 110.135 175.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -133.03 140.37 47.69 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.255 1.422 . . . . 0.0 110.592 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -124.21 145.42 48.45 Favored Pre-proline 0 N--CA 1.471 0.6 0 C-N-CA 125.093 1.357 . . . . 0.0 110.86 -176.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.01 161.9 44.21 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.28 -14.19 29.6 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.469 1.509 . . . . 0.0 115.438 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.4 p -152.38 -170.89 3.77 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 125.815 1.646 . . . . 0.0 111.968 175.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -113.32 11.7 18.68 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 127.145 2.178 . . . . 0.0 112.16 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -54.28 136.36 43.28 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 118.427 0.558 . . . . 0.0 110.831 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.3 mtmt -128.0 140.64 51.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.359 1.063 . . . . 0.0 110.096 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -116.67 122.44 44.55 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.102 1.361 . . . . 0.0 108.793 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -90.1 101.76 14.47 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.48 1.112 . . . . 0.0 110.911 179.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.23 126.26 51.43 Favored Pre-proline 0 N--CA 1.479 0.989 0 CA-C-O 118.667 -0.683 . . . . 0.0 111.769 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.5 131.93 29.5 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.665 2.91 . . . . 0.0 112.339 -177.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.528 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.2 m -72.42 -26.12 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 177.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -70.48 -40.53 73.58 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 125.12 1.368 . . . . 0.0 112.713 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.31 70.3 33.37 Favored Pre-proline 0 CA--C 1.549 0.929 0 C-N-CA 124.619 1.168 . . . . 0.0 112.526 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -68.41 -26.14 35.08 Favored 'Trans proline' 0 CA--C 1.536 0.601 0 C-N-CA 122.513 2.142 . . . . 0.0 112.379 -177.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 45.8 p-80 -73.95 -22.48 59.63 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.888 1.275 . . . . 0.0 113.665 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 m -62.41 -37.67 86.69 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-N 119.766 1.166 . . . . 0.0 112.998 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 33.6 m -75.22 -13.09 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 113.141 0.793 . . . . 0.0 113.141 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.42 8.89 65.58 Favored Glycine 0 CA--C 1.539 1.534 0 C-N-CA 125.735 1.636 . . . . 0.0 115.388 -175.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.519 HD23 ' CE2' ' A' ' 7' ' ' PHE . 15.3 tp -67.19 126.29 28.75 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 119.372 1.586 . . . . 0.0 110.452 175.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -138.24 168.37 19.89 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 125.629 1.572 . . . . 0.0 111.493 174.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -70.51 136.6 49.52 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.728 1.211 . . . . 0.0 109.818 174.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.3 -52.69 6.69 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.523 0.729 . . . . 0.0 110.625 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -164.52 130.47 2.89 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.794 1.638 . . . . 0.0 110.21 178.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -129.0 157.94 74.27 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 125.37 1.468 . . . . 0.0 111.92 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -70.99 166.68 28.34 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 123.493 2.795 . . . . 0.0 112.918 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -97.71 -27.49 14.32 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.88 1.272 . . . . 0.0 113.91 179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.252 1.196 0 C-N-CA 127.172 2.189 . . . . 0.0 114.816 177.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.728 0.299 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.56 149.98 18.58 Favored Glycine 0 CA--C 1.535 1.3 0 C-N-CA 125.285 1.421 . . . . 0.0 112.232 176.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -136.77 27.4 3.0 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 124.827 1.251 . . . . 0.0 113.268 -178.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 mtp -131.56 118.9 20.75 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 125.905 1.682 . . . . 0.0 111.571 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -132.73 155.53 48.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 126.555 1.942 . . . . 0.0 110.156 175.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -136.84 169.76 17.22 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.168 1.787 . . . . 0.0 111.051 -177.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.405 ' HB3' HG21 ' A' ' 23' ' ' VAL . 27.7 m-85 -73.13 119.28 17.16 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 121.463 -0.773 . . . . 0.0 112.463 175.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -89.94 157.94 45.26 Favored Pre-proline 0 N--CA 1.478 0.954 0 C-N-CA 126.521 1.928 . . . . 0.0 112.81 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.73 132.18 22.83 Favored 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 122.878 2.385 . . . . 0.0 111.264 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -5.48 82.1 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 124.946 1.26 . . . . 0.0 114.455 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -62.59 131.52 49.31 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 118.609 1.205 . . . . 0.0 110.55 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 51.4 mttt -68.24 114.34 6.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.2 0.6 . . . . 0.0 110.359 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.5 m -126.85 153.36 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.099 1.36 . . . . 0.0 110.691 178.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 p -99.91 123.22 52.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.646 1.178 . . . . 0.0 109.607 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.9 tp -138.46 100.21 8.49 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 124.403 1.081 . . . . 0.0 110.325 176.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -68.54 160.38 49.54 Favored 'Trans proline' 0 CA--C 1.549 1.257 0 C-N-CA 122.499 2.132 . . . . 0.0 112.168 176.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -76.19 -7.99 27.38 Favored 'Cis proline' 0 CA--C 1.544 0.99 0 N-CA-C 114.476 0.914 . . . . 0.0 114.476 -0.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -59.52 -40.54 87.47 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.918 1.287 . . . . 0.0 112.404 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.67 -23.71 18.38 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 126.663 2.078 . . . . 0.0 114.064 175.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.1 t -145.32 142.84 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.18 1.792 . . . . 0.0 108.872 174.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.36 171.54 32.88 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 125.735 1.636 . . . . 0.0 111.365 174.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.59 135.48 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 C-N-CA 124.435 1.094 . . . . 0.0 109.852 175.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.405 HG21 ' HB3' ' A' ' 7' ' ' PHE . 41.0 t -72.58 137.78 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 123.537 0.735 . . . . 0.0 109.475 175.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.31 -41.26 7.53 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.502 1.121 . . . . 0.0 112.973 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.06 175.18 38.81 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 124.715 1.15 . . . . 0.0 113.527 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 mp -85.41 106.04 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.738 1.215 . . . . 0.0 109.257 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -102.27 115.65 31.0 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.528 1.131 . . . . 0.0 110.314 174.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.88 120.45 24.73 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.114 -0.991 . . . . 0.0 111.499 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -109.88 138.26 46.5 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 126.005 1.722 . . . . 0.0 111.179 175.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.1 m -69.84 112.13 6.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.808 1.643 . . . . 0.0 111.438 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.19 123.11 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 125.207 1.403 . . . . 0.0 110.164 -178.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.1 25.42 10.82 Favored 'General case' 0 N--CA 1.481 1.112 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -177.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.87 -6.95 79.44 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 126.027 1.775 . . . . 0.0 115.5 -176.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 129.83 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.531 1.533 . . . . 0.0 110.587 175.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 m -73.33 119.87 18.16 Favored 'General case' 0 N--CA 1.47 0.535 0 O-C-N 120.808 -1.183 . . . . 0.0 109.106 175.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -112.42 135.4 53.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.138 0.975 . . . . 0.0 110.058 177.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -70.3 135.33 48.8 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.759 0.824 . . . . 0.0 111.546 175.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -136.55 127.88 28.29 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 125.5 1.52 . . . . 0.0 111.101 177.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.504 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 24.7 m-85 -67.46 112.29 4.57 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -72.97 102.51 3.49 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.931 0.893 . . . . 0.0 108.936 175.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.5 t -87.71 148.53 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 123.584 0.754 . . . . 0.0 110.04 176.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -131.91 145.56 51.59 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 125.039 1.336 . . . . 0.0 110.979 175.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -129.86 145.29 56.48 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 125.293 1.437 . . . . 0.0 111.236 -175.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -70.59 159.11 53.86 Favored 'Trans proline' 0 CA--C 1.542 0.892 0 C-N-CA 122.416 2.077 . . . . 0.0 112.658 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.51 -14.5 46.07 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 125.774 1.654 . . . . 0.0 115.675 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 p -155.05 179.49 9.09 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 126.254 1.822 . . . . 0.0 112.017 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -105.84 13.65 29.23 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.252 1.821 . . . . 0.0 113.131 175.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 75.2 m -56.17 137.79 51.1 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.891 0.876 . . . . 0.0 110.774 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 37.3 mtmt -128.99 140.83 51.47 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.696 1.198 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.43 128.15 56.19 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.852 1.261 . . . . 0.0 108.761 175.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -97.0 99.07 10.61 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.65 1.18 . . . . 0.0 110.621 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.574 HG21 HD22 ' A' ' 62' ' ' LEU . 99.5 t -90.69 126.24 56.64 Favored Pre-proline 0 N--CA 1.478 0.974 0 C-N-CA 123.7 0.8 . . . . 0.0 110.652 -176.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.9 131.6 26.02 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 123.242 2.628 . . . . 0.0 112.057 -178.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.504 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 32.2 m -67.3 -22.64 29.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -74.83 -46.28 37.66 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.196 0.998 . . . . 0.0 112.565 -178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -135.4 70.72 67.36 Favored Pre-proline 0 CA--C 1.545 0.759 0 C-N-CA 124.676 1.19 . . . . 0.0 111.316 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.04 -31.53 19.1 Favored 'Trans proline' 0 CA--C 1.535 0.53 0 C-N-CA 122.244 1.963 . . . . 0.0 111.924 -176.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.5 p80 -70.96 -23.23 62.18 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 124.121 0.968 . . . . 0.0 113.542 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.9 t -62.23 -40.59 96.64 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.636 1.174 . . . . 0.0 112.811 -177.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.1 p -70.99 -13.54 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 C-N-CA 124.418 1.087 . . . . 0.0 113.276 174.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.4 7.66 51.27 Favored Glycine 0 CA--C 1.538 1.515 0 C-N-CA 125.806 1.67 . . . . 0.0 115.238 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.574 HD22 HG21 ' A' ' 52' ' ' VAL . 15.9 tp -73.8 130.14 39.34 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 119.599 1.699 . . . . 0.0 111.308 175.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 51.4 mmm-85 -141.25 165.19 28.21 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 125.781 1.632 . . . . 0.0 111.584 174.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -69.21 140.62 54.57 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.809 1.243 . . . . 0.0 110.129 174.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.63 86.85 2.37 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.304 1.441 . . . . 0.0 110.248 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -71.16 95.27 1.23 Allowed 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 123.982 0.913 . . . . 0.0 110.592 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.67 155.28 30.88 Favored Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 124.886 1.274 . . . . 0.0 112.79 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -66.96 123.07 10.5 Favored 'Trans proline' 0 CA--C 1.538 0.693 0 C-N-CA 123.242 2.628 . . . . 0.0 111.445 -179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -129.31 93.09 3.49 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.597 1.559 . . . . 0.0 110.095 -179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 . . . . . 0 C--O 1.253 1.242 0 C-N-CA 125.066 1.346 . . . . 0.0 112.927 178.559 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 N-CA-C 110.569 -0.16 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.58 -171.0 54.98 Favored Glycine 0 CA--C 1.536 1.36 0 O-C-N 121.194 -0.941 . . . . 0.0 113.372 -176.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -146.57 20.01 1.33 Allowed 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 125.28 1.432 . . . . 0.0 114.085 -175.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.83 10.12 40.15 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.148 1.379 . . . . 0.0 114.353 -174.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -127.31 146.1 50.56 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.935 1.694 . . . . 0.0 111.13 -176.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -142.0 -64.21 0.43 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 124.346 1.058 . . . . 0.0 111.011 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.46 ' CE2' HD23 ' A' ' 62' ' ' LEU . 18.4 m-85 -82.46 121.89 27.33 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.258 1.023 . . . . 0.0 112.057 176.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.7 mtt180 -88.1 158.93 49.15 Favored Pre-proline 0 N--CA 1.474 0.77 0 C-N-CA 125.986 1.714 . . . . 0.0 112.973 177.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.58 132.85 22.82 Favored 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.87 2.38 . . . . 0.0 110.783 177.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.82 -6.7 77.37 Favored Glycine 0 CA--C 1.535 1.296 0 CA-C-O 119.432 -0.649 . . . . 0.0 114.687 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.35 130.31 45.48 Favored 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 118.819 1.31 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 106.86 1.35 Allowed 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.836 0.854 . . . . 0.0 110.168 175.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.8 m -122.17 154.49 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.49 1.116 . . . . 0.0 111.375 177.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 p -99.9 129.56 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 124.615 1.166 . . . . 0.0 109.966 174.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.453 HD22 HD13 ' A' ' 62' ' ' LEU . 9.6 tp -144.84 100.0 4.67 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 123.984 0.913 . . . . 0.0 110.624 175.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.15 160.11 51.2 Favored 'Trans proline' 0 CA--C 1.549 1.228 0 C-N-CA 122.453 2.102 . . . . 0.0 112.366 176.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -75.95 -8.57 26.82 Favored 'Cis proline' 0 CA--C 1.543 0.938 0 N-CA-C 114.376 0.875 . . . . 0.0 114.376 0.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -58.74 -40.0 82.54 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.123 1.369 . . . . 0.0 112.486 177.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.59 -22.44 20.81 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 126.737 2.113 . . . . 0.0 114.084 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 45.3 t -145.33 127.82 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 C-N-CA 125.874 1.67 . . . . 0.0 108.818 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -125.28 165.05 18.61 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.665 1.603 . . . . 0.0 111.578 175.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.6 t -131.01 119.99 46.16 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 125.086 1.354 . . . . 0.0 109.599 177.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.45 127.83 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.426 0.69 . . . . 0.0 110.225 174.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -92.85 -52.07 4.78 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 125.144 1.377 . . . . 0.0 112.504 175.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.2 179.0 48.65 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.502 1.048 . . . . 0.0 113.483 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.417 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -90.21 128.19 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.571 0 C-N-CA 124.849 1.259 . . . . 0.0 109.961 178.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.54 115.78 24.72 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 126.397 1.879 . . . . 0.0 111.24 174.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.1 mt-30 -82.4 112.76 19.65 Favored 'General case' 0 CA--C 1.544 0.73 0 O-C-N 121.911 -0.493 . . . . 0.0 111.067 175.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.4 119.17 38.04 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 127.141 2.176 . . . . 0.0 110.842 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.3 p -63.45 103.07 0.48 Allowed 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 126.275 1.83 . . . . 0.0 112.202 174.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 95.3 t -130.12 127.09 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 126.127 1.771 . . . . 0.0 109.824 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 t 56.57 25.46 9.91 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 121.038 -1.039 . . . . 0.0 113.636 -177.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.3 -3.96 84.9 Favored Glycine 0 CA--C 1.539 1.545 0 C-N-CA 125.599 1.571 . . . . 0.0 115.379 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -114.96 123.2 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 125.638 1.575 . . . . 0.0 110.765 177.176 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.62 119.91 14.58 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 120.909 -1.119 . . . . 0.0 109.379 175.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -105.8 134.12 49.44 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.436 0.694 . . . . 0.0 109.406 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.417 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.95 140.59 45.67 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 121.597 0.713 . . . . 0.0 110.883 176.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -140.41 128.88 22.71 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 125.708 1.603 . . . . 0.0 111.013 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.485 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.0 m-85 -70.54 113.79 8.0 Favored 'General case' 0 CA--C 1.531 0.23 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 174.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -72.22 102.5 3.09 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 124.72 1.208 . . . . 0.0 108.887 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 t -87.24 148.63 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 O-C-N 121.439 -0.788 . . . . 0.0 110.141 175.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -130.04 145.15 51.65 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.789 1.635 . . . . 0.0 109.911 175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -129.81 144.77 54.34 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 125.203 1.401 . . . . 0.0 110.691 -176.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -69.47 162.8 40.49 Favored 'Trans proline' 0 CA--C 1.542 0.907 0 C-N-CA 122.543 2.162 . . . . 0.0 112.595 177.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.92 -21.59 9.41 Favored Glycine 0 CA--C 1.538 1.507 0 C-N-CA 125.758 1.647 . . . . 0.0 115.299 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 m -147.53 -175.14 4.74 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.705 2.002 . . . . 0.0 111.332 -177.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 5.7 ppt_? -111.04 7.48 21.51 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 125.841 1.656 . . . . 0.0 113.129 174.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.6 m -54.62 144.25 22.29 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 124.537 1.135 . . . . 0.0 110.837 177.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.6 ptmt -140.76 140.77 34.85 Favored 'General case' 0 N--CA 1.462 0.173 0 C-N-CA 124.891 1.276 . . . . 0.0 110.822 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -114.95 131.26 56.95 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 124.419 1.088 . . . . 0.0 108.783 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -95.89 98.83 10.71 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 123.967 0.907 . . . . 0.0 109.206 -178.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.591 HG21 HD22 ' A' ' 62' ' ' LEU . 93.4 t -85.14 126.32 67.84 Favored Pre-proline 0 N--CA 1.476 0.866 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.827 -178.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -65.7 127.75 18.58 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.286 2.658 . . . . 0.0 111.883 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.485 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.2 m -65.25 -23.14 32.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 176.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -72.37 -46.24 56.25 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.258 1.023 . . . . 0.0 112.029 -178.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.64 70.73 59.05 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 124.848 1.259 . . . . 0.0 110.886 178.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -69.86 -28.26 24.98 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 121.845 1.697 . . . . 0.0 111.832 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 37.7 p-80 -73.58 -20.73 60.54 Favored 'General case' 0 CA--C 1.54 0.571 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 175.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.4 p -66.27 -34.96 79.18 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 120.137 1.335 . . . . 0.0 112.89 -175.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -74.78 -13.36 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 125.657 1.583 . . . . 0.0 112.836 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.3 5.53 55.87 Favored Glycine 0 CA--C 1.538 1.476 0 C-N-CA 125.893 1.711 . . . . 0.0 115.227 -176.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.591 HD22 HG21 ' A' ' 52' ' ' VAL . 9.6 tp -72.33 117.69 14.3 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.573 1.687 . . . . 0.0 110.921 174.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 5.6 mmt85 -135.94 165.34 25.88 Favored 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 126.017 1.727 . . . . 0.0 111.662 174.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -68.9 122.62 19.02 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 125.918 1.687 . . . . 0.0 110.004 176.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -80.9 81.01 7.27 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.215 1.006 . . . . 0.0 110.41 175.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tp -58.22 101.22 0.07 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.014 1.726 . . . . 0.0 111.405 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -84.95 165.4 37.27 Favored Pre-proline 0 CA--C 1.553 1.065 0 C-N-CA 123.933 0.893 . . . . 0.0 112.064 -176.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -74.41 -38.03 2.17 Favored 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.722 2.281 . . . . 0.0 112.894 174.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -92.25 -48.19 6.82 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 124.234 1.014 . . . . 0.0 113.197 177.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 . . . . . 0 C--O 1.254 1.299 0 C-N-CA 125.935 1.694 . . . . 0.0 113.252 -179.503 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 121.07 175.18 15.1 Favored Glycine 0 CA--C 1.537 1.442 0 C-N-CA 125.513 1.53 . . . . 0.0 113.187 -172.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.45 148.4 24.47 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 125.999 1.719 . . . . 0.0 111.663 175.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.62 141.21 14.35 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 126.586 1.954 . . . . 0.0 109.508 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -129.58 161.71 29.91 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 126.047 1.739 . . . . 0.0 111.208 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 15.7 mp0 -80.43 -69.4 0.6 Allowed 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.49 0.716 . . . . 0.0 111.806 176.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.506 ' CE2' HD23 ' A' ' 62' ' ' LEU . 21.1 m-85 -93.34 118.02 30.78 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.109 1.363 . . . . 0.0 112.01 179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.0 mtt180 -88.5 158.9 48.0 Favored Pre-proline 0 N--CA 1.476 0.848 0 C-N-CA 125.866 1.666 . . . . 0.0 112.919 176.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -69.82 137.07 34.43 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.009 2.473 . . . . 0.0 111.487 175.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.76 -13.17 54.45 Favored Glycine 0 CA--C 1.535 1.317 0 C-N-CA 123.746 0.689 . . . . 0.0 114.364 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -60.68 134.08 56.73 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 118.571 1.185 . . . . 0.0 110.431 175.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.5 112.15 5.82 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 124.992 1.317 . . . . 0.0 109.471 178.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.69 158.48 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.223 1.009 . . . . 0.0 111.702 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.14 126.03 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 C-N-CA 125.662 1.585 . . . . 0.0 110.234 175.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 tp -143.68 101.28 5.05 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 124.482 1.113 . . . . 0.0 110.407 175.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.08 160.09 51.29 Favored 'Trans proline' 0 CA--C 1.55 1.309 0 C-N-CA 122.458 2.106 . . . . 0.0 112.416 177.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -75.62 -8.0 25.5 Favored 'Cis proline' 0 CA--C 1.544 0.98 0 N-CA-C 114.374 0.875 . . . . 0.0 114.374 -0.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -59.35 -40.93 88.0 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 125.123 1.369 . . . . 0.0 112.498 178.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.34 -21.48 31.62 Favored Glycine 0 N--CA 1.474 1.188 0 C-N-CA 126.373 1.94 . . . . 0.0 113.711 175.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p -145.43 143.9 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 C-N-CA 126.595 1.958 . . . . 0.0 109.053 174.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.35 171.25 26.49 Favored Glycine 0 CA--C 1.528 0.896 0 C-N-CA 125.802 1.668 . . . . 0.0 112.134 175.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.99 119.16 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.273 1.429 . . . . 0.0 109.958 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -66.61 140.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.35 1.06 . . . . 0.0 110.177 175.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -111.34 -42.33 3.93 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 125.306 1.443 . . . . 0.0 113.327 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.57 175.93 40.9 Favored Glycine 0 CA--C 1.532 1.105 0 C-N-CA 124.71 1.147 . . . . 0.0 113.437 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -88.3 128.87 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 125.078 1.351 . . . . 0.0 109.972 179.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.04 115.62 23.49 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.757 1.623 . . . . 0.0 110.714 174.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.6 mt-30 -80.25 112.74 17.86 Favored 'General case' 0 CA--C 1.541 0.618 0 O-C-N 121.513 -0.742 . . . . 0.0 111.464 174.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -98.77 117.02 32.31 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 126.61 1.964 . . . . 0.0 110.484 178.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.7 m -70.06 101.49 1.83 Allowed 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.918 1.687 . . . . 0.0 111.215 176.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -126.27 129.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 126.133 1.773 . . . . 0.0 110.361 -177.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.1 t 53.69 25.45 5.03 Favored 'General case' 0 N--CA 1.48 1.063 0 O-C-N 120.86 -1.15 . . . . 0.0 113.892 -176.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.1 -7.68 70.21 Favored Glycine 0 CA--C 1.541 1.656 0 C-N-CA 126.091 1.805 . . . . 0.0 115.706 -175.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.42 129.56 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 CA-C-N 119.338 1.569 . . . . 0.0 110.842 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -84.39 119.88 25.62 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 120.898 -1.126 . . . . 0.0 109.488 178.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.1 mtp180 -113.06 134.09 54.69 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.395 0.678 . . . . 0.0 109.849 178.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.74 143.19 49.69 Favored 'General case' 0 CA--C 1.54 0.594 0 CA-C-O 121.455 0.645 . . . . 0.0 111.676 177.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.7 m-85 -141.88 128.83 20.68 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.779 1.632 . . . . 0.0 111.369 178.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.536 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 23.1 m-85 -73.7 119.91 18.57 Favored 'General case' 0 N--CA 1.466 0.375 0 C-N-CA 123.046 0.539 . . . . 0.0 110.523 175.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -75.32 102.51 5.11 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.565 1.146 . . . . 0.0 110.012 175.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.07 114.61 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 124.041 0.937 . . . . 0.0 110.449 174.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -97.62 145.3 26.42 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.599 1.56 . . . . 0.0 110.186 174.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -123.15 144.82 44.43 Favored Pre-proline 0 N--CA 1.471 0.619 0 C-N-CA 124.661 1.185 . . . . 0.0 111.14 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -68.57 160.82 47.73 Favored 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 122.363 2.042 . . . . 0.0 112.319 177.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.54 -12.27 41.1 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.483 1.516 . . . . 0.0 115.764 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.7 t -155.07 -171.17 3.73 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 125.991 1.717 . . . . 0.0 111.511 178.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 24.1 mtp85 -110.86 11.6 22.38 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 126.547 1.939 . . . . 0.0 112.222 174.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.3 m -52.19 135.71 31.52 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.587 0.755 . . . . 0.0 110.602 175.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 8.4 mtmm -125.4 140.72 52.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.838 1.255 . . . . 0.0 109.826 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.86 125.47 46.51 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 124.361 1.064 . . . . 0.0 109.188 175.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -92.5 103.88 16.25 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 124.666 1.187 . . . . 0.0 111.134 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.557 HG21 HD22 ' A' ' 62' ' ' LEU . 98.9 t -90.7 127.51 52.07 Favored Pre-proline 0 N--CA 1.481 1.099 0 C-N-CA 123.765 0.826 . . . . 0.0 111.084 -177.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -65.87 126.37 15.83 Favored 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.665 2.91 . . . . 0.0 112.573 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.536 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 21.4 m -66.89 -25.74 35.24 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -71.33 -39.12 71.58 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.061 1.345 . . . . 0.0 112.924 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.33 70.83 33.2 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 124.634 1.174 . . . . 0.0 111.945 176.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.59 -34.75 11.3 Favored 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 121.885 1.723 . . . . 0.0 111.526 -175.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -71.11 -24.91 62.38 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 113.779 1.029 . . . . 0.0 113.779 174.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.8 t -61.58 -39.67 91.98 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 124.558 1.143 . . . . 0.0 112.676 -177.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.1 m -72.41 -10.08 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 175.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.74 3.71 59.35 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 126.192 1.853 . . . . 0.0 115.188 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 52' ' ' VAL . 7.1 tp -70.74 118.9 14.11 Favored 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 119.519 1.66 . . . . 0.0 110.95 176.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 22.5 mmt180 -133.42 166.95 21.34 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 126.258 1.823 . . . . 0.0 111.04 175.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 40.2 mttp -73.33 127.89 33.93 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.027 1.331 . . . . 0.0 109.919 175.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.15 165.35 23.41 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.702 1.201 . . . . 0.0 111.619 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.44 120.85 7.9 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.191 1.396 . . . . 0.0 111.44 -177.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.25 159.57 85.05 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 123.605 0.762 . . . . 0.0 111.854 176.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.93 -38.98 3.56 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.892 2.395 . . . . 0.0 113.348 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -78.99 -44.27 22.69 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.988 0.915 . . . . 0.0 112.861 175.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.238 0 C-N-CA 127.221 2.208 . . . . 0.0 115.033 -171.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -110.63 -91.39 2.08 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 120.817 -1.177 . . . . 0.0 112.218 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -155.6 46.74 0.49 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 125.375 1.47 . . . . 0.0 112.853 -175.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.4 129.52 40.56 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 121.252 -0.905 . . . . 0.0 111.863 175.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 29.4 tptt -143.11 94.69 2.66 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.193 1.397 . . . . 0.0 111.012 178.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -107.09 174.44 5.89 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.375 1.47 . . . . 0.0 112.343 178.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.48 ' CE2' HD13 ' A' ' 62' ' ' LEU . 17.0 m-85 -79.23 117.67 20.45 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.072 0.949 . . . . 0.0 112.619 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.1 mtp180 -88.83 156.72 49.63 Favored Pre-proline 0 N--CA 1.477 0.918 0 C-N-CA 126.244 1.817 . . . . 0.0 113.144 178.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.45 134.27 28.21 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.009 2.473 . . . . 0.0 111.476 179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.7 -8.83 67.4 Favored Glycine 0 CA--C 1.536 1.351 0 C-N-CA 125.242 1.401 . . . . 0.0 114.22 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -59.37 129.29 41.31 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 118.727 1.264 . . . . 0.0 110.587 175.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -68.3 110.68 4.19 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.471 1.108 . . . . 0.0 109.493 174.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.32 155.09 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 C-N-CA 124.5 1.12 . . . . 0.0 111.127 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -96.79 129.09 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.896 0.879 . . . . 0.0 110.017 174.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.2 tp -143.67 100.28 5.13 Favored Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.106 0.962 . . . . 0.0 110.19 175.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.36 161.37 46.15 Favored 'Trans proline' 0 CA--C 1.55 1.324 0 C-N-CA 122.643 2.229 . . . . 0.0 112.593 177.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -75.47 -8.29 25.11 Favored 'Cis proline' 0 CA--C 1.543 0.948 0 N-CA-C 114.435 0.898 . . . . 0.0 114.435 0.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.47 -43.44 84.06 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.241 1.416 . . . . 0.0 112.443 176.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.08 -22.78 27.42 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 126.383 1.944 . . . . 0.0 113.738 175.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 142.65 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 126.013 1.725 . . . . 0.0 109.176 175.024 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -154.91 170.64 33.17 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 125.94 1.733 . . . . 0.0 111.651 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.1 137.41 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 124.394 1.078 . . . . 0.0 109.867 175.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -75.92 143.71 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 123.665 0.786 . . . . 0.0 109.658 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -107.84 -43.33 4.48 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.307 1.443 . . . . 0.0 112.693 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.17 175.49 40.33 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.467 1.032 . . . . 0.0 113.553 178.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.496 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.9 104.96 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 C-N-CA 125.362 1.465 . . . . 0.0 109.33 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.06 115.67 30.29 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 124.207 1.003 . . . . 0.0 109.851 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.21 112.79 17.87 Favored 'General case' 0 CA--C 1.541 0.599 0 O-C-N 121.118 -0.989 . . . . 0.0 111.889 174.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -83.35 173.57 11.44 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 124.966 1.306 . . . . 0.0 111.623 174.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.9 t -117.64 115.19 24.59 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 127.15 2.18 . . . . 0.0 109.959 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.3 p -147.96 132.28 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 C-N-CA 125.134 1.374 . . . . 0.0 110.879 176.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 55.26 25.55 7.52 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -179.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 72.86 12.16 78.56 Favored Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.92 1.248 . . . . 0.0 114.951 -173.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.21 114.45 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 126.717 2.007 . . . . 0.0 110.066 -176.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.9 m -70.21 119.88 15.06 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 121.806 -0.559 . . . . 0.0 110.754 174.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.2 mtt180 -120.1 134.12 55.34 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 124.523 1.129 . . . . 0.0 110.744 178.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -74.25 140.21 44.86 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.083 0.953 . . . . 0.0 112.016 176.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -141.59 128.42 20.51 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.655 1.582 . . . . 0.0 111.123 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.17 116.78 11.88 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 121.513 -0.742 . . . . 0.0 110.802 175.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.9 tt0 -74.89 102.65 4.82 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.41 1.084 . . . . 0.0 109.677 174.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.7 t -91.82 110.27 22.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.437 1.095 . . . . 0.0 109.411 175.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -100.53 132.26 46.01 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.904 1.282 . . . . 0.0 110.056 178.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -110.26 144.56 30.36 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 124.417 1.087 . . . . 0.0 111.597 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -68.21 161.25 45.38 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 122.43 2.087 . . . . 0.0 112.503 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.05 -18.8 20.07 Favored Glycine 0 CA--C 1.538 1.481 0 C-N-CA 125.646 1.593 . . . . 0.0 115.446 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -149.03 -173.09 4.28 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.773 1.629 . . . . 0.0 111.31 -178.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.6 ttm-85 -109.5 12.48 24.45 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 125.32 1.448 . . . . 0.0 112.927 174.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -54.09 132.59 43.09 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.468 1.107 . . . . 0.0 110.518 174.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 31.1 mtmt -125.15 140.77 52.58 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 125.031 1.332 . . . . 0.0 109.168 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 131.05 54.58 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 124.38 1.072 . . . . 0.0 108.9 175.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.66 103.59 13.88 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.586 1.154 . . . . 0.0 110.275 -174.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.602 HG11 HD12 ' A' ' 62' ' ' LEU . 88.9 t -93.7 128.24 42.66 Favored Pre-proline 0 N--CA 1.475 0.801 0 CA-C-O 118.445 -0.788 . . . . 0.0 111.029 -174.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -64.85 127.03 17.74 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.106 2.537 . . . . 0.0 111.822 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 26.1 m -63.54 -23.95 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 175.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.4 mt-10 -74.14 -45.44 48.77 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.489 1.115 . . . . 0.0 112.316 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.1 70.63 73.89 Favored Pre-proline 0 CA--C 1.546 0.793 0 C-N-CA 124.721 1.208 . . . . 0.0 111.062 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -70.71 -32.68 14.21 Favored 'Trans proline' 0 CA--C 1.535 0.575 0 C-N-CA 122.442 2.095 . . . . 0.0 111.734 -176.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 47.2 p-80 -72.52 -25.97 61.59 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 124.252 1.021 . . . . 0.0 113.526 174.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t -61.86 -39.57 92.34 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 124.761 1.224 . . . . 0.0 112.816 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -69.27 -13.38 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.77 0.828 . . . . 0.0 113.037 174.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.56 10.48 47.24 Favored Glycine 0 CA--C 1.537 1.446 0 C-N-CA 125.843 1.687 . . . . 0.0 114.849 -176.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.602 HD12 HG11 ' A' ' 52' ' ' VAL . 0.5 OUTLIER -69.9 128.91 38.0 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-N 119.023 1.411 . . . . 0.0 110.599 177.04 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 7.9 mtt-85 -136.4 157.36 46.97 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.675 1.59 . . . . 0.0 110.672 174.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.3 mttt -73.31 133.88 44.01 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 174.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.94 177.81 7.43 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-O 121.021 0.438 . . . . 0.0 110.138 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -149.57 114.78 5.46 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.587 0.755 . . . . 0.0 111.03 -177.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -102.65 158.37 31.9 Favored Pre-proline 0 CA--C 1.55 0.968 0 C-N-CA 125.305 1.442 . . . . 0.0 111.861 178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -69.61 168.13 22.26 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 123.333 2.688 . . . . 0.0 112.743 176.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -121.88 91.29 3.48 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.53 1.532 . . . . 0.0 110.872 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 . . . . . 0 N--CA 1.486 1.332 0 C-N-CA 128.913 2.885 . . . . 0.0 117.611 177.878 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 120.957 0.408 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.62 51.37 0.14 Allowed Glycine 0 CA--C 1.533 1.193 0 C-N-CA 123.989 0.804 . . . . 0.0 113.745 -175.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.2 m-70 -129.28 163.91 24.64 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 125.674 1.589 . . . . 0.0 111.739 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -99.53 95.72 7.18 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.936 1.294 . . . . 0.0 111.207 177.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 tptt -141.45 15.11 2.19 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.059 1.344 . . . . 0.0 113.726 176.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -105.97 168.67 8.97 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 124.683 1.193 . . . . 0.0 112.262 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.471 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.1 m-85 -74.26 131.99 41.7 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.625 -0.672 . . . . 0.0 112.532 175.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 42.7 mtt-85 -101.43 156.7 34.86 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 126.33 1.852 . . . . 0.0 112.504 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.75 134.19 27.41 Favored 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 122.757 2.305 . . . . 0.0 111.346 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.83 -5.97 80.26 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.345 1.45 . . . . 0.0 113.886 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -63.11 129.23 39.45 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 118.536 1.168 . . . . 0.0 110.533 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 ttmt -73.49 109.2 6.83 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 123.961 0.904 . . . . 0.0 109.399 -179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.6 162.69 22.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 124.878 1.271 . . . . 0.0 110.923 -178.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 131.58 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.298 1.039 . . . . 0.0 109.892 174.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 tp -146.23 101.27 4.12 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 124.242 1.017 . . . . 0.0 110.167 175.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.46 160.36 50.09 Favored 'Trans proline' 0 CA--C 1.549 1.251 0 C-N-CA 122.309 2.006 . . . . 0.0 112.42 177.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.89 -7.97 26.38 Favored 'Cis proline' 0 CA--C 1.545 1.032 0 N-CA-C 114.296 0.845 . . . . 0.0 114.296 0.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -57.84 -43.04 85.61 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 125.144 1.378 . . . . 0.0 112.557 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.0 -21.31 37.58 Favored Glycine 0 CA--C 1.534 1.246 0 C-N-CA 126.197 1.856 . . . . 0.0 113.591 175.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.34 148.02 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 C-N-CA 126.524 1.929 . . . . 0.0 109.307 174.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.75 168.71 34.98 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 125.741 1.639 . . . . 0.0 111.196 174.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.0 130.68 61.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 C-N-CA 123.958 0.903 . . . . 0.0 109.774 175.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.7 t -68.71 145.74 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 176.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.75 -38.13 4.04 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.327 1.051 . . . . 0.0 113.411 179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.38 173.6 37.79 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.455 1.026 . . . . 0.0 113.308 178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.465 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.93 130.16 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 125.101 1.36 . . . . 0.0 109.852 178.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.25 115.81 23.03 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.442 1.497 . . . . 0.0 110.108 175.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -81.19 112.73 18.8 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.375 0.67 . . . . 0.0 111.198 175.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -98.11 118.24 34.27 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 127.06 2.144 . . . . 0.0 110.733 176.309 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -64.79 103.38 0.7 Allowed 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 126.875 2.07 . . . . 0.0 111.094 174.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.3 t -131.35 125.25 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 C-N-CA 125.222 1.409 . . . . 0.0 110.516 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.06 25.5 10.85 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 124.447 1.099 . . . . 0.0 113.793 -177.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.72 -10.46 69.91 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 126.187 1.851 . . . . 0.0 115.303 -176.049 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.4 m -107.57 127.55 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 119.151 1.476 . . . . 0.0 110.69 177.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.4 119.78 23.56 Favored 'General case' 0 N--CA 1.467 0.424 0 O-C-N 120.941 -1.099 . . . . 0.0 109.95 176.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -104.67 133.96 48.64 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.732 0.813 . . . . 0.0 109.819 177.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.465 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.94 144.19 47.4 Favored 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.535 0.684 . . . . 0.0 111.653 176.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -143.26 129.43 19.76 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.834 1.654 . . . . 0.0 111.197 178.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.546 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.2 m-85 -74.64 117.59 16.64 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.169 0.588 . . . . 0.0 110.883 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -73.82 102.49 4.05 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 124.398 1.079 . . . . 0.0 110.599 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.6 t -92.19 109.83 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.546 1.138 . . . . 0.0 110.258 175.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -95.29 139.2 31.93 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 124.851 1.26 . . . . 0.0 110.219 174.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -115.83 143.14 30.17 Favored Pre-proline 0 N--CA 1.47 0.526 0 C-N-CA 124.57 1.148 . . . . 0.0 111.041 -178.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -67.74 161.62 42.99 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.383 2.055 . . . . 0.0 112.334 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.65 -12.53 40.41 Favored Glycine 0 CA--C 1.539 1.574 0 C-N-CA 125.282 1.42 . . . . 0.0 115.414 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.92 -171.84 3.98 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.388 1.475 . . . . 0.0 112.091 177.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -108.1 10.28 28.12 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.782 1.633 . . . . 0.0 112.732 174.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.7 m -52.56 131.66 34.4 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 123.419 0.688 . . . . 0.0 110.502 175.029 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.5 mtmt -124.09 140.87 52.56 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 124.155 0.982 . . . . 0.0 109.152 175.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.73 129.62 53.72 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 124.289 1.036 . . . . 0.0 109.543 175.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -98.42 98.81 9.98 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.363 1.065 . . . . 0.0 110.068 -175.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.581 HG21 HD22 ' A' ' 62' ' ' LEU . 96.9 t -84.41 127.44 65.98 Favored Pre-proline 0 N--CA 1.476 0.87 0 C-N-CA 123.469 0.707 . . . . 0.0 110.875 -176.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.16 124.74 13.44 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 123.57 2.847 . . . . 0.0 112.644 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.546 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -65.76 -26.27 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 178.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -69.09 -40.24 78.54 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 125.443 1.497 . . . . 0.0 112.851 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -140.11 70.85 34.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 C-N-CA 124.351 1.06 . . . . 0.0 112.66 176.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.13 -36.35 7.45 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 121.995 1.797 . . . . 0.0 111.63 -175.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.4 p-80 -68.89 -26.61 65.2 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 174.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 27.5 m -64.08 -34.18 77.44 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.44 -13.61 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 CA-C-N 118.727 0.694 . . . . 0.0 112.181 174.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.12 5.59 54.54 Favored Glycine 0 CA--C 1.538 1.529 0 C-N-CA 126.289 1.899 . . . . 0.0 114.765 -175.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.581 HD22 HG21 ' A' ' 52' ' ' VAL . 7.3 tp -75.8 124.32 27.1 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.09 1.445 . . . . 0.0 111.293 175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -146.27 162.2 38.61 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.127 1.371 . . . . 0.0 110.927 174.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.3 132.13 50.57 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.857 0.863 . . . . 0.0 110.112 175.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.74 172.85 6.91 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.946 0.898 . . . . 0.0 111.226 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.0 tp -142.4 129.37 20.71 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.711 0.804 . . . . 0.0 111.537 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.88 159.64 74.38 Favored Pre-proline 0 CA--C 1.552 1.039 0 C-N-CA 124.466 1.106 . . . . 0.0 112.677 175.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.04 85.61 0.99 Allowed 'Trans proline' 0 CA--C 1.544 1.014 0 C-N-CA 123.957 3.104 . . . . 0.0 111.922 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -125.66 -57.3 1.46 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 126.108 1.763 . . . . 0.0 112.573 175.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 . . . . . 0 C--O 1.253 1.275 0 C-N-CA 126.346 1.858 . . . . 0.0 111.832 -179.499 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.29 0 CA-C-O 119.474 -0.298 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 177.89 -45.35 0.1 OUTLIER Glycine 0 N--CA 1.474 1.233 0 C-N-CA 124.059 0.838 . . . . 0.0 113.487 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -67.69 166.32 15.4 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 124.13 0.972 . . . . 0.0 111.584 174.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.8 ttm -77.16 119.11 20.39 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.161 0.984 . . . . 0.0 111.035 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.4 mmtt -125.85 155.53 41.03 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 126.569 1.948 . . . . 0.0 111.249 179.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -91.62 170.44 9.92 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.942 1.297 . . . . 0.0 113.512 174.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.474 ' HB3' HG21 ' A' ' 23' ' ' VAL . 24.2 m-85 -80.49 114.81 19.65 Favored 'General case' 0 CA--C 1.536 0.44 0 O-C-N 121.168 -0.957 . . . . 0.0 112.169 175.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 40.7 mtt180 -81.1 158.38 69.93 Favored Pre-proline 0 N--CA 1.477 0.896 0 C-N-CA 126.089 1.756 . . . . 0.0 113.732 177.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.7 133.71 24.43 Favored 'Trans proline' 0 CA--C 1.537 0.642 0 C-N-CA 122.389 2.059 . . . . 0.0 111.209 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.6 -7.09 74.85 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 125.236 1.398 . . . . 0.0 114.202 -179.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -62.52 133.41 54.92 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.6 1.2 . . . . 0.0 110.706 178.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -72.51 110.83 7.18 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 123.49 0.716 . . . . 0.0 110.257 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.6 m -127.28 157.35 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 124.638 1.175 . . . . 0.0 111.963 -177.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.54 127.6 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 124.585 1.154 . . . . 0.0 110.358 175.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.3 tp -142.22 100.48 5.81 Favored Pre-proline 0 CA--C 1.543 0.691 0 C-N-CA 124.762 1.225 . . . . 0.0 109.73 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.24 160.58 49.27 Favored 'Trans proline' 0 CA--C 1.549 1.265 0 C-N-CA 122.535 2.157 . . . . 0.0 112.215 177.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.53 -7.99 28.51 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 N-CA-C 114.319 0.853 . . . . 0.0 114.319 0.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.5 m-85 -58.61 -42.89 89.23 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.205 1.402 . . . . 0.0 112.263 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.79 -24.6 20.0 Favored Glycine 0 CA--C 1.531 1.055 0 C-N-CA 126.686 2.089 . . . . 0.0 114.094 175.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.9 t -143.93 142.2 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 126.022 1.729 . . . . 0.0 108.815 175.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -153.43 169.93 32.23 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 125.539 1.543 . . . . 0.0 111.434 175.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 29.4 m -132.33 131.56 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.443 1.097 . . . . 0.0 110.218 175.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 7' ' ' PHE . 45.2 t -69.52 140.93 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.695 0 C-N-CA 123.702 0.801 . . . . 0.0 109.586 177.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -106.42 -44.3 4.55 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 125.097 1.359 . . . . 0.0 112.332 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 177.22 178.77 47.16 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.453 1.025 . . . . 0.0 113.397 175.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.441 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.2 mp -87.7 120.05 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 124.917 1.287 . . . . 0.0 109.844 176.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.2 116.72 30.24 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.154 0.982 . . . . 0.0 111.034 175.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -82.9 114.7 21.37 Favored 'General case' 0 CA--C 1.545 0.77 0 O-C-N 121.461 -0.774 . . . . 0.0 110.787 176.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 19.0 mmt-85 -96.87 126.03 41.73 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 127.626 2.37 . . . . 0.0 111.234 175.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.6 p -70.34 108.5 4.25 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.89 1.276 . . . . 0.0 111.576 175.181 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.5 t -131.96 125.43 55.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 125.249 1.419 . . . . 0.0 109.857 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 64.9 m 53.46 26.12 5.24 Favored 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 114.328 1.233 . . . . 0.0 114.328 -176.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.45 -5.68 83.95 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 125.775 1.655 . . . . 0.0 115.221 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.7 m -109.32 123.36 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 C-N-CA 125.403 1.481 . . . . 0.0 110.859 176.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -72.66 120.22 17.97 Favored 'General case' 0 CA--C 1.534 0.344 0 O-C-N 120.784 -1.197 . . . . 0.0 109.82 175.039 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -110.03 134.35 52.24 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.253 1.021 . . . . 0.0 109.847 177.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.441 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.66 140.84 46.37 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.398 0.679 . . . . 0.0 112.067 177.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -140.93 129.16 22.24 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 125.495 1.518 . . . . 0.0 111.426 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.511 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -71.78 119.33 15.79 Favored 'General case' 0 N--CA 1.468 0.464 0 O-C-N 121.766 -0.584 . . . . 0.0 109.798 175.363 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 35.7 mt-30 -75.44 102.6 5.24 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.426 1.09 . . . . 0.0 110.128 175.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.0 t -93.56 107.66 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 120.99 -1.069 . . . . 0.0 110.089 175.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -92.89 144.4 25.31 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.517 1.127 . . . . 0.0 109.91 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -122.1 143.5 39.12 Favored Pre-proline 0 CA--C 1.541 0.614 0 C-N-CA 124.262 1.025 . . . . 0.0 111.175 -177.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -68.09 161.2 45.37 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 80.17 -9.88 44.89 Favored Glycine 0 CA--C 1.538 1.5 0 C-N-CA 125.114 1.34 . . . . 0.0 115.616 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.6 t -154.81 -171.49 3.86 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 119.007 1.404 . . . . 0.0 112.558 177.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -108.25 9.07 28.08 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.892 2.077 . . . . 0.0 113.129 175.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 16.0 m -55.15 132.86 48.46 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.027 0.931 . . . . 0.0 111.81 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.8 mtmp? -126.82 142.88 51.42 Favored 'General case' 0 N--CA 1.463 0.218 0 C-N-CA 123.984 0.914 . . . . 0.0 108.99 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.61 132.45 55.14 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 125.262 1.425 . . . . 0.0 109.879 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -103.28 102.46 12.42 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 124.248 1.019 . . . . 0.0 110.306 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 62' ' ' LEU . 91.3 t -91.82 127.72 48.85 Favored Pre-proline 0 N--CA 1.476 0.855 0 C-N-CA 123.962 0.905 . . . . 0.0 111.183 -175.538 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -65.22 126.6 16.65 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.255 2.637 . . . . 0.0 112.128 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.511 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.0 m -64.94 -23.09 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 175.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -70.5 -47.02 62.54 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.944 1.698 . . . . 0.0 112.071 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.91 71.04 57.06 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.825 1.25 . . . . 0.0 111.409 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.16 -32.5 12.94 Favored 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 122.671 2.247 . . . . 0.0 111.956 -175.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -71.06 -25.81 62.8 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.121 0.968 . . . . 0.0 113.25 175.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -63.01 -38.68 92.18 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 124.72 1.208 . . . . 0.0 113.04 -176.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.19 -11.88 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 124.275 1.03 . . . . 0.0 113.216 174.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.55 5.91 55.23 Favored Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.087 1.803 . . . . 0.0 114.941 -177.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 52' ' ' VAL . 0.6 OUTLIER -65.6 127.2 30.94 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 118.77 1.285 . . . . 0.0 110.346 177.082 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 62.6 mtm-85 -133.22 155.36 49.5 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.184 1.793 . . . . 0.0 110.907 175.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 7.5 tttm -74.18 133.57 42.74 Favored 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -72.62 171.81 11.79 Favored 'General case' 0 CA--C 1.546 0.81 0 CA-C-O 121.359 0.6 . . . . 0.0 110.564 175.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -140.45 143.94 35.83 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.94 0.896 . . . . 0.0 110.624 -179.48 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.51 159.2 85.75 Favored Pre-proline 0 CA--C 1.553 1.068 0 C-N-CA 123.396 0.679 . . . . 0.0 111.465 175.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -70.36 -9.91 26.93 Favored 'Trans proline' 0 CA--C 1.543 0.937 0 C-N-CA 123.043 2.495 . . . . 0.0 113.896 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -129.34 23.21 5.55 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 127.013 2.125 . . . . 0.0 113.435 -175.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 . . . . . 0 N--CA 1.487 1.387 0 C-N-CA 128.639 2.776 . . . . 0.0 114.853 -174.526 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.281 0 N-CA-C 112.092 0.404 . . . . 0.0 112.092 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 91.41 168.94 41.65 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.852 1.215 . . . . 0.0 113.375 -176.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -113.39 86.95 2.49 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 125.761 1.624 . . . . 0.0 110.664 -175.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 30.2 ttm -140.98 74.38 1.46 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.986 1.314 . . . . 0.0 111.384 -178.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.54 70.42 0.73 Allowed 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.669 1.588 . . . . 0.0 112.24 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -68.17 -69.91 0.29 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 124.598 1.159 . . . . 0.0 112.346 177.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -89.59 123.21 33.45 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.073 0.949 . . . . 0.0 111.91 177.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -95.42 156.33 37.72 Favored Pre-proline 0 N--CA 1.476 0.842 0 C-N-CA 125.961 1.704 . . . . 0.0 112.887 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -68.87 131.56 22.8 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 122.895 2.397 . . . . 0.0 111.359 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.72 -5.24 82.69 Favored Glycine 0 CA--C 1.537 1.417 0 C-N-CA 124.874 1.226 . . . . 0.0 114.691 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -60.66 132.2 53.13 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 119.042 1.421 . . . . 0.0 111.009 175.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -67.76 109.84 3.53 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.977 0.911 . . . . 0.0 109.541 174.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.1 m -123.85 154.01 30.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.783 1.233 . . . . 0.0 110.728 178.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.0 p -99.71 126.96 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.644 1.178 . . . . 0.0 109.882 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.432 HD22 HD13 ' A' ' 62' ' ' LEU . 8.6 tp -141.59 100.74 6.11 Favored Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 124.433 1.093 . . . . 0.0 110.378 175.464 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.05 160.25 50.68 Favored 'Trans proline' 0 CA--C 1.549 1.248 0 C-N-CA 122.405 2.07 . . . . 0.0 112.242 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -75.96 -7.98 26.6 Favored 'Cis proline' 0 CA--C 1.543 0.952 0 N-CA-C 114.46 0.908 . . . . 0.0 114.46 -0.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -58.72 -42.71 89.35 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.026 1.331 . . . . 0.0 112.405 178.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.91 -22.07 36.14 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 126.372 1.939 . . . . 0.0 114.092 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.9 p -145.44 151.15 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 C-N-CA 126.489 1.916 . . . . 0.0 109.432 175.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -161.02 169.94 36.73 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 125.971 1.748 . . . . 0.0 111.192 175.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 m -133.77 131.55 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 C-N-CA 124.706 1.202 . . . . 0.0 110.035 175.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 44.2 t -70.71 142.08 16.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 123.254 0.622 . . . . 0.0 109.792 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -105.55 -39.48 6.09 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.864 1.266 . . . . 0.0 113.096 179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.09 176.1 38.9 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 124.872 1.225 . . . . 0.0 113.348 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.444 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.3 mp -87.39 118.39 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 C-N-CA 125.357 1.463 . . . . 0.0 109.818 178.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.26 115.74 29.27 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.901 1.28 . . . . 0.0 109.91 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -81.41 112.81 19.02 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 121.522 -0.737 . . . . 0.0 111.92 175.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.88 115.01 26.8 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 126.457 1.903 . . . . 0.0 111.383 177.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.49 107.89 2.63 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 127.344 2.258 . . . . 0.0 111.815 175.084 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.3 t -136.82 126.01 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 125.774 1.63 . . . . 0.0 110.331 -177.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.3 t 57.58 25.58 11.78 Favored 'General case' 0 N--CA 1.481 1.089 0 O-C-N 120.93 -1.106 . . . . 0.0 113.746 -178.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 85.38 -10.12 65.09 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 125.956 1.741 . . . . 0.0 115.376 -176.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.2 m -104.02 129.75 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 119.09 1.445 . . . . 0.0 110.779 175.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.8 m -89.39 120.04 30.38 Favored 'General case' 0 N--CA 1.47 0.529 0 O-C-N 121.062 -1.023 . . . . 0.0 110.343 176.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -107.17 134.15 50.7 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.004 0.921 . . . . 0.0 110.423 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.444 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.18 139.03 46.04 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.528 0.731 . . . . 0.0 111.577 177.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -140.11 127.62 21.51 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.848 1.659 . . . . 0.0 111.518 179.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.549 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 20.4 m-85 -71.27 119.53 15.54 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.457 0.703 . . . . 0.0 110.027 174.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -78.15 102.44 7.53 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.228 1.011 . . . . 0.0 110.555 175.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.93 111.85 24.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 C-N-CA 124.219 1.008 . . . . 0.0 109.87 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.8 132.03 47.78 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.975 1.31 . . . . 0.0 110.213 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -109.21 145.33 31.57 Favored Pre-proline 0 N--CA 1.472 0.673 0 C-N-CA 123.807 0.843 . . . . 0.0 111.559 -175.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.51 160.76 47.91 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 122.368 2.046 . . . . 0.0 112.246 177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 -16.81 19.08 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 125.528 1.537 . . . . 0.0 115.513 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.8 m -147.99 -173.02 4.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.281 1.832 . . . . 0.0 111.258 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -111.23 9.72 21.75 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 126.078 1.751 . . . . 0.0 111.922 175.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.5 m -52.23 134.1 33.61 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.774 1.23 . . . . 0.0 110.587 175.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 12.7 mtmt -126.65 140.85 52.1 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.173 0.989 . . . . 0.0 109.31 177.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.45 123.97 44.3 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 124.215 1.006 . . . . 0.0 109.087 175.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -91.85 107.29 19.1 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.658 1.183 . . . . 0.0 111.103 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.635 HG21 HD22 ' A' ' 62' ' ' LEU . 97.4 t -96.33 127.48 40.06 Favored Pre-proline 0 N--CA 1.48 1.05 0 C-N-CA 123.643 0.777 . . . . 0.0 111.514 -178.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -66.15 130.56 24.49 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.57 2.847 . . . . 0.0 111.944 -178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 29.8 m -66.11 -23.89 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 176.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -74.3 -44.22 53.54 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.682 0.793 . . . . 0.0 112.68 -177.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.94 70.81 57.03 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 124.472 1.109 . . . . 0.0 111.088 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -70.21 -30.05 20.79 Favored 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.281 1.988 . . . . 0.0 111.85 -175.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.1 p80 -71.52 -22.38 61.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.366 1.066 . . . . 0.0 113.462 174.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 t -63.99 -37.31 86.97 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 124.766 1.226 . . . . 0.0 112.743 -176.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.5 m -74.29 -10.66 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 C-N-CA 124.303 1.041 . . . . 0.0 113.355 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.79 2.65 59.64 Favored Glycine 0 CA--C 1.54 1.604 0 C-N-CA 126.203 1.858 . . . . 0.0 115.392 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.635 HD22 HG21 ' A' ' 52' ' ' VAL . 11.8 tp -70.26 123.63 22.14 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 119.567 1.683 . . . . 0.0 111.216 175.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 20.4 mtt85 -139.52 165.51 27.04 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.577 1.551 . . . . 0.0 111.773 174.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -67.82 129.79 41.0 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 125.107 1.363 . . . . 0.0 110.363 175.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -82.83 81.38 8.57 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 124.152 0.981 . . . . 0.0 110.366 175.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.92 109.15 0.77 Allowed 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 126.189 1.796 . . . . 0.0 111.486 -178.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.24 159.26 81.35 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 124.35 1.06 . . . . 0.0 113.065 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -72.32 177.86 6.79 Favored 'Trans proline' 0 CA--C 1.545 1.043 0 C-N-CA 124.015 3.143 . . . . 0.0 112.734 174.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.6 74.0 1.53 Allowed 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 126.168 1.787 . . . . 0.0 111.581 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.252 1.215 0 C-N-CA 124.644 1.178 . . . . 0.0 113.851 -178.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.26 174.26 48.81 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.437 1.018 . . . . 0.0 112.86 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -117.09 47.12 1.55 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.508 1.123 . . . . 0.0 112.952 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 mtt -73.71 156.28 38.07 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 124.62 1.168 . . . . 0.0 111.294 175.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 45.8 mttt -137.74 95.72 3.1 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.72 1.608 . . . . 0.0 111.6 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -75.89 169.28 18.46 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.394 1.078 . . . . 0.0 112.514 174.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.452 ' CE2' HD23 ' A' ' 62' ' ' LEU . 14.5 m-85 -76.73 131.27 38.66 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.885 0.874 . . . . 0.0 112.364 175.024 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 -97.53 158.32 33.28 Favored Pre-proline 0 N--CA 1.477 0.875 0 C-N-CA 125.951 1.701 . . . . 0.0 113.025 178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.28 133.54 26.71 Favored 'Trans proline' 0 CA--C 1.537 0.659 0 C-N-CA 123.078 2.518 . . . . 0.0 111.266 176.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.87 -5.79 81.06 Favored Glycine 0 CA--C 1.534 1.253 0 C-N-CA 125.352 1.453 . . . . 0.0 113.933 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -60.98 129.34 40.9 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 118.753 1.277 . . . . 0.0 110.172 178.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 18.1 mttt -70.97 108.42 4.54 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.361 1.064 . . . . 0.0 109.577 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.25 158.83 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.755 1.222 . . . . 0.0 111.272 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -98.97 130.74 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 124.623 1.169 . . . . 0.0 109.639 175.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.457 HD22 HD13 ' A' ' 62' ' ' LEU . 8.5 tp -146.44 100.59 4.09 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 123.967 0.907 . . . . 0.0 110.338 174.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -69.45 160.79 48.45 Favored 'Trans proline' 0 CA--C 1.549 1.225 0 C-N-CA 122.377 2.052 . . . . 0.0 112.479 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -75.64 -8.69 25.86 Favored 'Cis proline' 0 CA--C 1.544 0.982 0 N-CA-C 114.392 0.882 . . . . 0.0 114.392 0.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 -57.7 -43.05 84.87 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.1 1.36 . . . . 0.0 112.362 177.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.44 -22.89 27.8 Favored Glycine 0 CA--C 1.532 1.145 0 C-N-CA 126.534 2.016 . . . . 0.0 113.955 175.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 37.8 t -145.32 141.1 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 126.105 1.762 . . . . 0.0 108.728 175.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.28 168.56 30.85 Favored Glycine 0 CA--C 1.529 0.968 0 C-N-CA 126.093 1.806 . . . . 0.0 111.645 174.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 14.2 m -130.74 132.46 64.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 124.037 0.935 . . . . 0.0 110.01 175.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.57 141.08 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 124.177 0.991 . . . . 0.0 109.636 177.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.03 -40.91 5.09 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.249 1.02 . . . . 0.0 112.961 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 171.02 176.01 39.93 Favored Glycine 0 CA--C 1.53 0.989 0 C-N-CA 124.835 1.207 . . . . 0.0 113.086 179.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.477 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.4 mp -87.1 120.93 37.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 125.266 1.426 . . . . 0.0 109.625 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.72 115.68 27.45 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.004 1.322 . . . . 0.0 110.61 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -79.81 113.12 17.72 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.46 0.704 . . . . 0.0 112.274 175.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -99.09 123.36 43.33 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 126.345 1.858 . . . . 0.0 111.722 176.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.3 t -65.1 113.2 3.77 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 126.063 1.745 . . . . 0.0 111.4 174.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.23 125.33 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 C-N-CA 125.861 1.665 . . . . 0.0 109.868 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.1 t 56.96 25.92 11.2 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 120.835 -1.166 . . . . 0.0 113.603 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.48 -9.1 65.66 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 126.252 1.882 . . . . 0.0 115.269 -175.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.1 p -108.18 124.14 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.53 1.532 . . . . 0.0 110.964 177.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.82 120.19 21.63 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.122 -0.986 . . . . 0.0 109.424 175.062 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.4 mtt180 -105.35 134.32 48.66 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 124.278 1.031 . . . . 0.0 110.274 176.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.477 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -70.75 141.85 51.45 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.631 0.772 . . . . 0.0 112.245 175.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -142.24 128.36 19.71 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 126.01 1.724 . . . . 0.0 111.358 178.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.541 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.1 m-85 -71.53 119.2 15.34 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 121.667 -0.646 . . . . 0.0 110.192 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -75.93 102.5 5.6 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.569 1.148 . . . . 0.0 110.401 176.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.4 t -93.46 109.04 21.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 O-C-N 120.987 -1.071 . . . . 0.0 109.947 177.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.55 133.58 41.93 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.886 1.274 . . . . 0.0 110.265 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -111.14 144.9 31.37 Favored Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.951 0.9 . . . . 0.0 111.499 -176.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.1 Cg_endo -68.13 158.91 55.39 Favored 'Trans proline' 0 CA--C 1.542 0.88 0 C-N-CA 122.346 2.031 . . . . 0.0 112.283 177.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.87 -14.14 44.61 Favored Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.463 1.506 . . . . 0.0 115.378 -179.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 57.6 p -152.36 -175.44 5.27 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 126.527 1.931 . . . . 0.0 111.725 178.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.95 7.26 31.98 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 126.148 1.779 . . . . 0.0 112.008 175.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.1 m -50.33 128.53 19.84 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 124.425 1.09 . . . . 0.0 110.444 175.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 9.1 mttm -123.23 140.84 52.6 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 124.684 1.194 . . . . 0.0 109.675 174.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -119.42 131.96 55.74 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 124.388 1.075 . . . . 0.0 109.148 174.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -100.23 100.24 11.03 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.539 1.136 . . . . 0.0 110.19 -175.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.656 HG21 HD22 ' A' ' 62' ' ' LEU . 96.6 t -87.95 127.59 57.17 Favored Pre-proline 0 N--CA 1.478 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.232 -176.756 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -64.97 127.31 18.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.194 2.596 . . . . 0.0 111.867 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.541 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 24.0 m -63.36 -23.95 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 175.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -73.2 -47.11 46.33 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.917 1.287 . . . . 0.0 112.245 -178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -134.08 70.84 73.89 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 124.379 1.071 . . . . 0.0 111.181 178.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -71.31 -35.19 8.79 Favored 'Trans proline' 0 CA--C 1.535 0.536 0 C-N-CA 122.127 1.885 . . . . 0.0 111.577 -176.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -71.29 -24.45 62.15 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.464 1.106 . . . . 0.0 113.548 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.3 t -60.69 -42.44 97.18 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.002 1.321 . . . . 0.0 112.888 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.08 -14.36 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 124.001 0.92 . . . . 0.0 113.394 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.42 6.23 55.27 Favored Glycine 0 CA--C 1.539 1.57 0 C-N-CA 125.833 1.682 . . . . 0.0 114.864 -175.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.656 HD22 HG21 ' A' ' 52' ' ' VAL . 9.8 tp -74.98 119.6 19.38 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 119.229 1.515 . . . . 0.0 110.788 175.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 52.1 mtt180 -139.93 163.7 31.97 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.718 1.207 . . . . 0.0 111.964 175.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 21.8 mtpt -64.78 127.18 30.46 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.734 1.214 . . . . 0.0 109.828 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 176.25 6.65 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.931 0.892 . . . . 0.0 110.861 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -149.2 119.75 7.44 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.89 0.876 . . . . 0.0 110.411 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.9 160.04 72.01 Favored Pre-proline 0 CA--C 1.554 1.103 0 C-N-CA 123.104 0.562 . . . . 0.0 111.567 176.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -69.68 169.91 17.7 Favored 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 122.898 2.399 . . . . 0.0 112.314 175.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.97 125.47 49.49 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.577 1.551 . . . . 0.0 110.326 177.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 . . . . . 0 C--O 1.254 1.318 0 C-N-CA 125.535 1.534 . . . . 0.0 113.887 175.298 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 N-CA-C 112.203 0.445 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.91 -84.07 1.14 Allowed Glycine 0 CA--C 1.534 1.246 0 O-C-N 120.336 -1.478 . . . . 0.0 112.873 -177.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -147.72 89.63 1.78 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.139 1.376 . . . . 0.0 111.525 179.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 10.4 ttm -152.96 -52.78 0.11 Allowed 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.12 1.155 . . . . 0.0 114.12 177.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -137.73 72.73 1.42 Allowed 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 126.246 1.818 . . . . 0.0 110.244 175.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 55.5 mm-40 -119.65 168.22 11.25 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.264 1.426 . . . . 0.0 111.575 177.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.472 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.7 m-85 -74.19 126.86 31.52 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 124.01 0.924 . . . . 0.0 112.799 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 46.8 mtp180 -96.0 156.91 36.61 Favored Pre-proline 0 N--CA 1.478 0.927 0 C-N-CA 125.678 1.591 . . . . 0.0 112.994 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.29 134.64 29.51 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 123.126 2.551 . . . . 0.0 111.5 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.86 -6.12 79.77 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.355 1.455 . . . . 0.0 114.303 -178.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -60.62 129.28 40.78 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 118.971 1.385 . . . . 0.0 110.611 176.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -69.77 113.76 7.33 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.765 0.826 . . . . 0.0 109.264 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 32.0 m -126.86 158.86 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.979 1.311 . . . . 0.0 110.838 179.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.2 p -99.99 130.06 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 124.204 1.002 . . . . 0.0 109.573 175.072 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -145.13 100.64 4.51 Favored Pre-proline 0 CA--C 1.542 0.668 0 C-N-CA 124.275 1.03 . . . . 0.0 110.207 175.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.9 160.27 50.49 Favored 'Trans proline' 0 CA--C 1.55 1.316 0 C-N-CA 122.436 2.091 . . . . 0.0 112.4 177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_endo -76.09 -8.27 27.18 Favored 'Cis proline' 0 CA--C 1.543 0.966 0 N-CA-C 114.372 0.874 . . . . 0.0 114.372 -0.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -58.03 -43.1 86.59 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.101 1.361 . . . . 0.0 112.369 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.29 -23.42 24.66 Favored Glycine 0 CA--C 1.533 1.168 0 C-N-CA 126.564 2.031 . . . . 0.0 113.789 174.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.5 t -145.36 140.34 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 C-N-CA 126.05 1.74 . . . . 0.0 108.741 174.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.55 170.02 30.43 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 126.011 1.767 . . . . 0.0 111.515 174.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -132.03 134.75 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 C-N-CA 124.056 0.942 . . . . 0.0 110.223 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -72.58 141.97 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.029 0.931 . . . . 0.0 109.899 178.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.65 -40.84 4.96 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 125.082 1.353 . . . . 0.0 113.046 -179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.78 175.07 37.95 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.64 1.114 . . . . 0.0 113.381 178.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.48 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -85.55 129.3 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 C-N-CA 125.266 1.426 . . . . 0.0 109.984 178.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -122.19 115.71 22.88 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 125.757 1.623 . . . . 0.0 110.664 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 9.5 mt-30 -80.57 112.8 18.27 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.571 0.748 . . . . 0.0 111.76 175.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.07 118.23 36.35 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.413 2.285 . . . . 0.0 110.656 179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 59.5 m -68.38 106.4 2.49 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 125.032 1.333 . . . . 0.0 111.308 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.1 140.91 39.57 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 C-N-CA 126.077 1.751 . . . . 0.0 110.091 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t 54.07 25.33 5.48 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.495 -1.378 . . . . 0.0 114.188 -178.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.76 86.7 Favored Glycine 0 CA--C 1.539 1.562 0 C-N-CA 125.074 1.321 . . . . 0.0 115.549 -175.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.21 129.83 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 126.196 1.799 . . . . 0.0 111.462 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -75.66 119.95 20.4 Favored 'General case' 0 N--CA 1.466 0.34 0 O-C-N 120.657 -1.277 . . . . 0.0 109.029 175.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.6 mtt180 -113.05 134.12 54.67 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.178 0.991 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -71.55 143.57 49.87 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.588 0.709 . . . . 0.0 111.398 175.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -142.98 129.7 20.37 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 126.047 1.739 . . . . 0.0 110.826 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.562 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.3 m-85 -75.36 117.4 17.12 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.363 0.665 . . . . 0.0 111.312 175.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -73.95 102.63 4.18 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.958 0.903 . . . . 0.0 110.04 174.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -91.16 110.22 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.412 1.085 . . . . 0.0 108.853 175.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -100.82 133.36 45.41 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.74 1.216 . . . . 0.0 109.906 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -109.44 146.44 33.98 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 124.145 0.978 . . . . 0.0 111.519 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -68.65 160.62 48.67 Favored 'Trans proline' 0 CA--C 1.541 0.858 0 C-N-CA 122.346 2.031 . . . . 0.0 112.186 176.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.41 -13.41 40.57 Favored Glycine 0 CA--C 1.54 1.621 0 C-N-CA 125.328 1.442 . . . . 0.0 115.569 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 56.2 p -152.16 -168.01 2.94 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.865 1.666 . . . . 0.0 111.603 176.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -112.07 10.39 20.36 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 125.995 1.718 . . . . 0.0 112.257 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 m -52.71 132.32 36.03 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 124.102 0.961 . . . . 0.0 110.847 175.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.5 ptpp? -124.41 141.3 52.18 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.275 1.43 . . . . 0.0 110.243 175.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.3 128.61 51.28 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 123.931 0.892 . . . . 0.0 109.386 175.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -97.5 99.69 11.11 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.402 1.081 . . . . 0.0 110.239 -176.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.555 HG21 HD22 ' A' ' 62' ' ' LEU . 95.0 t -85.78 127.65 61.74 Favored Pre-proline 0 N--CA 1.476 0.845 0 C-N-CA 123.668 0.787 . . . . 0.0 110.588 -177.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 123.195 2.597 . . . . 0.0 111.77 179.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.562 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 20.7 m -64.8 -23.51 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 176.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -73.64 -42.52 61.31 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.997 0.919 . . . . 0.0 112.453 -177.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.72 70.71 51.36 Favored Pre-proline 0 CA--C 1.544 0.73 0 C-N-CA 124.776 1.231 . . . . 0.0 110.689 178.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -69.38 -30.35 24.17 Favored 'Trans proline' 0 CA--C 1.534 0.479 0 C-N-CA 121.857 1.704 . . . . 0.0 111.719 -175.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 30.4 p80 -71.59 -22.04 61.78 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 114.038 1.125 . . . . 0.0 114.038 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 40.7 p -66.41 -35.05 79.35 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 120.138 1.336 . . . . 0.0 112.945 -174.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.3 -10.39 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 125.455 1.502 . . . . 0.0 112.981 174.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.41 2.82 58.8 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.281 1.896 . . . . 0.0 115.223 -176.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.555 HD22 HG21 ' A' ' 52' ' ' VAL . 6.9 tp -72.67 123.23 22.85 Favored 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 119.367 1.583 . . . . 0.0 111.829 177.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 6.1 ptt180 -146.35 163.56 35.17 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 125.82 1.648 . . . . 0.0 110.854 174.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -62.36 131.93 50.91 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 118.291 0.496 . . . . 0.0 110.113 175.01 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -79.12 173.35 12.67 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.082 0.953 . . . . 0.0 110.809 174.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -152.56 121.86 6.73 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.741 1.216 . . . . 0.0 111.276 -177.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.88 158.11 84.5 Favored Pre-proline 0 CA--C 1.551 1.012 0 C-N-CA 123.584 0.753 . . . . 0.0 111.555 174.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.48 164.94 32.38 Favored 'Trans proline' 0 CA--C 1.542 0.906 0 C-N-CA 123.178 2.586 . . . . 0.0 112.461 176.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.82 117.06 8.98 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 125.948 1.699 . . . . 0.0 110.326 -177.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 . . . . . 0 N--CA 1.486 1.335 0 C-N-CA 128.57 2.748 . . . . 0.0 116.541 -177.179 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.763 -0.088 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.64 67.77 0.05 OUTLIER Glycine 0 CA--C 1.533 1.199 0 C-N-CA 123.527 0.584 . . . . 0.0 114.432 179.399 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.27 -23.99 19.12 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 114.288 1.218 . . . . 0.0 114.288 175.024 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 mtt -120.05 82.81 1.95 Allowed 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.685 1.594 . . . . 0.0 111.233 177.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.48 113.02 16.12 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.589 0.756 . . . . 0.0 109.32 174.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.06 -72.26 0.69 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.537 1.135 . . . . 0.0 111.06 176.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' A' ' 62' ' ' LEU . 13.4 m-85 -83.9 133.45 34.72 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.998 0.919 . . . . 0.0 112.377 175.326 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 -101.09 156.61 34.94 Favored Pre-proline 0 N--CA 1.474 0.754 0 C-N-CA 126.018 1.727 . . . . 0.0 112.812 179.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -68.92 132.66 25.19 Favored 'Trans proline' 0 CA--C 1.537 0.635 0 C-N-CA 123.081 2.52 . . . . 0.0 111.169 177.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.92 -6.35 79.12 Favored Glycine 0 CA--C 1.534 1.24 0 C-N-CA 125.196 1.379 . . . . 0.0 113.843 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.7 129.36 40.68 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 118.706 1.253 . . . . 0.0 110.34 179.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.7 tttt -72.26 110.65 6.85 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.604 0.762 . . . . 0.0 109.561 -179.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.8 m -125.01 159.41 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.381 1.073 . . . . 0.0 111.639 -177.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -99.75 130.15 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.669 1.188 . . . . 0.0 109.65 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 11.5 tp -146.29 100.78 4.13 Favored Pre-proline 0 CA--C 1.542 0.659 0 C-N-CA 124.157 0.983 . . . . 0.0 110.225 175.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -69.52 160.75 48.57 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.45 2.1 . . . . 0.0 112.623 177.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -75.76 -8.55 26.18 Favored 'Cis proline' 0 CA--C 1.543 0.974 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -57.8 -42.84 85.05 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.099 1.36 . . . . 0.0 112.444 177.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.88 -22.79 26.77 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 126.445 1.974 . . . . 0.0 113.827 175.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -145.45 140.92 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 C-N-CA 125.942 1.697 . . . . 0.0 108.763 175.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.04 169.51 30.76 Favored Glycine 0 CA--C 1.531 1.053 0 C-N-CA 126.054 1.787 . . . . 0.0 111.465 174.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.4 m -131.59 134.57 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 124.151 0.981 . . . . 0.0 110.135 174.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -71.71 143.04 14.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 123.91 0.884 . . . . 0.0 109.852 177.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -109.05 -44.56 3.94 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.196 1.398 . . . . 0.0 112.764 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.69 174.81 40.18 Favored Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.488 1.042 . . . . 0.0 113.459 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.452 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -85.32 128.95 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 C-N-CA 125.065 1.346 . . . . 0.0 110.017 178.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.64 115.74 23.31 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.856 1.662 . . . . 0.0 110.028 175.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -81.1 112.87 18.87 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.601 0.76 . . . . 0.0 111.625 174.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 14.7 mmm180 -101.52 118.25 36.57 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 126.079 1.752 . . . . 0.0 111.426 178.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.41 96.44 0.68 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 127.296 2.239 . . . . 0.0 110.837 175.055 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 47.2 t -134.0 140.15 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 C-N-CA 125.573 1.549 . . . . 0.0 109.704 -178.083 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 t 55.78 25.4 8.33 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 120.901 -1.124 . . . . 0.0 113.806 -176.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.82 10.31 86.13 Favored Glycine 0 CA--C 1.539 1.578 0 C-N-CA 124.906 1.241 . . . . 0.0 115.138 -175.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.5 p -130.95 129.7 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 125.971 1.708 . . . . 0.0 111.313 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 97.9 p -76.37 119.89 20.86 Favored 'General case' 0 CA--C 1.537 0.463 0 O-C-N 120.994 -1.067 . . . . 0.0 109.381 175.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -114.21 134.11 55.15 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.541 0.736 . . . . 0.0 109.843 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.452 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 142.02 46.34 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 121.495 0.664 . . . . 0.0 111.545 177.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -141.73 127.16 18.81 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.853 1.661 . . . . 0.0 111.193 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.521 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 19.6 m-85 -73.65 117.51 15.51 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 123.287 0.635 . . . . 0.0 111.087 174.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 38.0 tt0 -73.32 104.26 4.28 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.609 1.164 . . . . 0.0 109.786 174.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.5 t -93.79 109.34 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.416 1.086 . . . . 0.0 109.53 175.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -99.88 129.42 45.97 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.947 1.299 . . . . 0.0 110.236 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -106.51 145.5 31.15 Favored Pre-proline 0 N--CA 1.474 0.75 0 C-N-CA 124.011 0.924 . . . . 0.0 111.617 -176.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -68.27 159.57 52.67 Favored 'Trans proline' 0 CA--C 1.542 0.901 0 C-N-CA 122.404 2.07 . . . . 0.0 112.375 177.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.15 -14.54 43.9 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.537 1.541 . . . . 0.0 115.405 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 96.0 p -152.54 -173.98 4.75 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.4 1.88 . . . . 0.0 111.443 177.234 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 21.0 ttt180 -107.94 15.51 24.34 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.424 1.49 . . . . 0.0 111.943 174.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.0 m -56.24 134.27 53.09 Favored 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.618 0.767 . . . . 0.0 110.307 174.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 15.1 mtmt -126.41 140.77 52.22 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 124.971 1.308 . . . . 0.0 109.309 176.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -121.88 130.07 53.07 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 123.896 0.878 . . . . 0.0 109.389 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -98.56 99.02 10.12 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 110.17 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.605 HG21 HD22 ' A' ' 62' ' ' LEU . 99.1 t -86.98 127.91 57.85 Favored Pre-proline 0 N--CA 1.477 0.916 0 C-N-CA 123.628 0.771 . . . . 0.0 110.91 -176.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -65.24 128.21 19.97 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 123.225 2.617 . . . . 0.0 111.91 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 25.4 m -64.25 -23.79 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 113.827 1.047 . . . . 0.0 113.827 175.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -73.91 -43.91 56.86 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.86 0.864 . . . . 0.0 112.339 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -137.34 70.81 54.1 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.732 1.213 . . . . 0.0 110.97 178.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.64 -32.91 14.1 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 122.192 1.928 . . . . 0.0 111.454 -176.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -70.4 -25.03 63.04 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 124.079 0.952 . . . . 0.0 113.496 174.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 12.5 m -63.55 -35.78 81.62 Favored 'General case' 0 N--CA 1.482 1.138 0 CA-C-N 119.835 1.198 . . . . 0.0 113.48 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.7 p -73.02 -15.06 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-N 118.582 0.628 . . . . 0.0 112.069 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.79 5.77 53.26 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 126.169 1.842 . . . . 0.0 114.628 -175.123 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.605 HD22 HG21 ' A' ' 52' ' ' VAL . 7.0 tp -75.92 115.35 15.53 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 118.936 1.368 . . . . 0.0 111.315 176.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -137.56 164.21 29.3 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 124.931 1.292 . . . . 0.0 111.451 174.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 51.7 mttp -62.7 124.37 20.83 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.439 1.496 . . . . 0.0 109.939 175.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -70.25 169.68 13.25 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.931 0.892 . . . . 0.0 111.353 175.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.9 116.43 5.07 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.636 0.774 . . . . 0.0 111.745 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -72.03 158.1 88.26 Favored Pre-proline 0 CA--C 1.554 1.098 0 C-N-CA 123.568 0.747 . . . . 0.0 112.337 175.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -70.0 110.93 2.72 Favored 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.966 3.11 . . . . 0.0 111.764 176.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -144.61 101.41 3.67 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.193 1.397 . . . . 0.0 110.905 178.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.253 1.25 0 C-N-CA 125.374 1.47 . . . . 0.0 114.298 177.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -58.57 158.69 17.96 Favored Glycine 0 CA--C 1.537 1.461 0 C-N-CA 124.372 0.987 . . . . 0.0 114.706 178.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.5 p80 -124.97 -34.25 2.81 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 125.829 1.652 . . . . 0.0 113.799 -175.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tmt? -72.62 -44.17 62.31 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 124.248 1.019 . . . . 0.0 111.411 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mmtp -87.39 165.36 15.64 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.436 1.495 . . . . 0.0 110.834 174.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -131.09 -76.02 0.52 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.063 1.345 . . . . 0.0 110.702 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -83.91 117.81 23.58 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 123.782 0.833 . . . . 0.0 112.636 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 60.4 mtt-85 -81.7 158.77 67.76 Favored Pre-proline 0 N--CA 1.477 0.895 0 C-N-CA 125.87 1.668 . . . . 0.0 113.242 176.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -70.59 132.4 21.92 Favored 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 122.901 2.4 . . . . 0.0 110.838 175.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.84 -6.13 79.66 Favored Glycine 0 CA--C 1.536 1.391 0 O-C-N 121.476 -0.765 . . . . 0.0 114.829 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -63.72 132.98 52.71 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 118.724 1.262 . . . . 0.0 110.994 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 25.9 mttt -69.87 104.28 2.44 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.286 0.635 . . . . 0.0 111.365 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.7 m -117.53 156.59 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 125.193 1.397 . . . . 0.0 111.253 178.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 p -102.84 128.18 55.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 125.554 1.541 . . . . 0.0 109.753 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.491 HD22 HD13 ' A' ' 62' ' ' LEU . 7.6 tp -143.89 99.87 5.08 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.461 1.104 . . . . 0.0 110.327 175.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -68.55 159.47 53.41 Favored 'Trans proline' 0 CA--C 1.55 1.29 0 C-N-CA 122.336 2.024 . . . . 0.0 112.16 176.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -76.29 -8.48 27.9 Favored 'Cis proline' 0 CA--C 1.544 0.998 0 N-CA-C 114.297 0.845 . . . . 0.0 114.297 0.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -59.69 -39.84 85.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.975 1.31 . . . . 0.0 112.672 178.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.38 -23.41 18.92 Favored Glycine 0 CA--C 1.534 1.258 0 C-N-CA 126.701 2.095 . . . . 0.0 114.302 174.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.18 131.03 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 126.079 1.752 . . . . 0.0 108.29 174.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -126.54 167.54 18.94 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.851 1.691 . . . . 0.0 112.84 175.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -133.2 114.4 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.252 1.421 . . . . 0.0 110.123 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.1 t -65.79 128.16 28.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.825 0.85 . . . . 0.0 109.517 175.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.45 -44.96 7.64 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.611 1.164 . . . . 0.0 112.639 177.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.51 176.92 43.25 Favored Glycine 0 CA--C 1.532 1.149 0 C-N-CA 125.126 1.345 . . . . 0.0 113.265 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.414 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.1 mp -87.68 110.12 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 125.185 1.394 . . . . 0.0 109.384 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.61 115.69 30.77 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.422 1.089 . . . . 0.0 109.868 174.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -80.03 112.76 17.64 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.297 -0.877 . . . . 0.0 111.276 175.025 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 9.0 mtp85 -96.85 145.66 25.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.988 1.315 . . . . 0.0 112.015 176.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 p -83.48 112.61 20.12 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.194 1.798 . . . . 0.0 111.054 175.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -147.07 145.23 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 124.638 1.175 . . . . 0.0 110.747 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 37.8 m 51.66 25.38 2.81 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -178.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.82 11.97 84.89 Favored Glycine 0 CA--C 1.54 1.601 0 C-N-CA 124.895 1.235 . . . . 0.0 115.406 -176.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 p -131.46 149.62 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 126.247 1.819 . . . . 0.0 111.482 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.7 p -87.97 120.04 28.92 Favored 'General case' 0 N--CA 1.466 0.361 0 O-C-N 121.196 -0.94 . . . . 0.0 109.171 174.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -118.16 134.11 55.3 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.714 0.806 . . . . 0.0 110.121 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.414 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -73.73 137.41 43.99 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.57 0.748 . . . . 0.0 111.672 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 -139.26 126.71 21.61 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.52 1.528 . . . . 0.0 111.341 178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.523 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -68.94 118.78 12.29 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.648 -0.657 . . . . 0.0 110.067 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 34.2 tt0 -77.37 102.52 6.83 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 123.407 0.683 . . . . 0.0 110.075 175.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.1 t -91.08 106.52 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.986 0.914 . . . . 0.0 109.94 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -94.15 139.02 31.53 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.961 1.304 . . . . 0.0 110.625 175.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -114.51 146.73 36.54 Favored Pre-proline 0 CA--C 1.542 0.642 0 C-N-CA 124.616 1.166 . . . . 0.0 111.203 -177.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -68.37 159.61 52.6 Favored 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 122.208 1.939 . . . . 0.0 112.144 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.19 -12.97 47.84 Favored Glycine 0 CA--C 1.539 1.579 0 C-N-CA 125.342 1.448 . . . . 0.0 115.619 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 39.9 p -153.96 -170.37 3.54 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.621 1.568 . . . . 0.0 112.082 175.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 30.2 mtp180 -109.24 11.19 25.53 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.724 2.009 . . . . 0.0 112.097 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.1 m -54.92 132.7 47.27 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.74 0.816 . . . . 0.0 110.05 174.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.43 140.96 52.34 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 125.407 1.483 . . . . 0.0 110.225 176.527 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -120.81 123.24 42.12 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.206 1.002 . . . . 0.0 109.223 174.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -90.0 110.17 21.16 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.602 1.161 . . . . 0.0 111.285 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.625 HG21 HD22 ' A' ' 62' ' ' LEU . 98.4 t -98.85 126.94 36.8 Favored Pre-proline 0 N--CA 1.48 1.049 0 C-N-CA 123.814 0.846 . . . . 0.0 111.695 -179.047 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -66.12 127.7 18.1 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 123.344 2.696 . . . . 0.0 111.847 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.523 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 28.3 m -64.15 -22.21 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 176.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.09 -45.91 58.82 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.943 1.297 . . . . 0.0 112.346 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -138.97 70.7 42.14 Favored Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 124.821 1.248 . . . . 0.0 111.095 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.4 ' O ' HG12 ' A' ' 60' ' ' VAL . 61.6 Cg_endo -71.79 -34.08 9.33 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.045 1.83 . . . . 0.0 111.778 -175.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -68.72 -24.96 64.53 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 175.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -62.6 -39.66 94.47 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 125.139 1.375 . . . . 0.0 112.915 -177.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.9 p -71.17 -13.59 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.233 1.013 . . . . 0.0 113.203 175.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.06 0.21 48.04 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 126.079 1.799 . . . . 0.0 115.035 -177.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.625 HD22 HG21 ' A' ' 52' ' ' VAL . 13.2 tp -69.63 118.72 12.86 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.278 1.539 . . . . 0.0 110.922 175.085 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -135.16 169.34 17.6 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.892 1.277 . . . . 0.0 111.203 175.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 54.7 mttt -71.11 124.78 25.21 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 125.15 1.38 . . . . 0.0 110.299 175.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.23 -46.42 12.7 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.928 0.891 . . . . 0.0 110.982 174.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -159.65 -179.14 7.62 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.926 1.691 . . . . 0.0 111.529 178.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -141.12 160.53 57.49 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 125.386 1.474 . . . . 0.0 112.483 175.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -73.45 -32.59 7.81 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 123.626 2.884 . . . . 0.0 113.947 -177.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -128.6 -36.82 1.83 Allowed 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 126.384 1.874 . . . . 0.0 112.168 -178.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 . . . . . 0 C--O 1.254 1.321 0 C-N-CA 127.913 2.485 . . . . 0.0 114.45 176.812 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 112.208 0.447 . . . . 0.0 112.208 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.95 -155.97 9.42 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 124.796 1.189 . . . . 0.0 113.298 174.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -102.08 157.05 17.15 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 125.246 1.418 . . . . 0.0 112.211 176.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -93.51 132.93 37.33 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.229 1.412 . . . . 0.0 111.377 175.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mtmt -143.33 85.72 1.87 Allowed 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 126.842 2.057 . . . . 0.0 110.378 175.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -92.94 169.42 10.45 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.132 0.973 . . . . 0.0 111.396 174.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.444 ' CE2' HD23 ' A' ' 62' ' ' LEU . 17.9 m-85 -77.15 122.63 25.28 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.387 -0.821 . . . . 0.0 112.584 176.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -85.59 158.53 56.93 Favored Pre-proline 0 N--CA 1.476 0.826 0 C-N-CA 125.44 1.496 . . . . 0.0 113.123 176.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -70.07 133.93 26.15 Favored 'Trans proline' 0 CA--C 1.538 0.715 0 C-N-CA 123.06 2.507 . . . . 0.0 111.038 175.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.79 -8.18 70.69 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 123.823 0.725 . . . . 0.0 114.076 -179.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -62.42 130.59 45.91 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 118.641 1.221 . . . . 0.0 110.748 -178.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -66.84 106.19 1.81 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.816 0.847 . . . . 0.0 110.608 176.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.6 m -121.83 155.17 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.882 1.273 . . . . 0.0 111.138 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 p -99.71 131.79 46.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 C-N-CA 124.467 1.107 . . . . 0.0 109.763 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.458 HD22 HD13 ' A' ' 62' ' ' LEU . 8.4 tp -146.02 99.75 4.29 Favored Pre-proline 0 CA--C 1.542 0.647 0 C-N-CA 124.357 1.063 . . . . 0.0 110.475 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.84 159.87 52.01 Favored 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.393 2.062 . . . . 0.0 112.406 177.346 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -75.83 -8.76 26.49 Favored 'Cis proline' 0 CA--C 1.544 0.993 0 N-CA-C 114.407 0.887 . . . . 0.0 114.407 0.157 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -59.08 -40.93 86.75 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.119 1.368 . . . . 0.0 112.599 177.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 89.03 -22.16 23.93 Favored Glycine 0 CA--C 1.533 1.214 0 C-N-CA 126.625 2.06 . . . . 0.0 114.364 175.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.3 t -145.48 125.64 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 125.848 1.659 . . . . 0.0 108.802 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -121.57 165.33 14.54 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 125.919 1.723 . . . . 0.0 112.73 175.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.4 t -132.11 114.13 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 125.326 1.45 . . . . 0.0 109.972 178.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.8 t -65.04 131.56 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.664 0.786 . . . . 0.0 109.93 175.036 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -99.61 -47.19 5.19 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.471 1.509 . . . . 0.0 112.808 175.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.73 176.04 44.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.152 0.882 . . . . 0.0 113.621 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.47 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.5 mp -86.19 127.96 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 C-N-CA 125.227 1.411 . . . . 0.0 109.876 178.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.39 115.62 23.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.285 1.434 . . . . 0.0 109.978 174.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -81.12 112.79 18.8 Favored 'General case' 0 CA--C 1.541 0.617 0 O-C-N 121.569 -0.707 . . . . 0.0 111.061 174.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -94.59 113.11 24.88 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 126.319 1.848 . . . . 0.0 110.612 176.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 m -69.14 96.82 0.84 Allowed 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.659 1.584 . . . . 0.0 111.107 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.3 t -122.16 121.05 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 124.971 1.308 . . . . 0.0 110.515 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.2 t 58.84 31.34 21.16 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.785 1.234 . . . . 0.0 113.582 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.74 8.02 88.03 Favored Glycine 0 CA--C 1.537 1.424 0 C-N-CA 124.975 1.274 . . . . 0.0 114.748 -174.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.7 t -122.51 108.47 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 126.242 1.817 . . . . 0.0 109.703 -177.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.0 m -73.33 119.88 18.18 Favored 'General case' 0 N--CA 1.468 0.451 0 O-C-N 121.695 -0.628 . . . . 0.0 109.956 174.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 25.1 mtm-85 -115.26 133.95 55.58 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.635 0.774 . . . . 0.0 110.228 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -72.73 141.2 48.15 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.437 0.637 . . . . 0.0 111.305 176.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -141.03 126.53 18.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.55 1.54 . . . . 0.0 111.243 178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.55 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 21.8 m-85 -71.87 118.6 14.92 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.432 0.693 . . . . 0.0 110.179 175.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -76.08 103.23 6.03 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.686 1.195 . . . . 0.0 110.235 175.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.4 t -93.31 106.34 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 124.403 1.081 . . . . 0.0 110.635 177.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -93.13 134.22 35.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.199 1.4 . . . . 0.0 110.821 176.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -109.78 145.93 33.03 Favored Pre-proline 0 CA--C 1.541 0.612 0 C-N-CA 124.418 1.087 . . . . 0.0 111.029 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -68.11 160.53 48.35 Favored 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 122.312 2.008 . . . . 0.0 112.311 176.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.57 -13.77 39.59 Favored Glycine 0 CA--C 1.54 1.618 0 C-N-CA 125.479 1.514 . . . . 0.0 115.775 179.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.9 p -152.43 -174.75 5.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 126.264 1.826 . . . . 0.0 111.51 176.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -105.93 10.5 32.37 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 125.044 1.337 . . . . 0.0 112.69 174.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.6 m -52.31 132.1 33.74 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 123.937 0.895 . . . . 0.0 110.532 174.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -123.36 141.96 51.46 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 125.7 1.6 . . . . 0.0 109.991 175.071 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -122.07 122.7 39.87 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 124.13 0.972 . . . . 0.0 108.976 175.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -89.79 105.05 17.54 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.557 1.143 . . . . 0.0 111.347 -178.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.649 HG21 HD22 ' A' ' 62' ' ' LEU . 95.3 t -92.2 128.6 44.49 Favored Pre-proline 0 N--CA 1.481 1.119 0 C-N-CA 123.715 0.806 . . . . 0.0 111.26 -178.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -65.2 127.86 19.25 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.305 2.67 . . . . 0.0 111.882 178.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.55 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 23.8 m -64.34 -23.39 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 113.856 1.058 . . . . 0.0 113.856 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -74.64 -43.98 52.71 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.154 0.982 . . . . 0.0 112.583 -177.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -136.18 70.71 62.14 Favored Pre-proline 0 CA--C 1.545 0.764 0 C-N-CA 124.351 1.06 . . . . 0.0 110.851 177.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.27 -34.54 9.77 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.22 1.947 . . . . 0.0 111.303 -175.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -70.44 -24.22 62.86 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.073 0.949 . . . . 0.0 113.52 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -64.19 -38.13 89.97 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.222 1.009 . . . . 0.0 112.716 -176.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.4 p -71.57 -14.17 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 C-N-CA 124.085 0.954 . . . . 0.0 112.538 175.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.85 -4.27 42.15 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 126.82 2.152 . . . . 0.0 114.906 -177.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.649 HD22 HG21 ' A' ' 52' ' ' VAL . 7.4 tp -67.64 120.43 14.01 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 119.002 1.401 . . . . 0.0 111.037 177.24 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 17.5 ptp180 -141.47 163.38 33.08 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.046 1.339 . . . . 0.0 111.499 174.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 ttmt -66.99 126.65 29.81 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 123.832 0.853 . . . . 0.0 110.864 175.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.84 176.06 9.93 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.72 1.208 . . . . 0.0 111.094 174.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 39.0 tp -148.58 131.19 15.88 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 124.551 1.14 . . . . 0.0 111.143 178.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -92.79 159.05 36.91 Favored Pre-proline 0 CA--C 1.554 1.115 0 C-N-CA 125.082 1.353 . . . . 0.0 112.804 175.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.04 103.57 1.51 Allowed 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 124.304 3.336 . . . . 0.0 112.306 179.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.4 177.19 8.17 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 126.367 1.867 . . . . 0.0 112.265 178.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 127.868 2.467 . . . . 0.0 113.697 -179.77 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.252 0 CA-C-O 120.574 0.226 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 138.42 -66.0 0.54 Allowed Glycine 0 N--CA 1.473 1.148 0 C-N-CA 125.373 1.463 . . . . 0.0 112.881 178.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -127.49 33.88 4.77 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 125.464 1.506 . . . . 0.0 113.114 -178.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 tpt -102.51 139.54 37.96 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.606 1.563 . . . . 0.0 110.707 177.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.5 mmtm -121.61 90.81 3.38 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 126.135 1.774 . . . . 0.0 109.474 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -127.42 165.22 20.2 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.322 1.449 . . . . 0.0 112.366 178.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.568 ' CE2' HD23 ' A' ' 62' ' ' LEU . 19.4 m-85 -84.27 117.63 23.66 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.977 1.311 . . . . 0.0 111.779 175.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 26.1 mtm180 -90.62 158.29 42.93 Favored Pre-proline 0 N--CA 1.476 0.844 0 C-N-CA 125.454 1.502 . . . . 0.0 112.693 177.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -69.58 140.25 42.87 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.767 2.312 . . . . 0.0 111.71 177.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.37 47.58 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 123.585 0.612 . . . . 0.0 114.435 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -59.89 132.73 54.85 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.396 1.098 . . . . 0.0 110.292 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -67.88 109.44 3.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 123.425 0.69 . . . . 0.0 110.625 176.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.5 m -122.07 159.36 25.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.551 1.14 . . . . 0.0 111.686 178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.4 p -107.23 130.43 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.104 1.361 . . . . 0.0 109.501 175.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.8 tp -147.65 100.96 3.73 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 124.067 0.947 . . . . 0.0 110.384 175.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -70.32 160.41 49.64 Favored 'Trans proline' 0 CA--C 1.55 1.282 0 C-N-CA 122.433 2.089 . . . . 0.0 112.991 177.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -77.16 -8.14 30.75 Favored 'Cis proline' 0 CA--C 1.548 1.21 0 CA-C-N 118.667 0.56 . . . . 0.0 113.53 2.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -56.9 -42.86 80.68 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.272 1.429 . . . . 0.0 112.564 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.32 -24.37 16.94 Favored Glycine 0 CA--C 1.533 1.182 0 C-N-CA 126.302 1.906 . . . . 0.0 113.615 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.6 t -143.42 132.56 20.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 125.903 1.681 . . . . 0.0 108.939 175.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -131.83 175.27 19.81 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 125.555 1.55 . . . . 0.0 111.716 175.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 96.9 t -140.15 121.27 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.802 1.241 . . . . 0.0 109.373 175.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.8 t -64.19 140.14 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.779 0.832 . . . . 0.0 110.168 175.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.04 -47.7 3.51 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.637 1.575 . . . . 0.0 112.733 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 174.19 173.91 40.6 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.445 1.022 . . . . 0.0 113.14 179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.501 HG23 ' HB1' ' A' ' 37' ' ' ALA . 3.6 mp -83.32 104.73 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 124.725 1.21 . . . . 0.0 108.92 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -100.42 116.03 31.43 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.142 0.977 . . . . 0.0 109.27 175.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -81.68 112.82 19.21 Favored 'General case' 0 CA--C 1.542 0.663 0 O-C-N 121.355 -0.841 . . . . 0.0 111.977 175.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . . . . . . . . . 3.6 mmt180 -98.86 141.91 31.05 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 126.218 1.807 . . . . 0.0 111.674 177.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 m -83.92 111.02 18.86 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 126.024 1.73 . . . . 0.0 110.849 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.51 143.53 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.008 1.323 . . . . 0.0 110.729 179.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 1.9 t 54.42 25.44 6.08 Favored 'General case' 0 N--CA 1.482 1.13 0 O-C-N 120.634 -1.291 . . . . 0.0 114.093 -178.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.53 13.37 80.17 Favored Glycine 0 CA--C 1.538 1.484 0 O-C-N 120.698 -1.251 . . . . 0.0 115.193 -174.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.5 p -130.98 141.72 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 C-N-CA 125.998 1.719 . . . . 0.0 112.129 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.8 t -80.93 119.95 24.12 Favored 'General case' 0 C--O 1.238 0.465 0 C-N-CA 124.371 1.068 . . . . 0.0 108.263 175.139 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.2 mtp180 -120.31 134.39 55.27 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.537 1.135 . . . . 0.0 110.36 177.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.501 ' HB1' HG23 ' A' ' 26' ' ' ILE . . . -75.35 136.85 40.8 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.14 0.976 . . . . 0.0 112.2 177.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -139.43 129.34 24.9 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.657 1.583 . . . . 0.0 111.398 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.619 ' CZ ' HG12 ' A' ' 54' ' ' VAL . 17.7 m-85 -71.26 110.08 5.68 Favored 'General case' 0 CA--C 1.537 0.445 0 O-C-N 121.795 -0.566 . . . . 0.0 110.065 175.382 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -66.86 105.32 1.56 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.645 1.178 . . . . 0.0 109.51 175.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.405 ' HB ' ' HB3' ' A' ' 50' ' ' ALA . 11.2 t -86.22 113.78 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 123.728 0.811 . . . . 0.0 109.157 175.6 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 47.1 t0 -108.82 106.53 16.57 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 127.272 2.229 . . . . 0.0 110.915 -178.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -85.65 149.5 51.5 Favored Pre-proline 0 CA--C 1.546 0.819 0 O-C-N 121.126 -0.984 . . . . 0.0 112.045 -175.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -67.81 124.56 12.03 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.713 2.275 . . . . 0.0 111.376 177.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 69.07 21.0 75.32 Favored Glycine 0 CA--C 1.538 1.482 0 N-CA-C 115.212 0.845 . . . . 0.0 115.212 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -138.92 118.62 13.1 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.471 1.508 . . . . 0.0 111.433 -177.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -68.17 -18.04 64.5 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.485 1.114 . . . . 0.0 113.552 175.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -52.55 144.97 12.51 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 123.592 0.757 . . . . 0.0 110.559 175.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -133.44 141.31 47.76 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 124.497 1.119 . . . . 0.0 109.918 177.362 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -115.95 142.19 47.11 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.21 99.13 7.01 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 93.4 t -91.48 124.66 60.37 Favored Pre-proline 0 N--CA 1.477 0.888 0 C-N-CA 123.857 0.863 . . . . 0.0 110.131 -175.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -65.63 133.62 35.0 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.08 2.52 . . . . 0.0 111.623 -177.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 39' ' ' TYR . 31.7 m -66.49 -24.87 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 114.084 1.142 . . . . 0.0 114.084 176.001 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -73.21 -48.01 38.65 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.525 1.13 . . . . 0.0 112.045 -178.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 59' ' ' SER . . . -135.25 70.59 68.47 Favored Pre-proline 0 CA--C 1.545 0.772 0 C-N-CA 124.29 1.036 . . . . 0.0 111.489 178.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.401 ' O ' HG12 ' A' ' 60' ' ' VAL . 57.3 Cg_endo -69.2 -30.65 24.53 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.803 2.335 . . . . 0.0 111.787 -176.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -72.22 -23.67 61.27 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.043 0.937 . . . . 0.0 112.989 174.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.425 ' HB2' ' HB1' ' A' ' 56' ' ' ALA . 8.1 t -65.48 -33.0 74.91 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.212 1.005 . . . . 0.0 112.851 -175.302 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 57' ' ' PRO . 9.7 p -72.8 -14.8 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 124.258 1.023 . . . . 0.0 112.519 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 97.6 7.42 56.79 Favored Glycine 0 CA--C 1.539 1.58 0 C-N-CA 126.005 1.764 . . . . 0.0 114.739 -175.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.568 HD23 ' CE2' ' A' ' 7' ' ' PHE . 3.7 tp -75.12 126.12 30.35 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.917 1.359 . . . . 0.0 111.322 175.123 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -142.17 166.05 25.77 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.993 1.717 . . . . 0.0 112.119 175.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -76.41 128.0 33.97 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.497 1.119 . . . . 0.0 108.979 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.8 80.56 5.15 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 125.05 1.34 . . . . 0.0 110.282 175.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 tt -61.28 102.17 0.21 Allowed 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 125.764 1.626 . . . . 0.0 111.127 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.02 157.3 89.57 Favored Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 124.264 1.026 . . . . 0.0 112.142 -175.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.05 -32.59 21.19 Favored 'Trans proline' 0 CA--C 1.54 0.79 0 C-N-CA 122.541 2.16 . . . . 0.0 112.982 -179.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.88 118.37 12.2 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 126.507 1.923 . . . . 0.0 110.147 -177.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.223 0 C-N-CA 125.821 1.648 . . . . 0.0 112.817 179.095 . . . . . . . . 1 1 . 1 stop_ save_